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Strategies to improve myocardial reperfusion after primary PCI 
The value of pharmacological interventions and thrombus aspiration 
1. Het routinematig gebruik van medicijn-afgevende stents bij patienten met een ST­
elevatie myocardinfarct moet worden afgeraden. (dit proefschrift) 
2. Na de diagnosestelling van een ST-elevatie myocardinfarct moet zo spoedig mogelijk 
een oplaaddosis clopidogrel gegeven worden. (dit proefschrift) 
3. In het geval van meervatslijden dient de primaire PCI beperkt te blijven tot het aan 
het infarct gerelateerde vat. (dit proefschrift) 
4. Het gebruik van trombus aspiratie leidt in vergelijking met conventionele PCI tot een 
verbeterde myocard reperfusie en klinische uitkomst bij patienten met een ST­
elevatie myocardinfarct. (dit proefschrift) 
5. Trombus aspiratie is ook bij de meeste patienten met een non-ST-elevatie 
myocardinfarct toepasbaar en veilig. (dit proefschrift) 
6. Een valide vergelijking tussen zorgverleners is op basis van de huidige 
kwaliteitsevaluaties niet mogelijk. 
7. Het verschil in werkzaamheid tussen merk- en generieke geneesmiddelen is 
voornamelijk gebaseerd op het placebo-effect. 
8. Onderzoeksafdelingen afrekenen op impactfactoren leidt tot een grotere publicatie 
bias. 
9. Het tijdig omkeren op een verkeerd ingeslagen weg kan zowel in de bergsport als in 
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General introduction and scope 
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Chapter 1 
Acute myocardial infarction is a leading cause of death in adults in North America and 
Europe.1-2 Coronary plaque fissuring or rupture is the initial event of acute myocardial 
infarction leading subsequently to exposure of the underlying subendothelial matrix, 
activation of platelets, thrombin generation, and thrombus formation.3.4 An occlusive 
thrombus in the absence of significant collateral vessels most often results in acute ST­
segment elevation myocardial infarction (STEMI). 
The goal of treatment of patients with STEMI is to achieve rapid epicardial and myocardial 
reperfusion and to maintain this initial result at follow-up.5 There are two methods 
of treatment to re-open an occluded artery: administering a thrombolytic agent and 
percutaneous coronary intervention (PCI). In the 1990s and the beginning of the 2000s, 
many randomized controlled trials have shown that PCI for STEMI is associated with 
improved outcome compared to thrombolytic therapy.s-7 
Primary PCI involves dilatation of an acutely occluded coronary lesion, thereby 
restoring epicardial blood flow to the myocardium. This dilatation, however, also causes 
compression, fracturing and fissuring of the plaque and thrombus load. This accounts for 
some of the major complications (e.g. restenosis, (sub)acute closure, distal embolisation) 
associated with PCI, resulting in impaired epicardial and microvascular reperfusion.8-15 The 
aim of this thesis is to explore new strategies to reduce these PCl-related complications, 
and to improve epicardial and microvascular reperfusion after primary PCI. 
Part I Impaired epicardial reperfusion 
Restenosis 
A major limitation of PCI is the occurrence of restenosis, which occurs in 20-50% of 
patients treated with balloon angioplasty alone within the first months after a successful 
intervention.13-1 6 Restenosis is the arterial healing response seen after vascular injury 
caused by balloon dilatation. It is based on three processes; elastic recoil immediately after 
balloon dilatation, late vascular contraction (remodeling) and neointimal proliferation 
due to vascular injury.13•14 The implantation of coronary stents during PCI prohibits 
almost all elastic recoil and late vascular contraction of the dilated artery. However, stent 
implantation is unable to inhibit neointimal formation, but even enhances it, resulting 
in so-called in-stent restenosis. The incidence of in-stent restenosis ranges between 
between 10-30%.15-18 Drug-eluting stents (DES) have become the main approach to avoid 
in-stent restenosis. These stents are coated with anti-proliferative drugs and have shown 
to reduce the amount of in-stent neointimal hyperplasia compared to non-coated stents 
(bare metal stents, BMS).19-21 
In 2003 DES received expedited approval for clinical use based on the results of initial 
prospective randomized controlled trials enrolling mainly stable patients with discrete 
coronary lesions.22•23 Rapidly thereafter DES were also routinely used for off-label 
indications, such as STEMl.24•25 
Because of the fact that patients with STEMI have been categorically excluded from most 
of these trials, it remained unclear whether the experience with DES in stable patients 
could also be extrapolated to patients with STEMI. In Chapter 2 the safety and efficacy of 
DES vs. BMS in patients undergoing primary PCI for STEMI is investigated and discussed. 
Introduction 
Thrombotic complications 
The enhanced thrombotic environment of STEMI contributes to a higher risk of thrombotic 
complications during and after primary PCl.4 The combination of acetylsalicylic acid and an 
ADP-receptor inhibitor (dual antiplatelet therapy) is currently the optimal medical strategy 
to reduce this risk of thrombotic complications.5 For patients undergoing PCI for stable 
angina or acute coronary syndromes, several studies demonstrated that starting dual 
antiplatelet therapy before PCI (pretreatment) was associated with a further reduction of 
thrombotic complications compared to starting after the PCl.26•31 In patients treated with 
thrombolytic therapy, additional administration of the ADP-receptor inhibitor clopidogrel 
was associated with a higher incidence of early epicardial patency and improved clinical 
outcome.32 Based on these findings, dual antiplatelet therapy is often started on site 
by ambulance or emergency department staff directly after electrocardiographic 
confirmation of a STEMl.33 Early administration of these agents may induce early epicardial 
flow, more complete platelet inhibition and improve outcome after primary PCI for STEMI. 
Although no randomized data have been published on the impact of pretreatment with 
clopidogrel in the setting of primary PCI for STEMI, it is widely used in routine clinical 
practise. To evaluate the impact of clopidogrel on early reperfusion and clinical outcome, 
a systematic review was performed, of which the results are presented in chapter 3. 
Multivessel disease 
The majority of the patients presenting with STEMI have extensive coronary artery 
disease. As a consequence 40-60% of the patients have, besides the culprit vessel lesion, 
also one or more significant non-culprit vessel lesions.34•35 After treating the culprit vessel, 
significant lesions in non-culprit vessels suitable for PCI can be treated according to 3 
different strategies; (1) conservatively, (2) directly by means of a multivessel PCI or (3) 
during staged PCI procedures. Current guidelines discourage treatment of non-culprit 
vessel lesions in hemodynamic stable patients, mainly because of a possible increased 
risk of complications when performing PCI in the enhanced thrombotic and inflammatory 
environment of STEMl.36 
However, evidence is limited and no large randomized controlled trials have been 
performed or planned. Therefore it remains unclear whether treatment of non-culprit 
vessel lesions is required and when it should be performed in patients with STEMl.37 In 
Chapter 4 published data on these 3 current PCI strategies for multivessel disease in STEMI 
patients are evaluated. 
Part I I  Impaired microvascular reperfusion 
Primary PCI results in around 90% of the cases in complete restoration of epicardial 
flow. However, despite sufficient epicardial flow, suboptimal microvascular reperfusion 
is observed in a significant part of the patients after primary PCl.38 The occurrence of 
suboptimal microvascular reperfusion has been associated with larger infarct size, lower 
residual left ventricular ejection fraction, and higher mortality.38•39 Suboptimal reperfusion 




limit optimal microvascular reperfusion are microvascular dysfunction and reperfusion 
injury. Microvascular dysfunction can be caused by spontaneous and PCl-induced distal 
embolisation of atherothrombotic material into the distal microvasculature. In addition, 
microvascular dysfunction can be induced by vasospasm and/or inflammation.9•11 
Manual thrombus aspiration in STEMI 
The high frequency of suboptimal myocardial reperfusion after primary PCI and its 
association with adverse outcome has resulted in the development of various mechanic 
and manual devices to protect the microvasculature. Several small randomised controlled 
trials have been performed, demonstrating that manual thrombus aspiration might be a 
potential therapy to limit PCl-induced distal embolisation by removing atherothrombotic 
material exposed to the lumen.40·42 However, whether thrombus aspiration also results 
in a significant improvement of myocardial reperfusion and clinical outcome remained 
unclear. 
In chapter 5 the results of the large randomized controlled Thrombus Aspiration during 
Percutaneous Coronary Intervention in Acute Myocardial Infarction Study (TAPAS) are 
presented comparing conventional PCI with thrombus aspiration.42 In chapter 6 we 
investigated the one year clinical follow-up of the TAPAS. 
The efficacy rates of thrombus aspiration (as defined as successful retrieval of 
atherothrombotic material) ranges between 73 and 95 percent in published studies.43.44 
Because most of the published studies were not powered to investigate the effect of 
thrombus aspiration in selected patient subgroups, it is therefore currently unclear what 
the independent predictors are of effective thrombus aspiration and whether thrombus 
aspiration should be recommended for use in all patients or in a more selected population. 
The study presented in chapter 7, investigated what independent predictors are of 
effective thrombus aspiration in a population treated with routine thrombus aspiration. 
Uni- and multivariate analyses were performed to identify independent predictors of 
effective thrombus aspiration, which were subsequently tested for their discriminative 
and clinical value. 
Several manual thrombus aspiration devices are currently available, with different 
handling characteristics and lumen sizes_43·45 Currently, it is unknown whether large­
lumen-diameter catheters are superior in removing thrombus load when compared with 
medium-sized ones. 
In chapter 8 the results of a prospective cohort study are shown, which investigated 
whether a large-lumen-diameter catheter is capable of aspirating larger thrombotic 
components and results in improved angiographic outcome compared to a medium­
sized catheter. 
Manual thrombus aspiration in non-ST-elevation myocardial infarction 
(NSTEMI) 
Acute coronary syndromes are initiated by an eroded, fissured or ruptured atherosclerotic 
plaque, leading to subsequent platelet aggregation and thrombus formation. Myocardial 
necrosis occurs when the resultant thrombus induces epicardial occlusion, but may also be 
a sign of microvascular obstruction, owing to spontaneous or PCl-induced embolisation. 
Introduction 
At the present time, no published data on thrombus aspiration in patients with NSTEMI 
are available. In chapter 9 the results of a prospective cohort study are presented, in which 
the feasibility and safety of thrombus aspiration during PCI for NSTEMI were investigated. 
Direct stenting 
Some studies suggested that stenting without balloon predilatation (direct stenting) might 
also result in less distal embolisation and improved microvascular reperfusion compared 
to stenting with predilatation.46.47 Because in the thrombus aspiration studies the use of 
thrombus aspiration often resulted in sufficient antegrade coronary flow, predilatation 
before stenting was often not necessary. This resulted in a higher rate of stenting without 
predilatation compared to conventional PCI. As direct stenting is suggested to be superior 
compared to balloon predilatation followed by stenting, the beneficial effect of thrombus 
aspiration could (partly) be related to the effect of direct stenting. However, it is currently 
unclear what the value of direct stenting is in the context of primary PCI. 
In chapter 10 STEMI patients who underwent direct stenting were compared with 
patients who underwent thrombus aspiration prior to stenting in routine clinical practice, 
to investigate whether thrombus aspiration is also beneficial in patients eligible for direct 
stenting. 
Impact of the operator on microvascular reperfusion. 
A significant proportion of patients treated with primary PCI for STEMI suffer from serious 
adverse events such as incomplete myocardial reperfusion.38•39 Although, patient-related 
factors play a major role in the occurrence of these adverse events, it is currently unknown 
to which degree these adverse events are also operator related.48.49 
Therefore, in chapter 11 inter-operator variation was investigated using objective safety 
and efficacy endpoints during primary PCI for STEMI. The primary endpoint was incidence 
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INTRODUCTION 
The prognosis of patients with acute myocardial infarction (AMI) has been considerably 
improved following the introduction of reperfusion therapies. The primary aim in 
the acute phase of an AMI is rapid and sustained restoration of blood flow through 
the infarct-related artery. When logistically feasible, primary percutaneous coronary 
intervention (PCI) has emerged as the preferred reperfusion modality. Compared with 
balloon angioplasty, implantation of a baremetal stent (BMS) results in a lower rate of 
reocclusion and restenosis. Nevertheless, rates of target vessel revascularization after BMS 
implantation in patients with AMI range from 7 to 15%.1-2 
The clinical presentation of the restenotic process is most often recurrence of angina, and 
is usually not associated with death or myocardial infarction. BMS eliminate elastic recoil 
and negative remodelling. However, they may induce marked neointima proliferation, 
resulting in in-stent restenosis. In elective PCI, drug-eluting stents (DES) have been shown 
to reduce neointima proliferation and thereby the risk of in-stent restenosis. These initial 
positive outcomes have resulted in widespread use of DES in high-risk patients, such as 
patients with AMI. 
Kastrati et al. have reported their findings on the use of DES for primary PCl.3 The authors 
have performed a careful meta-analysis of eight randomized controlled trials (RCTs), 
comparing DES with BMS in 2786 patients. Individual patient data were available from 
seven of the eight studies (2476 patients). Therefore, this meta-analysis offers important 
time to event data regarding revascularization and thrombotic complications. This is of 
particular importance as it has become clear that DES may be associated with late acute 
stent thrombosis, a rare event but with often catastrophic clinical consequences. The 
authors concluded that DES in patients with AMI are effective [hazard ratio (HR) 0.38 for 
the risk of reintervention, P < 0.001] and safe (HR 0.80 for the risk of angiographic stent 
thrombosis, P = 0.43). However, before we can advocate widespread use of DES in patients 
with AMI, the following issues should be clarified. 
Is the external validity of DES vs. BMS trials in acute myocardial infarction 
compromised? 
Do the patients included in the DES vs. BMS trials in AMI represent a general 'all-comers' 
infarct population? In this regard, there are important differences in trial designs, in 
particular between PASSION and TYPHOON,4•5 the two largest trials published to date, 
contributing together 50% of the patients included in the meta-analysis of Kastrati et 
al. The PASSION trial reported no exclusion criteria regarding lesion characteristics and 
investigated DES in a population resembling real-world practice. However, this trial 
failed to show an advantage in target lesion revascularizaion (TLR) for DES vs. BMS (6.2 
vs. 7.4%, P = 0.23). In contrast, the TYPHOON trial had a long list of exclusion criteria 
(previous PCI in the infarct-related vessel, excessive tortuosity or calcification, ostial 
lesions, birfucation lesions, multiple lesions, massive thrombus in infarct-related vessel, 
etc.) and found lower rates of target vessel revascularization (TVR) for DES (5.6 vs. 1 3.4%, 
P < 0.001 ). These conflicting data strongly suggest that at the present time DES should 
not be recommended for use in all patients with AMI. As in elective patients, additional 
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analysis and RCTs of specific patient groups are necessary to assess which patients with 
AMI benefit from DES implantation and which do not. 
Late and very late stent thrombosis (>1 or >3 years after implantation} 
The drug and polymer composition of DES causes endothelial dysfunction, delayed 
endothelial healing, enhanced agonist-induced platelet aggregation, and hypersensitivity 
reactions.6-8 Particularly in the context of AMI, these features have raised concerns with 
regard to the potential higher risk of thrombotic complications when DES are implanted 
in a prothrombotic environment. Furthermore,the extent of the toxic effect of DES 
on the healing myocardium in AMI patients is largely uninvestigated.6•8 Despite these 
concerns, it should be noted that none of the published RCTs reported an increased risk 
of angiographic documented or possible stent thrombosis associated with DES. 
Noteworthy is that follow-up in most studies was limited to 1 year. A registry of 505 AMI 
patients from the Rotterdam group showed that the benefit of DES over BMS in terms of 
TVR was no longer apparent after 3 years follow-up.9 In this study, late stent thrombosis 
occurred in four patients (2. 1 .%) treated with DES in the third year of follow-up against 
none in the BMS group. This illustrates that, with regard to late stent thrombosis, large 
populations and longterm follow-up are needed to establish the true incidence of this 
serious complication. 
The clinical outcome of DES after 3-5 years 
With the exception of the PASSION trial, all RCTs found an early advantage of DES in AMI, 
in terms of less angiographic and clinical restenosis. As demonstrated in the previously 
mentioned Rotterdam registry, late thrombotic events can result in more TVR in DES 
patients, which can negate the benefit observed in the first years. Because of the suspected 
higher incidence of very late stent thrombosis associated with DES compared with BMS, 
there should be reservations regarding conclusions about the effect of DES on long-term 
clinical outcome, in particular when conclusions are based on trials with follow-up limited 
to 1 year. 
Cost-benefit ratio of DES 
Cost-ineffectiveness is a 'complication' of DES implantation which cannot be neglected. 
The initial costs of the procedure are clearly higher with the use of DES. However, because 
of the lower need for revascularization procedures, there may be cost savings over the 
entire course of patient care. Several studies have been published assessing the cost­
effectiveness of DES compared with BMS in elective patients. DES were found not to 
be cost-effective compared with conventional BMS, with the exception of patients at 
the highest risk of developing restenosis. In addition, in several RCTs, older generation, 
thick-strut BMS were used as the comparison to evaluate DES in AMI. As demonstrated 
by Kastrati et al., when two stents with different designs are compared, the stent with 
the thinner struts is associated with less angiographic and clinical restenosis.1 0 The new 
generation of BMS may therefore be associated with lower restenosis rates, thereby 
further improving costeffectiveness of BMS compared with DES in AMI. 
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Long-term fol low-up, i n  terms of  death/reinfarction, of  the previously described tria l s  
together with severa l important RCTs which are underway, such as HORIZONS AMI  [3400 
AMI patients randomized to pacl itaxel-emitting stents (PES) or BMS] and CEZAR [352 AMI 
patients randomized to PES or s i rol imus-eluting stents (SES)], wi l l  be necessary to resolve 
these issues. 
CONCLUSION 
The meta-ana lysis of Kastrati et a l .3 summarizes our cu rrent knowledge of RCTs i n  AMI. 
It can be concluded that prospective studies with long-term fol low-up, RCTs, and large 
registries wi l l  be necessary before we can conclude whether or not DES are associated 
with improved longterm c l in ica l outcome. Unti l that t ime, DES implantation on a routine 
basis in patients with AMI should not be recommended. 
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The objective of this study is to investigate the clinical outcome of a large cohort of patients 
with ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stents 
(DES) compared to bare metal stents (BMS). 
Background 
Several randomized controlled trials have demonstrated that PCI with the routine use of 
DES is safe and effective in patients with STEMI. However as randomized trials have strict 
inclusion criteria, further studies in unselected patient populations are needed. 
Methods 
We performed a retrospective cohort analysis of the Mayo Clinic PCI database. A total of 
552 consecutive STEMI patients who underwent a DES implantation between May 2003 
and April 2006 were included in the study and compared to 557 who had BMS for STEMI 
earlier. No specific patient subsets were excluded. 
Results 
Procedural success was achieved in 532 patients (96%). During initial hospitalization, 16 
patients (2.9%) died and 8 (1.5%) suffered from a recurrent myocardial infarction. The 
median follow-up was 23 months (IQR: 13-27 months). At 12 months post discharge, the 
rate of target lesion revascularization and death were 2.9% and 3.7%, respectively, and 
survival free of major adverse cardiac events (MACE) was 90.9%. These rates were similar 
to or lower than those of patients treated for STEMI with BMS prior to the availability of 
DES. 
Conclusion 
DES are safe and effective in the treatment of STEMI in an unselected cohort; 90.9% of 
patients are free of MACE at 12months post discharge. 
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INTRODUCTION 
Percutaneous coronary intervention (PCI), with the routine use of drug-eluting stents 
(DES), has been found to be safe and effective in prospective randomized trials enrolling 
mainly stable patients, with discrete coronary lesions.1 -3 Since patients with STsegment 
elevation myocardial infarction (STEMI) have been typically categorically excluded from 
randomized DES trials, it is currently unclear whether the experience in stable patients can 
be extrapolated to patients with STEMI. 
Small studies assessing the safety and feasibility of DES in STEMI suggest that DES have 
similar rates of thrombotic complications and lower rates of revascularization when 
compared to bare metal stents (BMS).4-1 0  Recently, two randomized trials have been 
published with different results: the TYPHOON study identified that sirolimus-eluting 
stents (SES) significantly reduced rate of target vessel revascularizations (TVR) at one year, 
while the PASSION trial found only nonsignificant differences.1 1,1 2  Since randomized trials 
have strict inclusion criteria, further studies in unselected patient populations are needed. 
Accordingly, we evaluated in hospital and long-term outcome in the Mayo Clinic registry 
of consecutive patients with STEMI treated with DES. 
METHODS 
Patients 
The study population consisted of patients who underwent DES placement for STEMI 
at the Mayo clinic, Rochester, Minnesota, in the period from May 2003 to October 2005. 
A group of patients treated for STEMI with BMS during the time frame January 1999 to 
March 2003 were also included for comparisonpurposes. 
All patients presenting with STEMI and treated with a SES (Cypher, Johnson & Johnson­
Cordis) or paclitaxel-eluting stent (PES) (Taxus, Boston Scientific) were included in this 
study. This included patients presenting in cardiogenic shock and patients undergoing 
rescue PCI after failed thrombolysis. Patients were only excluded if they refused permission 
for their records to be used for research, as required by Minnesota state law. 
The analysis was approved by the Institutional Review Board. 
Procedural Details 
PCI was performed using standard percutaneous techniques. Usually, only the infarct 
related vessel was treated. Predilatation was usually performed prior to stent placement 
at the operator's discretion. Adjunctive therapy included intravenous heparin during the 
procedure to achieve an activated clotting time of 200-250 sec with a glycoprotein llb/ 
Illa inhibitor and 250-300 sec without a glycoprotein llb/llla inhibitor. A glycoprotein llb/ 
Illa inhibitor was administered at operator discretion. Acetylsalicylic acid 325 mg was 
administered prior to the procedure and continued indefinitely. Clopidogrel was given 
with a loading dose of 300-600 mg at the beginning of the procedure; it was continued at 
a dose of 75 mg for at least 6 months after stent implantation. 
3 1  
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Table 1. Baseline characteristics and procedural details 
Variables DES (N=552) 
Age (years) 63 ± 1 4  
Ma les 367 (66) 
Pre-procedural shock 66 ( 1 2) 
Canadian Heart Class I l l  angina 1 39 (25) 
Body mass index (kg/m2) 28.4 ± 5 .3 
Diabetes mel l itus 92 ( 1 7) 
Hypertension 324 (66) 
Cholesterol >240 (mg/di) 3 1 9  (69) 
Smoking history 
Former smoker 1 62 (30) 
Current smoker 1 9 1 (36) 
Medical history 
CABG 29 (5) 
Ml >7 days 66 ( 1 2) 
PTCA 70 ( 1 3 )  
PVD 34 (6) 
CVA/TIA 42 (8) 
CHF 53 ( 1 0) 
Tumor/lymphoma/leukemia 58 ( 1 1 )  
Mu ltivessel d isease 359 (67) 
Primary PCI 366 (66) 
Location of the intervention 
Left main coronary artery 3 (0.6) 
Left anterior descending coronary artery 228 (41 )  
Left circumflex coronary artery 96 ( 1 7) 
Right coronary artery 249 (45) 
Vein graft 1 5  (3) 
No. of stents placed 1 .3 ± 0.7 
GP l i b/I l l a  use 448 (8 1 )  
Thrombectomy 1 7  (3) 
BMS (N=577) 
65 ± 1 4  
397 (69) 
94 ( 1 6) 
91 ( 1 6) 
28.9 ± 5.3 
1 09 ( 1 9) 
325 (60) 
345 (72) 
1 9 1 (33) 
1 82 (32) 
34 (6) 
90 ( 1 6) 
87 ( 1 5) 
32 (6) 
46 (8) 




7 ( 1 .2) 
256 (44) 
73 ( 1 3) 
257 (45) 
1 8  (3) 
1 .5 ± 0.7 
501 (87) 
1 3  (2) 
P-va lue 


























AngioJet use 1 8  (3) 27 (5) 0.22 
CABG = coronary artery bypass grafting, CHF  = congestive hearth fa i l u re, CVA = cerebrovascu lar accident, Ml = 
myocardial infarction, PTCA = percutaneous trans lumina l  coronary angioplasty, PVD = periphera l  vascu lar  d isease, 
TIA = transient ischemic attack. 
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M ATERI ALS 
The data were obta ined from the Mayo Cl in ic PCI reg istry. This computerized registry 
includes prospectively col lected basel ine, procedura l, and angiographic data on a l l  
patients undergoing an interventional procedure in the  Cardiac Catheterization Lab at 
the Mayo Cl in ic, and has supported multiple outcome studies. 
Basel ine data col lection is accompl ished by chart review and includes patient 
demographics, co-morbid ities, in-hospita l medications, compl ications, lesion and 
device-specific procedural  data, and d ismissa l medications. Fol low-up data was col lected 
prospectively post-procedure by telephone interviews at 6 months, 1 2  months, and yearly 
thereafter. Fol low-up data included symptom status, medications, and cardiac event data. 
Al l  subsequent cardiac hospital izations are reviewed by obta in ing the medical records 
from Mayo as wel l  as outside institutions. 
Definitions 
The primary endpoint of this study was the occurrence of major adverse cardiac events 
(MACE) at follow-up, defined as a l l-cause death, target vessel revascu larization (TVR) and 
nonfata l Ml .  TVR was defined as a repeat intervention (surg ical or percutaneous) d riven 
by any lesion located in the same vessel treated at the i ndex procedure. Target lesion 
revascularization (TLR) was defined as a repeat intervention (surg ical or percutaneous) 
driven by a lesion located in the same segment treated at the index procedure. M l  was 
considered when at least two of the th ree fol lowing criteria were met (1 ) Prolonged chest 
pain �20 min, (2) enzyme changes (more than double the upper normal l imits of Creatine  
kinase (CK), CK-MB, o r  Relative Index) (3) ST-T-wave changes o r  new Q-waves on seria l  
ECGs indicative of myocard ial damage. Shock was defined as prolonged systol ic  blood­
pressure <90 while not on inotropes or intra-aortic bal loon pump (IABP) support or 
systol ic blood-pressure < 1 1 0  whi le on inotropes or IABP support. Procedural  success was 
defined as <20% residual stenosis in the treated lesion with no in-hospita l death, Q-wave 
Ml or coronary a rtery bypass grafting (CABG). 
Statistical Methods 
Values are shown as means ± standard deviations or numbers of patients (percentages) . 
Fol low-up event ana lyses included only in-hospital su rvivors, with fol low- up sta rting on  
the  date of  discha rge. Kaplan-Meier methods were used to  estimate event-free surviva l 
rates. Comparisons between groups were tested using the two-sample Student's t-test, 
the Wi lcoxon rank sum test, Pearson's x2 test, or the log-rank test as appropriate for g iven 
data distributions. Logistic regression models were employed to estimate simple and 
partial odds ratios for the relationsh ip between DES vs. BMS and in-hospita l outcomes. 
Partial odds ratios are adjusted for the Mayo Cl in ic Risk Score. 1 3 Simi la rly, Cox regression 
models were used to estimate hazard ratios for surviva l endpoints. For each model, 
the covariates included were those that had a significant unadjusted association with 
the endpoint. The candidate variables considered for each Cox model were age, sex, 




Table 2. Kaplan-Meier estimates of adverse events at follow-up following successful PCI 
Variables DES (n=536) BMS (n=557) P-va lue 
Al l-cause morta l ity 0.93 
30 days 0.6 0.7 
6 months 1 .9 2.7 
1 2  months 3.7 4.2 
24 months 6.4 6.4 
Any re-Ml 0.3 1 
30 days 1 .0 1 . 1 
6 months 2.1 2.6 
1 2  months 2.7 4.3 
24 months 7.2 5.6 
TVR * 0.002 
30 days 1 . 1 2.4 
6 months 3 . 1  7.9 
1 2  months 6.2 1 0.4 
24 months 7.7 1 1 .5 
TLR <0.001 
30 days 0.8 2.4 
6 months 2 . 1  7.9 
1 2  months 2.9 1 0.4 
24 months 4.7 1 1 . 1  
MACE 0. 1 8  
3 0  days 2.3 3 . 1  
6 months 6.5 1 0.5 
1 2  months 9. 1  1 5 .3 
24 months 1 6.3 1 8.8 
* Includ ing TLR, MACE = major adverse cardiac events, Ml = myoca rd ia l  infarction, TLR = target lesion 
revascula rization, TVR = target vessel revascularization. 
of cholesterol >240, h istory of smoking, h istory of Ml ,  prior PCI, prior CABG, PVD, history 
of CVA/TIA, chronic renal d isease, COPD, metastatic cancer, LVEF, mu ltivessel d isease, 
thrombus in a ny lesion, maximum device size used, u rgency of PCI, number of segments 
treated, number of vesse ls treated, number of stents placed, GP l lb/l l la use, location of 
i ntervention, vein graft i ntervention, post-PCI TIM I  flow of 1 1/1 1 1 .  The proportional  hazards 
assumption was assessed by visua l  inspection of a smoothed relationship of the sca led 
Schoenfeld residuals over time. Statistica l ana lyses were completed us ing SAS version 9 . 1  
(SAS I nstitute, Cary, North Caro l ina) .  
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RESULTS 
Clinical and Angiographic Characteristics 
A total of 552 consecutive DES patients and 577 BMS patients were included in the study. 
Baseline characteristics are detailed in Table I. Patients treated with DES had a mean age 
of 63 ± 1 4  years and 66% were men. The BMS patients had similar age/gender distribution. 
Preprocedural shock was less common in the DES patients ( 1 2% vs. 1 6%, P = 0.035) as was 
a history of CHF ( 1 0% vs. 1 9%, P < 0.001 ). Primary PCI was also less common in the DES 
group (66% vs. 78%, P < 0.001 ) .  
Procedural Details and Outcomes 
Fewer stents on average were placed in DES patients than BMS patients ( 1 .3 ± 0.7 vs. 1 .5 
± 0.7, P = 0.001 ). The majority (88%) of DES stents placed were SES stents. A glycoprotein 
llb/llla receptor inhibitor was used slightly less in the DES patients (8 1 % vs. 87%, P = 
0.007). TIMI flow 3 was achieved for all lesions in 97% of the DES procedures, which was 
significantly better than the BMS procedures (92%, P = 0.001 ). The procedural success rate 
was high in both groups, 96% in DES procedures and 95% in BMS, P = 0.3 1 . Sixteen DES 
patients (2.9%) died inhospital, a proportion similar to the BMS group (n = 20, 3 .5%, P 
= 0.059). The occurrence of Ml and inhospital CABG were also similar between the two 
groups. 
Follow-Up 
The median period of follow-up after hospital discharge was 23 months (inner quartile 
range, 1 3-27 months) for the DES patients. Follow-up is substantially longer in the BMS 
group (median 61 months, IQR: 49-73) since they represent an earlier patient set. Follow­
up at 30 days, 6 months, 1 year, and 2 years was, respectively, 98%, 97%, 84%, and 46% 
complete in the DES group (all rates were higher in the BMS group). Post-discharge, 
follow-up outcomes at 30 days, 6 months, and 1 2  months are listed in Table II. At 1 2  
months, the cumulative incidence of death, any Ml, TVR, TLR, and MACE after 1 2  months 
was 3.7%, 2.7%, 6.2%, 2.9%, and 9. 1 % respectively (Table 1 1). Accordingly, the incidence of 
TVR at 1 2  months was reduced from 1 0.4% with BMS to 6.2% with DES, and at 24 months, 
the corresponding reduction was from 1 1 .5% to 7.7% (Fig. 1 ). With the endpoint of TLR 
at 1 2  months, the incidence was reduced from 1 0.4% to 2.9% (BMS versus DES) and at 
24 months was 1 1 . 1 % versus 4.7% (P < 0.001 ). The use of DES was not associated with a 
significant increase of allcause mortality (P = 0.93) or the combined endpoint of death/ 
reinfarction (P = 0.95) as compared with BMS (Figs. 2 and 3). 
Multiple proportional hazards regression models were used to investigate the partial effect 
of DES use on other follow-up endpoints (Table Ill). After adjusting for other risk factors, 
the effects of DES were similar to the unadjusted results, indicating that DES have similar 
long-term outcomes as BMS with regards to all cause mortality and any Ml. The composite 
endpoint of death, Ml, and target vessel revascularization was nearly significantly better (P 
= 0.055) in the DES treatment group after adjusting for other risk factors. 
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DISCUSSION 
This study shows that DES implantation in an unselected population with STEMI results 
in a low incidence of death, Ml, or target lesion or vessel revascularization at 12 months. 
Unadjusted results of all cause death and Ml were similar between BMS and DES. However 
as is true in other patient subsets at less high risk than STEMI patient, DES continues to be 
associated with significant decreases in TLR. 
There is limited information on the use of DES for STEMI. Until recently, only eight 
randomized studies on DES implantation in STEMI patients have been published.4-7,1 0,1 1  A 
recent meta-analysis combined data of four of these studies, but this included only 426 
patients treated with SES.1 4 This metaanalysis reported an incidence of 7.0% for death, 
10.8% for MACE, and 2.3% for TVR after 6-8 months. More recently, Pasceri et al. analyzed 
seven randomized trials enrolling 2,357 patients with a follow up of 8-12 months.1 5 In 
this analysis, the author identified that the incidence of death or recurrent Ml was similar 
between the two groups, but that TLR was much improved. TLR occurred in 4.8% of DES 
and 12.0% of BMS (RR 0.40, 95% Cl 0.30-0.54). Our population of 536 patients has, despite 
the performance of rescue PCI after failed thrombolysis in 17.3% and multivessel disease 
in almost half of the patients, an in hospital mortality rate of 3.7% and a low rate of TLR 
(2.9%) and MACE (9.1 %) at 12 months follow up post-discharge. The 6-month TVR rate 
(3. 1 %) in our population is very similar to that reported in the most recent meta analysis. 
Table 3. Unadjusted and adjusted hazard ratios and 95% confidence intervals for DES vs. BMS on 
long-term follow-up 
Endpoint Unadjusted hazard ratio Adjusted hazard ratio 
Death 1 .02 (0.65- 1 .62), p=0.93 0.92a (0.57-1 .49) p=0.74 
Death/re-Ml 1 .0 1  (0.72- 1 .42), p=0.95 0.93b (0.65-1 .32), p=0.67 
MACE 0.82 (0.62- 1 .09), p=0. 1 8  0.75c (0.56- 1 .0 1 ), p=0.055 
a. Adjusted for age, gender, angina class, history of CHF, hypertension, BMI, history of Ml, prior CABG, PVD, h istory 
of CV/VTIA, rena l  disease, COPD, metastatic cancer, multivessel disease, device size used, no. of segments treated 
and post-PC! TIMI flow. 
b. Adjusted for age, gender, angina class, history of CHF, hypertension, history of Ml, prior PCI, prior CABG, PVD, 
history of CV/VTIA, rena l  disease, metastatic cancer, mu ltivessel disease, device size, no. of segments treated, PCI i n  
RCA, and PC I  in vein graft. 
c. Adjusted for age, history of CHF, diabetes, hypertension, BMI, history of Ml, prior PCI, prior CABG, history of CVN 
TIA, rena l  disease, metastatic cancer, mu ltivessel disease, device size, no. of segments treated, no of stents placed, 
post-PC! TIMI flow. 
Earlier studies suggest that the drug and polymer composition of DES could cause 
delayed endothelial healing, 1 6• 1 7  enhanced agonist-induced platelet aggregation1 8  and 
hypersensitivity reactions. 1 9  These features raised concerns regarding the risk of stent 
thrombosis when DES are implanted in an actively thrombotic environment of a STEMI 
lesion. There were variable results in the two recent randomized trials that could not be 
detected in our study. In the TYPHOON, the incidence was 3.4%-3.6%, while in PASSION, 




Chapter 2 .2 -----------------------------
Limitations of the study 
This retrospective, s ingle-centre study of DES implantation in ST-elevation myocard ia l  
i nfa rction, suffers from the l imitations inherent to this particu lar study design. However, 
g iven the unselected and large population of DES procedures, it is representative of 
the dai ly practice of i nterventiona l  cardiology. Fol lowup events were not adjudicated 
to ascertain stent thrombosis rates. The definition used for in-hospital reinfarction may 
overestimate the actua l incidence of reinfarction. 
CONCLUSION 
The outcome of this study demonstrates excel lent outcomes of DES implantation in STEMI 
with continued significant improvement i n  TLR and TVR compared with BMS. However, 
more randomized tria l s  a re necessa ry to confirm the safety and feas ib i l ity of DES in the 
treatment of STEMI . 
Drug-eluting stents for STEM! 
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The main goa l of the in itia l treatment of ST-segment e levation myocard ial infa rction 
is prompt reperfusion of the i nfarct-related artery. The va lue  of pretreatment with 
c lopidogrel before primary percutaneous coronary intervention is currently unclear. 
Methods and Results 
Stud ies were retrieved through MEDLINE  and Cochrane Contro l led Tria l s  Register sea rches 
over the past 20 years. Two authors independently performed the study selection and 
data extraction. Randomized control led studies were incl uded when the research 
subjects were unselected patients with ST-elevation myocard ia l  i nfarction undergoing 
primary percutaneous coronary intervention. Pi lot tria ls, stud ies that en ro l led patients 
undergoing rescue percutaneous coronary intervention, and stud ies with angiographic 
assessment not performed by a core laboratory or 2 bl inded investigators were excluded. 
Thi rty-eight treatment g roups, i ncl uding 8429 patients, were inc l uded. In itia l patency 
was higher in treatment g roups i n  which patients received pretreatment with clopidogre l  
(34.3%; 95% confidence i nterva l , 32.9 to 35 .8) compared with those in which patients 
d id not receive clopidogre l  before in itia l coronary angiography (25.8%; 95% confidence 
i nterva l, 24.5 to 27. 1 ). I n  mu ltiva riate-weighted log istic regression ana lysis, pretreatment 
with clopidogrel was an  independent pred ictor of early reperfusion (odds ratio, 1 .5 1 ;  95% 
confidence interva l , 1 .3 1  to 1 .74; P<0.0001 ) and improved c l in ica l  outcome. 
Conclusions 
I n itia l patency and c l in ica l outcome were improved in treatment g roups that received 
pretreatment with clopidogrel .These resu lts in patients undergoing primary percutaneous 
coronary intervention are in l ine with the experience of pretreatment with clopidogrel in 
e lective patients, non-ST-elevation coronary syndromes, and th rombolytic stud ies. 
Impact of pretreatment with clopidogrel on initial patency and outcome in STEMI 
INTRODUCTION 
The main goal of the initial treatment of ST-segment elevation myocardial infarction 
(STEMI) is prompt reperfusion of the infarct-related artery. Compared with thrombolysis, 
primary percutaneous coronary intervention (PCI) in STEMI increases the rate of patency 
of the infarctrelated artery and reduces the rates of death, reinfarction, and stroke during 
follow-up.1 However, PCI remains associated with a significantly longer delay between first 
medical contact and start of treatment.2-3 In pursuit of minimizing myocardial damage, 
anti platelet and antithrombin agents are often started on site by ambulance or emergency 
department staff. Early administration of these agents, so-called pretreatment, may result 
in early reperfusion and more complete platelet inhibition during primary PCl.4-7 Post 
hoc analyses of large trials indicate that clinical outcome is improved in patients with 
patency on the coronary angiogram before primary PCI, suggesting that early reperfusion 
improves survival.8 
At the present time, no data have been published on the impact of pretreatment 
with clopidogrel in the setting of PCI for STEMI. Guidelines and recommendations for 
pretreatment with clopidogrel are based on experience in acute coronary syndromes and 
thrombolytic studies.9 Although data are lacking, pretreatment with clopidogrel is widely 
used in routine clinical practice. Evidence with regard to impact on early reperfusion and 
short-term outcome is necessary and should be examined in the context of available data 
from clinical trials. 
We performed a systematic review to compare the incidence of initial coronary artery 
patency and shortterm outcome in treatment groups of studies in which patients received 
pretreatment with clopidogrel with those in which patients did not receive clopidogrel 
before initial coronary angiography. 
METHODS 
Study Selection and Data Extraction 
We performed MEDLINE and Cochrane Controlled Trials Register searches for published 
articles over the past 20 years using the following keywords and Medical Subject Headings 
(MeSH) terms: "randomized;' "percutaneous coronary intervention;' "angioplasty;' "stent;' 
"balloon;' "dilatat*;' "myocard* infarct*;' "myocardial infarction" [MeSH], "angioplasty, 
transluminal, percutaneous coronary" [MeSH], "stents" [MeSH], and "balloon dilatation" 
[MeSH]. Reference lists of selected articles were reviewed for other potentiallyrelevant 
citations. 
Two independent reviewers (P.J.V. and T.S.) performed the study selection. Studies were 
selected if they were randomized and controlled; published in English, French, or German; 
and enrolled unselected patients with STEMI undergoing primary PCI. By unselected, 
we meant no inclusion or exclusion criteria relative to type of infarction (eg, size and 
location) or angiographic characteristics (eg, visible thrombus and Thrombolysis in 
Myocardial Infarction [TIMI] flow). Included studies had to report pre-PCI angiographic 
and clinical characteristics, symptom duration 24 hours, and information with regard to 




PCI, and studies in which ang iographic data were not assessed by a core laboratory or 
2 b l inded investigators. Subgroups of inc l uded studies reporting optiona l  pretreatment 
with clopidogrel, pretreatment with g lycoprotein l l b/l l l a  i nh ibitor, or fibrinolysis were 
exc luded from the ana lysis. 
Data extraction was performed independently by 2 reviewers (P.J .V. andT.S.) who col lected 
information  on study design; base l ine c l in ica l  characteristics; procedu ra l  deta i l s; and 
angiographic, short-term c l in ical, and safety outcomes. Authors were contacted in case of 
incomplete or unclear data. 
325 1 abstracts retrieved from electronic databases 
2994 abstracts excluded 
, 
257 complete articles assessed accord ing to selection criteria 
23 1 stud ies excluded, based on: 
, . 
26 stud ies included 
Substudy 
Selected population 
No initial ang iographic data 
No randomized trial 
No STEMI  
No 2 bl inded observers/ core lab 
P i lot-study 
Inclusion of rescue PCI 
No PCI performed 
Symptom duration >24 hrs 
No information about premed 
38 treatment groups extracted 
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1 4  
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Table 1. Main characteristics of the included subgroups 
Primary Sx 
author, year duration, 
of publication N hrs 
�6Z1J1rong, 1 00 <6 
Dorr, 2006 1 3  < 1 2  
Dorr, 2006 1 4  < 1 2  
Kaltoft, 2006 1 08 < 1 2  
Ka ltoft, 2006 1 07 < 1 2  
Svilaas, 2008 535 < 1 2  
Svilaas, 2008 536 < 1 2  
Laarman, 2006 3 1 0  <6 
Laarman, 2006 309 <6 
Stone, 2002 5 1 8  < 1 2  
Stone, 2002 528 < 1 2  
Stone, 2002 5 1 2  < 1 2  
Stone, 2002 524 < 1 2  
Bucciarelli, 2006 73 <24 
Gibson, 2006 1 42 <6 
Gabriel, 2006 38 < 1 2 
Silva, 2006 74 < 1 2 






Med ian 4,0 
Median 3,5 
Sx-to- UFH, Clopidogrel Timing pre-
admission, loading loading dose, treatment with 
hrs dose mg 
Pre-treatment with clopidogrel 
n/a Enoxa 300 1 mg/kg 
Mean 5,0 70 U/kg 300 
Mean 6,9 70 U/kg 300 
n/a 1 0000 U 300 
n/a 1 0000 U 300 
clopidogrel, hrs Design 
First medical 
contact-to-Clop: Lytics vs. median 0,9 
First medical- rescue PCI 
contact-to-PC!: vs. pPCI 
median 2, 1 
At emergency Excimer laser vs. department pPCI 
At emergency Excimer laser vs. department pPCI 
30-60 minutes Th b before arrival at ram ec-
catheterization tompt vs. 
lab P Cl 
30-60 minutes Th b before arrival at ram ec-
catheterization tompt vs. 






Excimer No laser 
Thromb- 3 1 -40 ectomy 
pPCI 3 1 -40 
Median 3,2 Median 2,7 5000 U 600 or emergency 
department. 
Thr9m�us Thrombus aspiration aspiration VS. pPCI 
30 
In  ambulance 
Median 3,1 Median 2,6 5000 U 600 or emergency 
department. 
Mean 3,0 n/a 1 0000 U 300 Directly at hospital arrival 
Mean 3,0 n/a 1 0000 U 300 Directly at hospital arrival 
n/a Median 1 ,8 5000 U 300 (or 500 Ticlopid i ne) Median 2,1 
n/a Median 1 ,6 5000 U 300 (or 500 Ticlopidine) Median 2,0 
n/a Median 1 ,9 5000 U 300 (or 500 Ticlopidine) Median 2,0 
n/a Median 1 ,8 5000 U 300 (or 500 Ticlopidine) Median 2,0 
No pre-treatment with clopidogrel 
Mean 5,6 n/a n/a No 
n/a n/a 60 U/kg No 
Mean 4, 1 n/a 5000 U No 
Mean 3,4 n/a 60 U/kg No 





DES vs. BMS DES 
DES vs. BMS BMS 
Balloon vs. 
stenp +/- Bal loon G I  
Bal loon vs. Bal loon + stenp +/-G I  GP I  
Bal loon vs. 
stenp +/- Stent G I  
Bal loon vs. 
stenp +/- Stent + GPI G I  
GIP vs. Al l  placebo 
Early vs. 
late GPI Late GPI 
Early vs. 
late GPI Late GPI 



















Table 1 .  Continued 
Primary Sx Sx-to- UFH, Clopidogrel Timing pre-
author, year of duration, Sx-to-PCI, admission, loading loading treatment with I ncluded 
publication N hrs h rs hrs dose dose, mg clopidogrel, hrs Design subgroup F-U 
Tolg, 2006 50 <8 Mean 4,7 n/a 5000 U No 
Metoprolol 
vs. Carvediol Metoprolol 1 4  
Tolg, 2006 49 <8 Mean 5,6 n/a 5000 U No 
Metoprolol 
vs. Carvediol Carvediol 1 4  
Inoue, 2005 75 < 1 2  n/a Mean 3,7 5000 U No 
Lytics?cre vs. p Cl pPCI 30 
Nicorandi l  
Ishii, 2005 1 85 <24 Mean 4,8 n/a 3000 U No vs. placebo Nicorandi l  No 
Nicorandil 
Ishii, 2005 1 83 <24 Mean 4,5 n/a 3000 U No vs. placebo Placebo No 
Clopidogrel 
vs. 
Parodi, 2005 66 < 1 2  Mean 3,5 n/a 70 U/kg No ticlopidine Clopidogrel 30 
Clopidogrel 
vs. 
Parodi, 2005 67 < 1 2  Mean 3 ,  1 n/a 70 U/kg No ticlopidine Ticlopidine 30 
G�ongyosi, 2 04 27 <6 n/a Mean 1 ,7 60 U/kg No 
Early vs. late 
GPI Late GPI 30 
van't Hof, 2004 256 <6 Median 3,3 n/a 5000 U No 
Early vs. late 
GPI Late GPI 30 
Andersen, *Median Lytics vs. 
2003 790 < 1 2  3,4 n/a 1 0000 U No pPCI pPCI 30 
Cutlip, 2003 30 < 1 2  n/a Median 2,1 n/a No 
Early vs. late 
GPI Late GPI 30 
Widimsky, 
2003 429 < 1 2  Mean 4,7 n/a 200 U/kg No 
Lytics vs. 
pPCI pPCI 30 
Bonnefoy, 
2002 421 <6 Med ian 3,2 n/a 5000 U No 
Lytics vs. 
pPCI pPCI 30 
Montalescot, 
2001 1 5 1 < 1 2  n/a n/a 70 U/kg No 
GPl-pre vs. 
placebo All 30 
High vs. 
H igh dose low dose 
Liem, 2000 299 <6 Med ian 3,3 Median 2,0 300 U/kg No heparin heparin lnh 
High VS. 
low dose Low dose 
Liem, 2000 285 <6 Median 3,5 Median 2,0 5000 U No heparin heparin lnh 
Schomig, 2000 7 1  < 1 2  n/a Median 2,5 5000 U No 
Lytics vs. 




2000 1 0 1  < 6  Mean 3,6 Mean 2,0 1 0000 U No vs. pPCI pPCI 30 
Ross, 1 999 304 <6 n/a Median 1 ,4 5000 U No 
Lytics?cre vs. p Cl pPCI 30 
Lytics vs. 
rescue PCI 
Vermeer, 1 999 75 <6 Mean 3,6 n/a 1 0000 U No vs. pPCI pPCI 42 
Sx ind icates symptom onset; U FH, u nfractionated heparin; Clop, c lop idogrel ;  l ab, laboratory; pPCI, pr imary PCI; NA, 
not ava i lable; DES, d rug-eluting stents; B MS,bare meta l stents; GPI ,  g lycoprotei n  l i b/ I l la  i n hibitor; l n h, in h ospital; a nd 
Pre, premedication. 
*Estimated value between 2 medians.  
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End Points and Definitions 
The primary end point was initial coronary artery patency before primary PCI. Secondary 
end points were short-term mortality, death/reinfarction, and in-hospital major bleeding. 
Pretreatment with clopidogrel was defined as any thienopyridine given before the initial 
coronary angiogram. Coronary artery patency was defined as TIMI grade 2/3 flow on the 
initial coronary angiogram. Major bleeding was defined as the need for blood transfusion 
during hospitalization. Unless otherwise specified, mortality included both cardiac and 
noncardiac deaths. Reinfarction rates were defined as reported in the trials. 
Statistical Analysis 
Percentages and absolute numbers of primary and secondary end points were calculated 
for each treatment group separately and all groups combined. Corresponding exact 95% 
confidence intervals (Cls) for single proportions were determined according to the Wi lson 
method. 10 In univariate analysis, the treatment effect of clopidogrel was calculated by 
using weighted logistic regression analysis. For this analysis, treatment groups were split 
into 2: the group that did and the group that did not experience the end point as defined 
by the number of patients presented in the individual studies. Logistic regression was then 
performed, with the outcome variable being end point reached (yes versus no) weighted 
on number of patients in the subgroups. To account for baseline differences between the 
(non randomized) treatment groups of selected studies and to investigate the robustness 
of our findings, we carried out a number of secondary analyses. First, we constructed a 
multivariate-weighted logistic regression analysis, including baseline demographic 
variables available. 
Second, jackknife estimation was used to establish the robust-ness of the reatment effect 
in the multivariate model. Finally, we calculated a propensity score based on matching 
of all baseline demographic variables. Missing demographic values were imputed with 
expectation maximization as the estimation method. All probability values were 2 tailed, 
with statistical significance set at 0.05. Analyses were performed with SPSS version 12.0.2 
(SPSS Inc, Chicago, 1 1 1 )  and STATA version 10 (STATA Corp, College Station, Tex). 
P.J. Vlaar and K. Dam man had full access to and take full responsibility for the integrity of 
the data. All authors have read and agree to the manuscript as written. 
RESULTS 
Twenty-six randomized controlled studies met our inclusion criteria (Figure 1 ). 1 1 -35 Thirty­
eight treatment groups comprising 8429 patients were extracted. All 8429 patients were 
pretreated with heparin and aspirin. Before pre-PCI coronary angiography, 41 14 of the 
8429 patients received a loading dose of clopidogrel. In 1 study, patients were pretreated 
with 600 mg clopidogrel36 (see Table 1 ). In all other included studies, a 300-mg loading 
dose of clopidogrel was given as pretreatment (In 1 study,26 ticlopidine 500 mg also was 
allowed). In the 4315 patients not pretreated, clopidogrel was administrated after PCI 
to all patients who underwent stent placement. All included studies were randomized 
controlled trials; however, differences were found with regard to trial design. 
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Table 2. Patency on the initial coronary angiogram prior to PCI and clinical outcome at 30 days 
TIMI grade 2/3 Mortality Death/reinfarction Major bleeding 
Primary author Subgroup % n/total % n/total % n/total % n/total 
Pre-treatment with clopidogrel 
Armstrong pPCI 29.6% 29/98 1 .0% 1/ 1 00 4.0% 4/1 00 n/a 
Dorr pPCI 53.8% 7/1 3  n/a n/a n/a 
Dorr Excimer laser 2 1 .4% 3/1 4  n/a n/a n/a 
Kaltoft Thrombus aspiration 3 1 .7% 33/1 04 0.0% 0/1 08 0.0% 0/1 08 1 .9% 2/1 08 
Kaltoft pPCI 3 1 .4% 33/1 05 0.9% 1 /1 07 1 .9% 2/1 07 0.0% 0/1 07 
Svi laas Thrombus aspiration 45.2% 238/526 2. 1 % 1 1 /529 2.8% 1 5/529 3.8% 20/529 
Svi laas pPCI 40.5% 2 1 5/53 1  4.0% 2 1 /53 1  5 . 1 %  27/53 1  3.4% 1 8/53 1  
Laarman DES 29.4% 9 1 /3 1 0  2.6% 8/308 3.2% 1 0/308 n/a 
Laarman BMS 28.5% 88/309 4.2% 1 3/306 4.9% 1 5/306 n/a 
Stone Bal loon 29.0% 1 50/5 1 8  2.5% 1 3/5 1 8  3.3% 1 7/5 1 8  3.7% 1 9/5 1 8  
Stone Bal loon+GPI 33.3% 1 76/528 1 . 1 %  6/528 1 .9% 1 0/528 5 . 1%  27/528 
Stone Stent 32.0% 1 64/5 1 2  2. 1 %  1 1 /5 1 2  3 . 1 % 1 6/5 1 2  4. 1 %  2 1 /5 1 2  
Stone Stent+GPI 34.0% 1 78/524 2.7% 1 4/524 3.4% 1 8/524 5.0% 26/524 
Tota l 34.3% 1 405/4092 2.4% 99/407 1 3.3% 1 34/407 1  4.2% 1 3 1 /3 1 42 
No pre-treatment with clopidogrel 
Bucciare l l i  A l l  6.8% 5/73 n/a n/a n/a 
Gibson Late GPI 36.6% 52/ 142 2.8% 4/1 42 4.2% 6/1 42 7.0% 1 0/1 42 
Gabriel Late GPI 26.3% 1 0/38 1 3.2% 5/38 1 5 .8% 6/38 7.9% 3/38 
Silva Thrombus aspiration 1 8.9% 1 4/74 0.0% 0/74 0.0% 0/74 n/a 
Silva pPCI 27.0% 20/74 0.0% 0/74 0.0% 0/74 n/a 
Tolg  Metoprolol 1 8.0% 9/50 0.0% 0/50* 2.0% 1 /50 n/a 
Tolg Carvediol 20.4% 1 0/49 2.0% 1 /49* 2.0% 1 /49* n/a 
I noue pPCI 29.3% 22/75 5.3% 4/75* 8.0% 6/75 n/a 
Ishi i  N icorandi l  1 5 .7% 29/ 1 85 n/a n/a n/a 
Ishi i Placebo 1 5.3% 28/1 83 n/a n/a n/a 
Parodi Clopidogrel 1 9.7% 1 3/66 1 .5% 1 /66 3.0% 2/66 n/a 
Parodi Ticlopidine 22.4% 1 5/67 3.0% 2/67 3.0% 2/67 n/a 
Gyongyosi Late GPI 33.3% 9/27 0.0% 0/27 3.7% 1 /27 n/a 
van't Hof Late GPI 33.6% 82/244 0.8% 2/247 1 .6% 4/247 n/a 
Andersen pPCI 32.0% 253/790 6.6% 52/790 8.2% 65/790 n/a 
Cutl ip Late GPI  26.7% 8/30 3.3% 1 /30 6.7% 2/30 6.7% 2/30 
Widimsky (Prague-2) pPCI 3 1 .0% 1 33/429 6.8% 29/429 8.2% 35/429 n/a 
Bonnefoy pPCI 1 9.6% 77/393 4.8% 20/42 1 6.4% 27/421 n/a 
Montalescot A l l  1 0.9% 1 0/92 6.6% 1 0/1 5 1  7.9% 1 2/1 5 1  n/a 
Liem High dose heparin 2 1 .7% 65/299 2.7% 8/299 4.0% 1 2/299 1 0.0% 30/299 
Liem Low dose heparin 2 1 . 1 %  60/285 4.2% 1 2/285 9. 1 % 26/285 6.0% 1 7/285 
Schomig pPCI 1 9.7% 1 4/71 4.2% 3/7 1 7.0% 5/71 n/a 
Widimsky (Prague-1 ) pPCI 26.7% 27/1 0 1  6.9% 7/1 0 1  7.9% 8/1 0 1  n/a 
Ross pPCI 33.9% 1 03/304 3.3% 1 0/304 5.9% 1 8/304 n/a 
Vermeer pPCI 23.6% 1 7/72 6.7% 5/75 8.0% 6/75 n/a 
Total 25.8% 1 085/42 1 3  4.6% 1 76/3865 6.3% 245/3865 7.8% 62/794 
Abbreviations as in Table 1 .  *Only cardiac d eaths were reported. 
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Angiographic End Point 
The incidence of patients with TIMI grade 2/3 flow on initial angiography was higher in 
patients receiving pretreatment with clopidogrel (34.3%; 95% Cl, 32.9 to 35.8) compared 
with control patients (25.8%; 95% Cl, 24.5 to 27.1; Table 2 and Figure 2). The unadjusted 
treatment effect of clopidogrel on early patency was an odds ratio (OR) of 1 .53 (95% Cl, 
1.39 to 1.68; P0.0001; Table 3). In multivariate analysis, clopidogrel pretreatment remained 
significantly associated with a higher percentage of patients with TIMI grade 2/3 flow (OR, 
1.51; 95% Cl, 1.31 to 1.74; P<0.0001 ). Jackknife estimation of the multivariate model and 
the propensity score-adjusted logistic regression analysis showed similar results (Table 4). 
Clinical and Safety Outcomes 
Short-term follow-up ranged from in-hospital to 42 days after PCI (Table 1 ). Mortality 
was lower in patients receiving pretreatment with clopidogrel (2.4%; 95% Cl, 2.0 to 3.0) 
compared with control patients (4.6%; 95% Cl, 3.9 to 5.3). The combined end point of death/ 
reinfarction also was lower in patients pretreated with clopidogrel (3.3%; 95% Cl, 2.8 to 3.9) 
compared with control patients (6.3%; 95% Cl, 5.6 to 7.2). The unadjusted treatment effect 
of clopidogrel was an OR of 0.52 (95% Cl, 0.41 to 0.67; P<0.0001) for mortality and an OR 
of 0.50 (95% Cl, 0.40 to 0.62; P<0.0001) for death/reinfarction (Table 3). In all multivariate 
logistic models, pretreatment with clopidogrel remained significantly associated with 
lower rates of mortality and death/reinfarction incidence (Table 4). A proper analysis of 
the end point of major bleeding was not possible because only a minority of the studies 
supplied data on this end point. 
Table 3. The effect of pre-treatment with clopidogrel on early reperfusion and adverse event rates in 
univariate weighted logistic regression analysis 
Unadjusted treatment effect 
OR (95%(1) p-value 
TIMl-2/3 1 .53 1 .39 - 1 .68 <0.0001 
Mortality 0.52 0.41 - 0.67 <0.0001 
Death/Reinfarction 0.50 0.40 - 0.62 <0.0001 
OR = Odds ratio for occurrence of eitherTIMl-2/3, Mortality and Death/Reinfarction for pre-treatment with 
clopidogrel. 
DISCUSSION 
This systematic review found a higher initial patency rate and improved clinical outcome in 
terms of mortality and death/reinfarction in treatment groups that received pretreatment 
with clopidogrel. 
Currently, the optimal timing to start therapy with clopidogrel for primary PCI in patients 
with STEMI is unclear. Substantial platelet inhibition can be achieved within 2 hours after 
a 300-mg loading dose of clopidogrel.37-39 Because primary PCI remains limited by a time 
delay of 1 to 2 hours between the first medical contact and PCI, the time is theoretically 
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Liem et al. (H igh dose heparin )  299 
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Figure 2. Forrest-tree plot of primary end point. Percentages of TIMI grade 2/3 flow with 
corresponding 95% Cls for single proportions are shown for each treatment group separately and for 
all groups combined. pPCI indicates primary PCI; DES, drugeluting stent; BMS, bare metal stent; and 
GPI, glycoprotein lib/Illa inhibitor. 
Impact of pretreatment with c\opidogrel on initia l patency and outcome in STEM! 
clopidogrel. Therefore, this may have an impact on initial patency rate.4•39.4° Furthermore, 
platelet inhibition in patients undergoing primary PCI is important because it will translate 
to better procedural outcome, eg, by prevention of periprocedural infarct extension.6•7•38•3 9  
However, because patients with STEMI may have enhanced platelet reactivity, they may 
require more aggressive platelet inhibition. In addition, several studies have demonstrated 
a faster onset of platelet inhibition and increased clinical effect of a 600-mg compared 
with a 300-mg loading dose.5•39.41 
Table 4. Effect of pre-treatment with clopidogrel on early reperfusion and adverse event rates in 
multivariate and propensity score adjusted weighted logistic regression analysis 
Multivariate adjusted Jackn ife estimation* Propensity score adjusted 
treatment effect* treatment effect 
OR (95%CI) p-value OR (95%(1) p-value OR (95%(1) p-va lue 
TIMl-2/3 1 .5 1  1 .3 1  - 1 .74 <0.000 1 1 .5 1  1 .3 1  - 1 .74 <0.0001 1 .53 1 .39 - 1 .68 <0.000 1 
Mortality 0.57 0.38 - 0.85 0.0055 0.57 0.40 - 0.81 0.001 9 0.52 0.41 - 0.67 <0.0001 
Death/Reinfarction 0.54 0.38 - 0.75 0.0003 0.54 0.39 - 0.73 0.0001 0.50 0.40 - 0.62 <0.0001 
*Adjusted for Age, Gender, history of Diabetes, history of Hypertension, Heparin dose (high vs. low dose), Symptom 
duration, Smoking and Year of publication. OR = Odds ratio for occurrence of eitherTIMl-2/3, Mortality and Death/ 
Reinfarction for pre-treatment with clopidogrel. 
The clinical effect of pretreatment with clopidogrel has been investigated only in the 
context of elective patients, acute coronary syndromes, and thrombolytic studies. In 
elective patients, pretreatment with clopidogrel before stenting reduced the incidence of 
acute thrombotic complications and improved clinical outcome.42-44 In the context of acute 
coronary syndromes, the Percutaneous Intervention in the Clopidogrel in Unstable angina 
to prevent Recurrent Events (PCI-CURE) study demonstrated that pretreatment with a 
300-mg loading dose of clopidogrel (given for a median of 6 days before PCI) significantly 
reduced the incidence of major adverse cardiovascular events.45 In addition, a substudy 
of this trial indicated that the benefit of pretreatment with clopidogrel was independent 
of the timing of PCI. The lowest absolute event rate was seen in patients treated within 
48 hours before PCl.46 In patients treated with thrombolysis for STEMI, additional 
administration of a 300mg loading dose of clopidogrel resulted in a higher patency rate 
of the infarct-related artery and reduced the incidence of ischemic complications.40 
At the present time, no randomized controlled data are available with regard to the impact 
of pretreatment with clopidogrel before PCI in patients with STEMI. Our systematic review 
found a higher initial patency rate and improved clinical outcome in treatment groups 
that received pretreatment with clopidogrel. With an overall sample size of 8429 patients, 
our review has adequate power for initial patency, mortality, and death/reinfarction. In 
addition, the clinical benefits of pretreatment with clopidogrel outweigh the increased risk 
of perioperative blood loss in the subset of patients who are referred to cardiac surgery.47 




This systematic review compared treatment groups of studies i n  which patients received 
pretreatment with clopidogre l  with those in which patients did not and therefore is 
not a substitute for pooled ana lyses of individua l  patient data or a meta-ana lysis of 
randomized contro l led tria ls. I n  addition, the incl usion of stud ies with d ifferent trial 
designs, PCI strategies (ba l loon angioplasty, stenting, excimer l aser, thrombus aspiration), 
and pharmacologica l therapies during and after PCI (glycoprotein l l b/l l la inh ibitors, 
-blockers, angiotensin-converti ng enzyme inh ibitors) cou ld  have induced heterogeneity 
in our resu lts. The resu lts and conclusions of this ana lysis should be i nterpreted with 
these l imitations in mind. However, we have carried out extensive ana lyses to assess the 
robustness of our findings. In these ana lyses, c lopidogre l  pretreatment was consistently 
associated with higher rates of TIM I  g rade 2/3 flow, lower morta l ity, and lower death/ 
reinfarction rates. Another l imitation was that mu ltivariate ana lysis was possible for 
only a l imited number of va riab les. Thus, the influence of some relevant variables such 
as symptom-to-ba l loon and symptom-to-drug times cou ld  not be analyzed. In addition, 
data on major b leeding were ava i lab le in on ly a l imited number of subgroups. 
CONCLUSIONS 
I n itia l  patency and c l i n ical outcome were improved in  treatment groups that received 
pretreatment with clopidogrel .  These resu lts in patients undergoing primary PCI are in 
l i ne with the experience of pretreatment with clopidogrel in elective patients, non-ST­
elevation coronary syndromes, and thrombolytic stud ies. 
Impact of pretreatment with clopidogrel on initial patency and outcome in STEM! 
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To investigate if in patients with ST-elevation myocardial infarction (STEMI) and multivessel 
disease (MVD), (1) PCI should be confined to the culprit or also non-culprit vessels, and (2) 
when performing PCI for non-culprit vessels, should this take place during primary PCI or 
staged procedures. 
Background 
A significant percentage of STEMI patients have MVD. However, the best PCI strategy for 
non-culprit vessel lesions is unknown. 
Methods 
Pairwise and network meta-analyses were performed of 3 PCI strategies for MVD in STEMI 
patients: (1) culprit vessel only PCI strategy (Culprit-PC!): defined as PCI confined to culprit 
vessel lesions only, (2) Multivessel PCI strategy (MV-PCI): PCI of culprit vessel as well as �1 
non-culprit vessel lesion and (3) Staged PCI strategy (Staged-PC!): PCI confined to culprit 
vessel, after which �1 non-culprit vessel lesions are treated during staged procedures. 
Prospective and retrospective studies were included when research subjects were patients 
with STEMI and MVD, undergoing PCI. The primary endpoint was short-term mortality. 
Results 
Four prospective and 14 retrospective studies, involving 40,280 patients, were included. 
Pairwise meta-analyses demonstrated that Staged-PC! was associated with lower short­
and long-term mortality as compared with Culprit-PC! and MV-PCI. MV-PCI was associated 
with highest mortality rates at both short- and long-term follow-up. In network analyses, 
Staged-PC! was also consistently associated with lower mortality. 
Conclusions 
This meta-analysis supports current guidelines discouraging performance of multivessel 
primary PCI for STEMI. When significant non-culprit vessel lesions are suitable for PCI, they 
should only be treated during staged procedures. 
Culprit vessel only versus multivessel and staged PCI for multivessel disease in STEMI 
INTRODUCTION 
The primary objective of percutaneous coronary intervention (PCI) in patients with ST­
elevation myocardial infarction (STEMI) is to restore epicardial flow and myocardial 
perfusion in the culprit vessel. However, the pathophysiological process of myocardial 
infarction is not limited to the culprit vessel.1 It is estimated that 40-65% of the patients 
presenting with STEMI have multivessel disease (MVD), which has been associated with 
worse clinical outcome as compared with single vessel disease.2 Patients with MVD have in 
addition to the culprit lesion, one or more significant lesions in non-culprit vessels. When 
non-culprit vessel lesions are suitable for PCI and coronary artery bypass grafting (CABG) 
is not preferred, they can be treated according to 3 different strategies. After having 
treated the culprit vessel, the operator can choose to treat non-culprit vessel lesions 
conservatively, directly by means of a multivessel PCI or during staged PCI procedures. 
Although current international guidelines do not recommend performance of PCI for 
non-culprit vessels in patients unless there is hemodynamic instability (class 1 1 1 , level of 
evidence C),3.4 no large randomized controlled trials have been performed or planned 
comparing these 3 strategies. Therefore, it remains uncertain whether treatment of non­
culprit vessels is required and when it should be performed in patients presenting with 
STEMI. 
I 2656 abstracts retrieved from electronic databases I 
� 2607 abstracts excluded , 
,, 
49 complete articles assessed according to selection criteria I 
31 studies excluded, based on: 
25 No STEMI 
4 No stratification to at least 2 of � the 3 PCI strategies. , 
1 Comparing complete vs. 
incomplete revascularisation 
1 Comparing 2 strategies for 
tandem lesions in IRV 
" 
I 1 8  studies were included I 
Figure 1 .  Flow diagram of study inclusion 
Recently several small prospective and large retrospective studies have been published 




review of a l l  publ ished data to summarize cu rrent evidence for these 3 current PCI 
strateg ies for MVD in  STEMI patients. Pa i rwise meta-ana lyses were performed to compare 
these PCI strategies and an  additional network ana lysis was carried out to investigate the 
robustness of the pai rwise meta-ana lyses, to combine both d i rect and ind i rect evidence, 
and to rank  these 3 PCI strategies. 
METHODS 
Definitions of the 3 PCI strategies 
The 3 PCI strategies for STEMI patients with MVD were defined as fol lows: 
1 .  The cu lprit vessel on ly PCI (Cu lprit-PC!) strategy was defined as PCI confined to cu lprit 
vessel lesions on ly. 
2. The Mu ltivessel PCI (MV-PCI) strategy was d efined as PCI in which lesions in the culprit 
vessel as wel l  as �, non-cu lprit vessel lesion were treated. All interventions should 
have had taken place with in  the same procedure. 
3. The Staged PCI (Staged-PCI) strategy was defined as PCI confined to cu lprit vessel 
lesions only, after which � ,  lesions in  non-cu lprit vessel were treated duri ng planned 
secondary procedure(s). The timing of staged PCI procedures was defined as reported 
in each study (see table 1 ). 
I n  stud ies investigati ng solely Culprit-PC! versus  MV-PCI the primary focus was often on ly 
on the strategy during the in itial procedure and no deta i l s  were g iven about whether or not 
p lanned staged procedures were a l lowed i n  patients treated accord ing to the Culprit-PO 
strategy. In these cases, stud ies were inc luded but the a ppl ied defin itions were extracted 
and used as qua l ity indicator. Authors were contacted in case of unclear defin itions. 
Study selection 
MEDLINE  and Cochrane Control led Tria ls  Reg ister searches were performed to identify 
relevant a rticles publ ished between 1 985 and August 20 1 0. The fol lowing keywords 
and Medical Subject Head ings (MeSH)-terms were used: "Percutaneous coronary 
intervention': ''Angioplasty': "Stent': "Balloon': "Di/atat*� "Multivessel': "Multi-vessel': 
''staged': "culprit': "infarct-related': "Myocard* infarct*': "Myocardial lnfarction[MeSHJ': 
''Angioplasty, Transluminal, Percutaneous Coronary[MeSHJ': "Stents[MeSHJ': and "Balloon 
Dilatation[MeSH]'� Reference l ists of selected a rticles were reviewed for other potentia l ly 
relevant a rticles. Two independent reviewers (P.V. and K.M.) performed the study selection .  
Both prospective and retrospective stud ies were considered for incl usion. Stud ies were 
selected if the study (sub)group consisted of STEMI patients with MVD who underwent 
acute PCI. At least su rviva l data had to be ava i lable  and stratified to at least 2 of the 3 PCI 
strategies for MVD. Studies investigating the impact of completeness of revascula risation 
(so comparing complete versus incomplete revascu la risation) or surg ical revascu larisation 
for MVD were excluded. In addition, stud ies i nvestigating PCI in  elective patients and 
acute coronary syndromes with MVD were a l so exc luded. No stu dies were excluded based 
on basel ine or angiographic criteria. 
Culprit vessel only versus multivessel and staged PCI for multivessel disease in STEM! 
Table 1. Main characteristics of included studies 
PCI Strategies, n 
Prim author, Sx-time, Culprit- MV- Staged- Timing of 
publication Setting hr PCI PCI PCI staged PCI Exclusion criteria FU,max 
Prospective studies 
LM, shock, CTO, lesions located in g raft or 
previously treated with PCI, thrombolytic 
Di Mario,2004 Mu lticenter 1 2  1 7  52 
therapy before PCI. No culprit lesion 
1 yr 
suitable for stenting. Diffuse calcification, 
severe tortuosity, risk of side branch 
occlusion. 
LM, shock, previous CABG, severe va lvu lar  
disease, no PCI  possible in non-culprit 
27.3±1 2.8 
vessel (diffuse >4 cm, diameter<2.5m m, 
Ochala,2004 Single center 1 2  48 44 
days 
severe tortuosity, lesion within orifices of 6 m  
large side branch) renal insufficiency or  1 
kidney, contraindications for anti platelet 
therapy, pregnancy. 
Politi,20 1 0  Single center 24 84 65 65 
56.8±1 2.9 LM, shock, previous CABG, severe va lvula r  2.5± 1 .4 
days disease, unsuccessful culprit PCI yr 
Khattab,2008 Single center 1 2  45 28 
LM, CTO, previous Ml, non-culprit vessel 
1 yr 
diameter<2.5mm, extensive ca lcification 
Retrospective studies 
Cavender,2009 Mu lticenter All 25802 3 1 34 
LM, thrombolytic therapy before PCI, 
lnhosp. 
staged PCI. 
LM, PCI in vein graft or for acute 
Corpus,2004 Single center 1 2  354 26 1 26 In  hospital occlusion after coronary angioplasty, 1 yr 
staged PCI after hospital d ischarge. 
Dziewier,20 1 0 Multicenter 707 70 Previous CABG. 1 yr 
Han,2008 Single center 1 49 93 7-1 5 days 
LM, shock, pulmonary edema, cardiac 1 yr 
rupture. 
LM, shock, previous open heart surgery, 
Hannan,201 O* Mu lticenter 24 3262 503 259 l nhospital thrombolytic therapy before PCI, missing 3,5 yr 
ejection fraction. 
LM, shock or hemodynamic instabil ity, 
Kong,2006 Multi center 24 1 350 632 cardiopulmonary resuscitation, previous l nhosp. 
MI/PCI/CABG. 
Mohamad,20 1 0 Single center 1 2  30 7 1 2  n/a 
Unable to undergo CAG<3 hrs of hospital 1 yr 
presentation. 
Poyen,2003 Single center 1 2  8 1  86 Shock. 2,5 yr 
Qarawani,2008 Single center 1 2  25 95 LM, shock. 1 yr 
Rigattieri,2007 Single center 1 2  46 64 l nhospital 
LM, shock, previous CABG, severe va lvu lar  1 yr  
disease. 
(Continued) 
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Table 1 .  Continued 
PCI Strategies, n 
Prim author, 
publication 
Sx-time, Culprit- MV- Staged- Timing of 
Setting hr PCI PC! PC! staged PCI Exclusion criteria 
Roe,2001 Multicenter 
Schaaf,201 0 Single center 6 
Toma,201 0  Multicenter 




1 24 37 
1 984 21 7 
1 56 1 47 96 
LM, PC! of side branch. 
Patients without shock. 
LM, second PCI in culprit vessel, 
rescue PC!, isolated inferior Ml , 
serious comorbidity, pregnancy or 
breastfeeding.  
In hos ital 




3 m  
1 .7±1 .0 yr 
*Different matched populations a re used in the pai rwise compa risons. CTO=ch ron ic total occlusion, FU=duration 
of avai lable follow-up, LM=left main stenosis, Ml=myocardia l  i nfarction ,  n/a=data not avai lable, shock=cardiogenic 
shock defined as reported in  the studies, Sx-time=time between symptom onset a nd hospital admission. 
Data extraction 
Data extraction was performed independently by 2 researchers (P.V. and K.M.). 
Information was collected with regard to study design, quality indicators, baseline clinical 
characteristics, procedural details, clinical outcomes and safety outcomes. Authors were 
contacted in case of incomplete or unclear data. 
Endpoints 
The primary endpoint was short-term (inhospital/30 days) mortality. Secondary endpoints 
were long-term mortality, reinfarction, any revascularization, major bleeding and stroke. 
Unless otherwise specified, mortality included both cardiac and non-cardiac death. Stroke 
included both ischemic and hemorrhagic stroke. Major bleeding was defined as the need 
for blood-transfusion during hospitalization. Reinfarction as well as MVD and cardiogenic 
shock were defined as reported in the studies. 
Statistical methods 
Absolute numbers and percentages of the endpoints were calculated for each study 
separately and all studies combined. For the direct pairwise meta-analyses, pooled 
estimates and 95% confidence intervals (Cl) were calculated assuming a random-effects 
model with inverse-variance weighting using the DerSimonian and Laird method to 
account for heterogeneity. The following pairs were analyzed: Culprit-PC! vs. MV-PCI, 
Culprit-PC! vs. Staged-PCI and MV-PCI vs. Staged-PCI. Heterogeneity across studies was 
tested by the Cochran's Q statistic and the 12 statistic. Funnel plots were used to assess 
potential publication bias. Subgroups were made based on design (prospective and 
retrospective studies) and shown for each comparison and endpoint. A subanalysis was 
performed on Culprit-PC! vs. MV-PCI in cardiogenic shock patients. Pairwise analyses were 
performed using Review Manager (version 5.0.24). 
Culprit vessel only versus mul tivessel and staged PCI for mul tivessel disease in STEMI 
A network analysis5•7 was carried out to investigate the robustness of our findings and 
to combine both direct and indirect evidence about the 3 PCI strategies. The analysis 
was carried out using three types of random effects models: a consistency model,7 an 
inconsistency model,7 and a node-splitting model.8 Vague priors were specified in all of 
the models: N(0, 1000) for effect parameters and U(0, 4) for variance parameters. As the 
evidence structure is a triangle, there is only one inconsistency factorw in the inconsistency 
model. In the node-splitting model, we split the node d (MV-PCI vs. Staged-PC!) into m,s 
direct evidence d Dir and d Ind indirect evidence. Inconsistency was assessed by (1) 
m, s m, s 
comparing deviance information criterion model fit accross the 3 models,7 (2) testing 
w-:1;0,7 and (3) testing d Dir -:1; d Ind .8 Both hypothesis tests were performed using the 
m, s m, s 
'Bayesian P value:0 All models were computed using Markov Chain Monte Carlo simulation 
in JAGS9 and R10  using three chains with over dispersed initial values. The models were run 
for 300,000 iterations, after which convergence was assessed using the Brooks-Gelman­
Rubin diagnostic. 1 1  After this, all inference was based on a further 100,000 iterations. 
All p values were 2-tailed, with statistical significance set at <0.05. This meta-analysis was 
performed in compliance with published recommendations for meta-analyses.1 2  
P.J. Vlaar and G.  van Valkenhoef had full access to and take full responsibility for the 
integrity of the data. 
RESULTS 
Eighteen studies, involving 40,280 patients, met our inclusion criteria (figure 1 ),13·30 All 
included STEMI patients with MVD underwent PCI. Of the 18 included studies, 4 studies 
were prospective studies and 14 were retrospective studies (table 1 ). Two retrospective 
studies compared PCI strategies between matched populations.1 5•25 Five studies compared 
all 3 PCI strategies, 1 3•1 7 1 O studies compared Culprit-PC! vs. MV-PCl, 1 0·27 2 studies Culprit-PC! 
vs. Staged-PCl,28•29 and 1 study MV-PCI vs. Staged-PCl.3O 
lln the majority of the studies MVD was defined as a significant stenosis in �1 major 
epicardial vessel or side branch, but in 2 studies a left main stenosis was also defined as 
two vessel disease.26•27 Significant was defined as �70% stenosis, except for 2 studies that 
used �50%.25•26 
The timing of staged procedures was in the majority of the studies during hospitalization or 
within 1 months after index PCI (table 1 ). Details about the quality of included prospective 
and retrospective studies are given in table 2 and 3. Six out of 14 retrospective studies 
were subanalyses of prospective registries. In addition, details a re given regarding the 
studies in which planned staged procedures were allowed in patients treated according 
the Culprit-PC! strategy. Assessment of funnel plots suggested no publication bias. 
Analyses were performed on short- and long-term mortality. Available evidence for the 
primary endpoint short-term mortality in pairwise and network comparisions is shown in 
Figure 2. A proper analysis on the secondary endpoints reinfarction, any revascularization, 
major bleeding and stroke was not possible because data was only available in a minority 




Rate of the three PCI strategies across cohort studies 
In cohort studies (total 37,436 pts)14-1 7,20,2 1  providing rates of all 3 PCI strategies for MVD in 
their populations, Culprit-PC! was always the preferred treatment strategy (30,260/37,436 
pts, 80.8%) as compared with MV-PCI (3,887 /37,436 pts, 10.4%) and Staged-PCI 
(3,289/37,436 pts, 8.8%). 
Baseline differences between the three PCI strategies 
A summary of baseline variables for each included study group are detailed in table 4. In 
addition, summaries of baseline mean/percentages are given for studies included in each 
pairwise analysis. In studies comparing Culprit-PC! vs. MV-PCI, patients treated according 
to Culprit-PC! were older (62.3 vs. 60.7yr) and had higher rates of three vessel disease (32.5 
vs. 28.8%). No differences were observed regarding sex (male, 72.7 vs. 73.0%), diabetes 
(23.0 vs. 22.4%) and cardiogenic shock (9.4 vs. 10.2%). 
The pairwise analyses 
Short-term mortality 
Pooled short-term outcome data are detailed in Figure 3A-C. The Staged-PCI strategy was 
superior in both the comparison with Culprit-PC! (OR 3.03, 95%CI 1.41-6.51, p=0.005), 
and MV-PCI (OR 5.31 , 95%CI 2.31-12.21, p<0.0001 ). In addition, mortality was lower in 
patients treated according to the Culprit-PC! strategy as compared with MV-PCI (OR 0.66, 
95%CI 0.48-0.89, p=0.007). Only in the pairwise analysis of Culprit-PC! vs. MV-PCI, signs of 
heterogeneity were found across the trials (I 2=47%). 
Two studies investigated Culprit-PC! versus MV-PCI in patients presenting in cardiogenic 
shock.20•26 A total of 3248 patients were included, of which 470 ( 1 4.4%) were treated 
according to the MV-PCI strategy. Short-term mortality was in both studies lower in 
patients treated according to the Culprit-PC! strategy (total effect: OR 0.68; 95%CI 0.56-
0.84, p=0.0003). 
(A) Pairwise meta-analyses 
1 5  studies 
Culprit only PCI 
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Figure 2. Evidence for primary endpoint short-term mortality in pairwise(A) and netwok(B) meta­
analyses. 
Culprit vessel on ly versus mu ltivessel and staged PCl for multivessel disease in STEMl 
Table 2. Quality of prospective studies 
Prim author, RCT Power Blinded assessment of Adjucation ITT- Definition of culprit- Completeness of 
publication calculation angiographic data of adverse analysis PCI regarding staged survival data 
events 
Di Mario,2004 Yes Yes Yes No n/a 
Ochala,2004 Yes No Yes No n/a 
Politi,20 1 0  Yes Yes No No Yes 
ITT =intention-to-treat, n/a=data not ava i lable. 














Schaaf,201 0  
Toma,201 0  
Varani,2008 
Control for confounders Bl inded assessment of Preferred PCI 
± (Subana lysis of 
prospective registry) 
± (Subanalysis of 
prospective registry) 
± (Subanalysis of 
prospective registry) 
± (Subanalysis of 
prospective registry) 
± (Subanalysis of 
prospective study) 
± (Subanalysis of 
prospective registry) 





















procedures al lowed 
No staged mean follow-up 
procedures al lowed used 
Definition of culprit- Completeness of 




procedures a l lowed 
No staged 
1 00% 
procedures a l lowed 
No staged 1 00% 
procedures al lowed 
No staged 
99.5% 
procedures a l lowed 
No staged 
n/a 
procedures a l lowed 
n/a n/a 
No staged n/a 
procedures al lowed 
Staged procedures 
98.8% 
a l lowed 
Staged procedures n/a 
a l lowed 
No staged 95.5% 
procedures a l lowed 






procedures al lowed 
+ =issue properly addressed, ± =issue possibly source of bias, - =issue l ikely to be source of bias, n/a=data not 





Pooled l ong-term outcome data are deta i led i n  Figure 4A-C. Also at long-term fol low-up 
Staged-PC! was associated with s ignificant lower morta l ity rates as compared with cu lprit­
PCI, and MV-PCI. No sign ificant heterogeneity was observed across tria ls . 
Table 4. Baseline characteristics of included studies 
Age.mean Male,% Diabetes,% Three vessel disease,% Shock,% 
Culprit- MV- Staged-Culprit- MV- Staged-Culprit- MV- Staged- Culprit- MV- Staged- Culprit- MV- Staged-
Strategy PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI 
Prospective studies 
Di Mario,2004 65.3 53.5 84.6 88.2 41 .2 1 1 .5 47. 1 30.8 Exel Exel 
Ochala,2004 65.0 67.0 72.9 75.0 3 1 .3 34. 1 n/a n/a Exel Exel 
Politi,20 1 0  66.5 64.5 64.1 76.2 76.9 80.0 23.8 1 3.8 1 8.5 25.0 29.2 44.6 Exel Exel Exel 
Khattab,2008 65.0 69.0 77.8 75.0 1 5 .6 7.1 48.9 60.7 4.4 3.6 
Retrospective studies 
Cavender,2009 62.0t 60.0t 72. 1 7 1 .5 23.4 24.7 n/a n/a 1 0.3 1 3.8 
Corpus,2004 63.0 n/a n/a 69.2 n/a n/a 1 7.0 n/a n/a n/a n/a n/a 3.4 n/a n/a 
Dziewier,20 1 0  n/a n/a n/a n/a n/a n/a 36.5 3 1 .4 n/a n/a 
Han,2008 61 .0 60.0 79.9 78.5 33.6 33.3 1 6. 1  1 8.3 Exel Exel 
Hannan,201 O* n/a n/a n/a 78.7 75.0 84.2 n/a n/a n/a 26.4 25.7 42. 1 Exel Exel Exel 
Kong,2006 62.0 60.0 72. 1 77.2 20.5 1 6.8 n/a n/a Exel Exel 
Mohamad,20 1 0  n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Poyen,2003 n/a n/a n/a n/a n/a n/a 40.7 1 4.0 Exel Exel 
Qarawani,2008 67.0 66.0 64.0 65.3 1 6.0 1 2.6 44.0 43.2 Exel Exel 
Rigattieri,2007 68.0 64.8 69.6 79.7 32.6 1 5 .6 47.8 29.7 Exel Exel 
Roe,2001 63.0t 64.0t 65.8 77.2 29.1 37.2 n/a n/a 27.8 27.8 
Schaaf,20 1 0  n/a n/a n/a n/a n/a n/a n/a n/a 1 00 1 00 
Toma,20 1 0  64.0t 64.0t 79.4 77.4 20.0 1 1 .5 3 1 .8 25.8 1 .2 1 .8 
Varani 2008 79.8 68.7 67.1 75.0 67.4 67.7 n/a n/a n/a 34.0 35.4 46.9 6.4 1 5.0 4.2 
Summary of baseline mean/percentage for studies included in each pairwise analysis 
Culprit- MV- Staged-Culprit- MV- Staged- Culprit- MV- Staged- Culprit- MV- Staged- Culprit- MV- Staged-
PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI PCI 
Culprit vs. MV-PCI 62.3 60.7 72.7 73.0 23.0 22.4 32.5 28.8 9.4 1 0.2 
Culprit vs. Staged-PCI 69.5 63.9 77.6 79.6 30.5 23.9 27.0 38.0 2.7 2 . 1  
MV vs. Staged-PC I 67.0 66.1 73.6 79.3 2 1 .2 24.8 28.0 43.6 2.9 0.9 
*Different matched popu lations  a re used in  the pairwise comparisons. t=median  instead of mean .  Excl=exel uded 
from a n a lysis, n/a= not avai lable or a n a lyzed. 
The network analysis 
Al l  models had adequate convergence. There was no s ign ificant i nconsistency in either 
short-term morta l ity (p=0.94 in the i nconsistency model, p=0.75 in the node-spl itt ing 
model a nd s imi lar devia nce information criteria for a l l  three models) or long-term 
morta l ity (p=0.90 in the i nconsistency model, p=0.78 in the node-spl itting model and 
simi la r  d eviance information criteria for a l l  three models). 
Culprit vessel only versus multivessel and staged PCI for multivessel disease in STEM! 
Posterior means and 95% credibility intervals for the relative effects (OR) are shown for 
each comparison and both short- and long-term mortality in Figure 3 and 4. 
In addition, the rank-probability of the 3 PCI strategies was investigated. This analysis 
demonstrated that for the primary endpoint short-term mortality the Staged-PC! strategy 
had a 0.9998 probability of being the best treatment as compared with Culprit-PC! 
(second rank probability of 0.94) and MV-PCI (third rank probability of 0.94). For long­
term mortality, the rank-probability analysis also demonstrated that Staged-PC! had 
0.995 probability of being the best treatment as compared with Culprit-PC! (second rank 
probability of 0.990) and MV-PCI (third rank probability of 0.996). 
Culprit only PCI Multivessel PCI 
Stud or Sub rou Events Total Events Total Wei ht 
Prospective studies 
Di Mario 2004 0 1 7  52 0.9% 
Khattab 2008 2 45 28 1 . 5% 
Politi 201 0  7 84 2 65 3.1 %  
Subtotal (95% Cl) 146 145 5.4% 
Total events 9 4 
Heterogeneity: Tau2 = 0.00; Chi2 = 0.52, df = 2 (P = 0.77); 12 = 0% 
Test for overall effect: Z = 1 .08 (P = 0.28) 
Retrospective studies 
Cavender 201 0 1 32 1  25802 246 3134 20.9% 
Corpus 2004 20 354 5 26 5.9% 
Dziewierz 201 0  42 707 9 70 9.2% 
Hannan 201 0  1 0  503 1 7  503 8.9% 
Kong 2006 3 1  1350 5 632 7.0% 
Poyen 2003 2 81 86 1 .5% 
Qarawani 2008 25 4 95 1 .7% 
Roe 2001 1 0  79 17  79 8.1 %  
Schaaf 2010 60 124 19 37 9.7% 
Toma 201 0  94 1983 25 217 14.5% 
Varani 2008 8 1 56 1 2  147 7.3% 
Subtotal (95% Cl) 31164 5026 94.6% 
Total events 1599 360 
Heterogeneity: Tau2 = 0.1 1 ;  Chi2 = 20.44, df = 10 (P = 0.03); 12 = 51 % 
Test for overall effect: Z = 3.04 {P = 0.002) 
Total (95% Cl) 31310 5171 100.0% 
Total events 1608 364 
Heterogeneity: Tau2 = 0.1 1 ;  Chi2 = 24.31, df = 1 3  (P = 0.03); 12 = 47% 
Test for overall effect: Z = 2.69 (P = 0.007) 
Network meta-analysis 
All studies (n=17) 
Odds Ratio 
IV, Random, 95% Cl 
0.98 (0.04, 25.20) 
1 .26 (0. 1 1 ,  14.53) 
2.86 (0.57, 14.27] 
1 .98 [0.57, 6.85] 
0.63 (0.55, 0.73) 
0.25 (0.09, 0.74) 
0.43 (0.20, 0.92) 
0.58 (0.26, 1 .28) 
2.95 [1 .14, 7.62] 
2.15 (0.19, 24.20] 
0.95 (0.10, 8.88) 
0.53 (0.23, 1 .24] 
0.89 (0.43, 1 .85) 
0.38 (0.24, 0.61) 
0.61 (0.24, 1 .53) 
0.62 [0.45, 0.84] 
0.66 [0.48, 0.89] 
0.70 [0.46, 1.14] 
Odds Ratio 
IV, Random, 95% Cl 
• 
• 
0.01 0.1 1 10 1 00 
Favours culprit only PCI Favours multivessel PCI 
Figure 3A. Results of pairwise and network meta-analyses of studies comparing Culprit-PCI vs. MV­
PCI for short-term mortality 
DISCUSSION 
This meta-analysis supports current guidelines advising to perform primary PCI for STEMI 
confined to the culprit vessel only. MV-PCI should be discouraged and significant non­
culprit vessel lesions should only be treated during planned staged procedures. 
Although considered safe, PCI remains associated with potential serious procedural 




Culprit only PCI Staged PCI 
Study or Subgroup Events Total Events Total Weight 
Prospective studies 
Politi 2010  7 84 0 65 7 .1% 
Subtotal (95% Cl) 84 65 7.1% 
Total events 7 0 
Heterogeneity: Not applicable 
Test for overall effect: Z = 1 .73 (P = 0.08) 
Retrospective studies 
Corpus 2004 20 354 3 1 26 38.8% 
Han 2008 1 149 0 93 5.7% 
Hannan 2010 5 259 3 259 28.3% 
Rigattieri 2007 4 46 0 64 6.8% 
Varani 2008 8 156 1 96 1 3.4% 
Subtotal (95% Cl) 964 638 92.9% 
Total events 38 7 
Heterogeneity: Tau2 = 0.00; Chi2 = 2.01 , df = 4 (P = 0.73); 12 = 0% 
Test for overall effect: Z = 2.46 (P = 0.01 ) 
Total (95% Cl) 1048 703 100.0% 
Total events 45 7 
Heterogeneity: Tau2 = 0.00; Chi2 = 3.03, df = 5 (P = 0.69); 12 = 0% 
Test for overall effect: Z = 2.83 (P = 0.005) 
Network meta-analysis 
All studies (n=1 7) 
Odds Ratio 
IV, Random, 95°0 Cl 
1 2.68 [0.71 , 226.19] 
12.68 [0.71, 226.19] 
2.46 [0.72, 8.41 ]  
1 .89 [0.08, 46.85] 
1 .68 [0.40, 7. 10] 
13.66 [0.72, 260.26] 
5.14 [0.63, 41 .72] 
2.71 [1.22, 6.01] 
3.03 [1 .41 , 6.51 ] 
5.33 [2.07, 1 7.01] 
0.01 
Odds Ratio 







0.1 10 1 00 
Favours culprit only PCI Favours staged PCI 
Figure 3B. Results of pairwise and network meta-analyses of studies comparing Culprit-PCI vs. 
Staged-PCI for short-term mortality 
Multivessel PCI Staged PCI 
Studv or Subgroup Events Total Events 
Prospective studies 
Ochala 2004 0 48 0 
Politi 2010 2 65 0 
Subtotal (95% Cl) 1 13  
Total events 2 0 
Heterogeneity: Not applicable 
Test for overall effect: Z = 1 .05 (P = 0.29) 
Retrospective studies 
Corpus 2004 5 26 3 
Hannan 2010  17  503 3 
Varani 2008 12  147 
Subtotal (95% Cl) 676 




1 09 7.4% 
1 26 30.7% 
259 45.4% 
96 1 6.4% 
481 92.6% 
Heterogeneity: Tau2 = 0.00; Chi2 = 1 .66, df = 2 (P = 0.44 ); 12 = 0% 
Test for overall effect: Z = 3.78 (P = 0.0002) 
Total (95% Cl) 789 
Total events 36 7 
590 100.0% 
Heterogeneity: Tau• = 0.00; Chi2 = 1 .66, df = 3 (P = 0.65); 12 = 0% 
Test for overall effect: Z = 3.92 (P < 0.0001 ) 
Network meta-analysis 
All studies (n=1 7) 
Odds Ratio Odds Ratio 
IV, Random, 95% Cl IV, Random, 95% Cl 
Not estimable 
5.1 6  [0.24, 109.55] 
5.16 [0.24, 109.55] 
9.76 [2. 17, 43.94] 
2.98 [0.87, 1 0.28] 
8.44 [1 .08, 66.04) 
5.32 [2.24, 12.65] � 
5.31 [2.31, 12.21] 
7.60 [2.80, 24.90] 
0.01 0.1 1 10 100 
Favours multivessel PCI Favours staged PCI 
Figure 3C. Results of pairwise and network meta-analyses of studies comparing MV-PCI vs. Staged­
PCI for short-term mortality 
Culprit vessel only versus multivessel and staged PCI for multivessel disease in STEMI 
International guidelines therefore recommend using PCI selectively in those cases in 
which the benefit of a revascularization outweighs the risk of complications. For elective 
PCI extensive research has resulted in the consensus that it should be performed 
selectively in significant coronary lesions that cause myocardial ischemia.3.4 For lesions 
that do not induce ischemia, the benefit of revascularization is less clear. In these patients 
an initial conservative medical strategy is likely to be as effective.3A,33 For lesions that do 
not induce ischemia, the benefit of revascularization is less clear. In these patients an initial 
conservative medical strategy is likely to be as effective. Current guidelines indicate that 
MV-PCI should not be performed in hemodynamic stable STEMI patients.3AOnly in patients 
with cardiogenic shock, PCI maybe recommended in all critically stenosed large epicardial 
coronary arteries. However, no randomized data have been published indicating that MV­
PCI is beneficial in cardiogenic shock patients. Because of limited evidence on this subject, 
different opinions exist on the use of MV-PCI for STEMI across centers and operators. This 
is illustrated by a recent analysis of the NCDR database, which found incidences of MV-PCI 
ranging between O up to 38% in some participating centers.20 One potential source of this 
variability may be the result of the operator considering that there were multiple infarct 
related artery lesions/arteries. 
It has been hypothesized that in selected STEMI patients (e.g. cardiogenic shock) PCI of 
non-culprit vessel in the acute phase is able to reduce (border zone) ischemia and improve 
survival.31 •32 In addition, when more than on culprit lesion is suspected, multivessel PCI 
may also beneficial.1 Multivessel PCI may also be more convenient for the patient as no 
secondary procedures are necessary. Further, there are logistic and economic reasons to 
perform multivessel PCI as it may limit staged procedures, reduces length of hospital stays 
and thereby medical costs. However, the present meta-analysis found that multivessel PCI 
during the acute phase of STEMI was associated with higher mortality rates as compared 
with culprit only or staged PCI. A small subanalysis in cardiogenic shock patients also did 
not show any mortality benefit of a multivessel PCI strategy in these patients. 
These results indicate that the possible benefits of multivessel PCI do not outweigh the 
adverse effects associated with this aggressive strategy. These adverse effects are likely to 
be explained by the following factors. 
First, the enhanced thrombotic and inflammatory environment of STEMI contributes to a 
higher risk of procedural complications as compared with elective procedures.34-38 Factors 
that increase that risk are related to the complexity and duration of the procedure, which 
is the case with multivessel PCI for STEMI. Although a secondary staged PCI may also 
relate to an increased risk of complications, our results indicate that the risk associated 
with a secondary staged PCI is lower than an acute PCI. 
Second, when performing multivessel PCI of significant non-culprit vessel, the PCI will be 
performed without objective evidence for the presence of myocardial ischemia. As the 
actual significance of a stenosis may be difficult to determine due to several factors in the 
acute phase of STEMl,38•39 routine multivessel PCI of non-culprit vessel lesions can result 
in PCI of clinical irrelevant lesions. The benefit of not treating non-culprit vessel lesions 
during the acute phase, is that coronary angiograms can be discussed within a joint heart 
team to determine the best strategy for each individual patient.3.4 In case of intermediate 
lesions, additional non-invasive ischemia tests and fractional flow reserve measurements 
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Subtotal (95% Cl) 146 142 6.8% 
Total events 16 9 
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Test for overall effect: Z = 0.85 (P = 0.40) 
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Network meta-analysis 
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Figure 4A. Results of pairwise and network meta-analyses of studies comparing Culprit-PCI vs. MV­
PCI for long-term mortality 
C ulprit only PCI Staged PCI Odds Ratio 
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Figure 4B. Results of pairwise and network meta-analyses of studies comparing Culprit-PCI vs. 
Staged-PCI for long-term mortality 
Culprit vessel only versus multivessel and staged PC! for multivessel disease in STEM! 
Limitations 
Because of l imited randomized data, this meta-analysis  i ncl uded both prospective 
and retrospective studies. As a consequence, the majority of the inc l uded studies 
were retrospective cohort ana lyses. The i ncl usion of stud ies with d ifferent desig ns and 
retrospective studies is l ike ly to have induced heterogeneity in the resu lts, as i l l u strated 
by the d ifferences found between prospective and retrospective stud ies. Fu rther, in 
most stud ies the operator's intent to perform one of the three PCI strategies was not 
prospectively registered and may be influenced by important patient characteristics for 
which we were not ab le to adjust. The resu lts and conclusions should be interpreted with 
these l imitations in mind. However, we have carried out a network ana lyses to assess the 
robustness of our findings and combin ing direct and i nd i rect evidence about the th ree 
strategies. In this ana lysis, Staged-PCI was a lso consistently associated with s ign ificant 
lower morta l ity rates at both short- and long-term fol low-up as compared with Cu lprit­
PCI and MV-PCI. On ly the comparison between Cu lprit-PC! and MV-PCI for short-term 
morta l ity lost sign ificance. Add itional  ana lyses demonstrated that this was not due to 
the indirect comparisons, but due to the fact that the d i rect comparison in the network 
ana lysis was performed according to the Bayesian instead of the DerSimonian and La i rd 
method. 
Furthermore, the ana lyses between Culprit-PC! and MV-PCI in the inc l uded stud ies were 
primari ly focused on the index PCI procedure. Therefore in some studies a lso staged PCI 
was a l lowed in the Culprit-PC! g roup. Th is may have i nfluenced the resu lts; however on ly 
the Culprit-PC! vs. MV-PCI and not the other pai rwise comparisons. I n  addition ,  when 
Multivessel PCI Staged PCI 
Stud or Sub rou Events Total Events 
Prospective studies 
Ochala 2004 0 48 0 
Politi 2010 6 65 4 
Subtotal (95% Cl) 1 1 3  
Total events 6 4 
Heterogeneity: Not applicable 
Test for overall effect: Z = 0.65 (P = 0.51 ) 
Retrospective studies 
Corpus 2004 5 26 12  
Hannan 2010 36 503 10  
Mohamad 2010 2 7 2 
Varani 2008 24 142 3 
Subtotal (95% Cl) 678 
Total events 67 27 
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Figure 4C. Results of pairwise and network meta-analysis of studies comparing MV-PCI vs. Staged-PCI 




excluding studies who allowed staged PCI procedures or did not provide information 
on this, still a significant short term mortality benefit of Culprit-PC! over MV-PCI was 
observed. Finally, the role of timing of staged PCI procedures, CABG, and use of non­
invasive ischemia testing in the management of MVD were not investigated nor discussed 
in the majority of the studies. 
In conclusion, this meta-analysis supports current guidelines discouraging performance of 
multivessel primary PCI for STEMI. When significant non-culprit vessel lesions are suitable 
for PCI, they should only be treated during staged procedures. More prospective research 
should be performed to investigate which strategy is superior, in both hemodynamic 
stable and unstable STEMI patients (CABG vs. Culprit-PC! vs. Staged-PC! vs. MV-PCI). We 
therefore propose a prospective international registry to investigate these strategies. To 
facilitate intention-to-treat comparisons between the different strategies for multivessel 
PCI, this registry should focus on registering the operator's intent to perform one of the 
strategies at the time of the initial PCI. 
Culprit vessel on ly versus multivessel and staged PCI for multivessel disease in STEMI 
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Primary percutaneous coronary intervention (PCI) is effective in opening the infarctrelated 
artery in patients with myocardial infarction with ST-segment elevation. However, 
the embolization of atherothrombotic debris induces microvascular obstruction and 
diminishes myocardial reperfusion. 
Methods 
We performed a randomized trial assessing whether manual aspiration was superior 
to conventional treatment during primary PCI. A total of 1071 patients were randomly 
assigned to the thrombus-aspiration group or the conventional-PC! group before 
undergoing coronary angiography. Aspiration was considered to be successful if there 
was histopathological evidence of atherothrombotic material. We assessed angiographic 
and electrocardiographic signs of myocardial reperfusion, as well as clinical outcome. The 
primary end point was a myocardial blush grade of 0 or 1 (defined as absent or minimal 
myocardial reperfusion, respectively). 
Results 
A myocardial blush grade of 0 or 1 occurred in 1 7.1 % of the patients in the thrombus­
aspiration group and in 26.3% of those in the conventional-PC! group (P<0.001 ). Complete 
resolution of ST-segment elevation occurred in 56.6% and 44.2% of patients, respectively 
(P<0.001 ). The benefit did not show heterogeneity among the baseline levels of the 
prespecified covariates. At 30 days, the rate of death in patients with a myocardial blush 
grade of 0 or 1, 2, and 3 was 5.2%, 2.9%, and 1.0%, respectively (P = 0.003), and the rate 
of adverse events was 14.1 %, 8.8%, and 4.2%, respectively (P<0.001 ). Histopathological 
examination confirmed successful aspiration in 72.9% of patients. 
Conclusions 
Thrombus aspiration is applicable in a large majority of patients with myocardial infarction 
with ST-segment elevation, and it results in better reperfusion and clinical outcomes than 
conventional PCI, irrespective of clinical and angiographic characteristics at baseline. 
(Current Controlled Trials number, ISRCTN16716833.) 
--------------------- Thrombus aspiration during primary PCI 
INTRODUCTION 
Acute myocard ial  infarction with ST-segment elevation is caused by the rupture or erosion 
of an atherosclerotic plaque, in itiating intra l umina l  thrombosis resu lting in pa rtia l  o r  
complete occlusion of  a coronary artery. 1 -3 Primary percutaneous coronary intervention 
(PCI)  is the preferred treatment for myocard ia l  infarction with ST-segment elevation and is 
effective in  opening the infarct-related a rtery.4-6 However, microvascu lar obstruction  with 
d imin ished myocardia l  perfusion occurs in a large proportion of patients with a patent 
epicardia l  vessel after primary PCI, and this event is associated with an increased i nfarct 
size, reduced recovery of ventricular function, and increased morta l ity.7-1 1 
Microvascu lar obstruction is related to the embol ization of plaque or thrombotic materia l 
downstream in  the i nfarct-related artery. 1 2• 1 3 Embol ization can occur spontaneously or by 
means of mechan ical fragmentation during PCl. 1 2-1 5 One coronary angiographic techn ique 
used to assess perfusion in  the myocard ia l  tissue is myocard ia l  b lush grading.7•9• 1 1  I n  c l in ica l  
practice, e lectrocard iographic (ECG) ana lysis of  the  degree of  resolution of  ST-segment 
elevation after PCI i s  often used.8•1 0•1 1  
The h igh frequency of suboptimal  myocard ia l  reperfusion after primary PCI has resu lted 
in  the development of va rious devices to protect the microcircu lation. 1 6-24 A 6-French­
compatible manualaspiration catheter is practica l for this pu rpose, s ince it is relatively 
flexible and nontraumatic in use. Many previous tria ls  have used findings on coronary 
angiography as selection criteria and have not performed a systematic ana lysis of 
the materia l retrieved during aspiration .  We therefore eva l uated the use of a manua l­
aspiration catheter to improve myocard ia l  perfusion d uring primary PCI in patients with 
myocardia l  infarction with ST-segment elevation. Our patients were randomly assigned 
to a treatment group before coronary angiogra phy was performed and therefore without 
consideration of angiographic selection criteria (such as the presence of a vis ible th rombus 
on angiography), and we conducted a h istopathological ana lysis of  the retrieved materia l 
as an additiona l eva luation of procedura l  efficacy.25 
METHODS 
Study Design and Population 
The Thrombus Aspiration du ring Percutaneous Coronary I ntervention in Acute Myocard ia l  
I nfarction Study (TAPAS) was a s ing le-center, prospective, randomized, open tria l involving  
the  bl inded eva luation of  end  points.25 The institutional review board of  the  University 
Medica l Center Groningen (Groningen, the Netherlands) approved the study. Al l  patients 
provided written informed consent. 
A l l  consecutive patients presenting to the Un iversity Medica l Center Groningen with a 
possible myocardia l  i nfarction with ST-segment elevation between January 2005 and 
December 2006 were considered el ig ible for participation. The inclusion criteria were 
symptoms suggesting acute myocard ia l  ischemia lasting more than 30 minutes, the onset 
of symptoms less than 1 2  hours previously, and ST-segment e levation of more than 0 . 1  mV 
in  two or more leads on the ECG. The exclusion criteria were the performance of a rescue  
PC I  after thrombolysis, the known existence of  a d isease resu lting in  a l ife expectancy of 
less than 6 months, and the lack of informed consent. 
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I 1 1 61 Patients were assessed for el igibi lity I 
90 Patients did not meet 
el igibi l ity criteria 
61 Had a diagnosis other 
than STEMI 
1 1  Underwent rescue PCI 
9 Had a known life -
expectancy of <6 mo 
S Did not provide written 
informed consent 




I 1 071  With STEMI were randomly assigned I to a treatment group 
535 Were assigned to 536 Were assigned to 
thrombus aspiration conventional PCI 
After diagnostic After diagnostic 
angiography: angiography: 
33 Did not under- 33 Did not under-
go PCI go PCI 
19 Had no cul- 17 Had no cul-
prit lesion - - prit lesion 
1 1  Had conser- 12 Had conser-
vative treat- vative treat-
ment ment 
3 Had acute 4 Had acute 
CABG CABG 
502 Underwent primary PCI 503 Underwent primary PCI 
295 Underwent thrombus aspira- 485 Underwent bal loon dilation 
tion followed by direct stentin� followed by direct stenting 
1 53 Underwent thrombus aspira- 12 U nderwent conventional PCI 
tion with additional balloon with additional thrombus 
di lation aspiration 
54 Had crossover to conventional 6 Had crossover to thrombus 
PCI aspiration 
490 Could be assessed in the 490 Could be assessed in the 
core laboratory for myocardial core laboratory for myocardial 
blush grade blush grade 
486 Could be assessed for resolution 496 Could be assessed for resolution 
of ST-segment elevation and for of ST-segment elevation and for 
residual ST-segment deviation residual ST-segment deviation 
529 Had clin ical follow-up 531 Had cl inical follow-up 
535 Were included in the 536 Were included in the 
intention-to-treat analysis intention-to-treat analysis 
Figure 1. Trial flow diagram 
80 
-------------------- Thrombus aspiration during primary PC! 
Randomization and Treatment 
Before diagnostic angiography was performed, patients were randomly assigned 
to undergo thrombus aspiration during PCI or conventional PCI, with the use of a 
computerized voice-response system. The randomization code was developed by means 
of a number generator used to select randomly permuted blocks of three to six patients, 
which were then stratified by the interventional cardiologist to achieve a balanced group 
assignment with regard to both the treatment group and the cardiologist performing the 
procedure.25 
For all patients, the first procedural step was the passing of a floppy, steerable guidewire 
through the target lesion. In patients in the conventional-PC! group, this step was followed 
by balloon dilation to establish antegrade flow. In patients in the thrombus-aspiration 
group, this step was followed by the advancing of the 6-French Export Aspiration Catheter 
(Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous 
aspiration; when necessary for stent delivery, balloon dilation was performed before 
stenting. In all patients, after the restoration of antegrade flow, intracoronary nitrates were 
given to ensure maximal epicardial vasodilation, in order to determine the size and length 
of the stent and to facilitate stent placement. All placed stents were bare-metal stents. 
Pharmacologic treatment before PCI included the administration of aspirin (a loading 
dose of 500 mg), heparin (5000 IU), and clopidogrel (a loading dose of 600 mg). Patients 
also received the glycoprotein llb/llla inhibitor abciximab, with the dose based on 
body weight, unless contraindicated, and additional heparin, with the dose based on 
the activated clotting time. Standard therapies after PCI included aspirin, clopidogrel, 
beta-blockers, lipid-lowering agents, and angiotensin-converting-enzyme inhibitors or 
angiotensin-II-receptor blockers, according to current guidelines.6 
End Points, Assessment of Outcomes, and Definitions 
The primary end point was the postprocedural frequency of a myocardial blush grade 
of 0 or 1 as detailed below.25 Secondary end points were the postprocedural frequencies 
of a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 3, complete resolution 
of ST-segment elevation, the absence of persistent ST-segment deviation, targetvessel 
revascularization, reinfarction, death, and the combination of major adverse cardiac 
events by 30 days after randomization. 
Coronary angiography was performed before and after the PCI. TIMI flow grades were 
assessed as previously described.26 Myocardial blush grades were assigned as previously 
described by Van 't Hof et al.7: 0, no myocardial blush; 1, minimal myocardial blush or 
contrast density; 2, moderate myocardial blush or contrast density but less than that 
obtained during angiography of a contralateral or ipsilateral non-infarct-related coronary 
artery; and 3, normal myocardial blush or contrast density, similar to that obtained during 
angiography of a contra lateral or ipsilateral non-infarctrelated coronary artery. Persistent 
myocardial blush suggests leakage of contrast medium into the extravascular space and 
is given a grade of 0. Angiographic evidence of a thrombus was assessed according to the 
criteria summarized by Mabin et al.27 Data from the coronary angiogram were analyzed at 
an independent core laboratory (Cordinamo). 25 
A 12-lead ECG was acquired at presentation and 30 to 60 minutes after PCI, and the ST-
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Table 1 .  Baseline demographic, clinical and angiographic characteristics* 
Characteristic Thrombus aspiration Conventional PCI P-va lue 
(N=535) (N=536) 
Cl in ical 
Age, yr 63± 1 3  63± 1 3 0.36 
Male sex, N/total (%) 363/535 (67.9) 392/536 (73. 1 )  0.06 
History, N/total (%) 
Hypertension 1 7 1 /5 1 7  (33 . 1 ) 1 95/526 (37. 1 )  0. 1 8  
Diabetes mel l itus 56/530 ( 1 0.6) 67 /532 ( 1 2.6) 0.30 
Hypercholesterolemia 1 1 5/485 (23.7) 1 30/480 (27. 1 )  0.23 
Myocardial infarction 50/528 (9.5) 57 /533 ( 1 0.7) 0.5 1 
PCI 39/526 (7.4) 38/53 1 (7.2) 0.87 
CABG 1 7  /529 (3.2) 22/533 (4. 1 )  0.43 
Cerebrovascular disease 1 7  /5 1 7  (3.3) 21 /522 (4.0) 0.53 
Cerebrovascular disease in fami ly 235/509 (46.2) 229/5 1 4  (44.6) 0.58 
Current smoking, N (%) 2 1 3/463 (46.0) 225/469 (48.0) 0.57 
Preinfarction angina 258/483 (53 .4) 233/476 (48.9) 0. 1 7  
Total ischemic time, min 0.6 1 
Median 1 90 1 85 
Interquarti le range 1 1 0-270 1 07-263 
Body mass index t 27±4 27±4 0.69 
Systolic blood pressure - mmHg 1 28±26 1 30±26 0.34 
Diastolic blood pressure - mmHg 74± 1 5  75± 1 6 0.65 
Heart rate - bpm 78±1 8 78± 1 9  0.98 
Angiographic 
N of diseased vessels, N/total (%) 0.84 
0 1 3/533 (2.4) 1 0/534 ( 1 .9) 
1 66/533 (3 1 . 1 )  1 57 /534 (29.4) 
2 1 75/533 (32.8) 1 74/534 (32.6) 
3 1 78/533 (33 .4) 1 93/534 (36. 1 )  
I nfarct related vessel, N/total (%) 0.62 
left anterior descending artery 221 /5 1 5  (42.9) 223/5 1 7  (43 . 1 )  
left circumflex artery 93/5 1 5  (1 8. 1 )  79/5 1 7  ( 1 5.3) 
right coronary artery 1 89/5 1 5  (36.7) 204/5 1 7  (39.5) 
other 1 2/5 1 5  (2.3) 1 1 /5 1 7  (2. 1 ) 
TIMI flow, N/tota l  (%) 0.23 
0 or 1 288/526 (54.7) 3 1 6/53 1  (59.5) 
(Continued) 
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Thrombus, N/total (%) 
Procedura l  
Door-to-bal loon time, min 
Median 
I nterquartile range 
Duration of fluoroscopy, min 
Median 
Interquarti le range 
Admin istration of glycoprotein l i b/I l la inh ibitor, N/ 
tota l (%) 
Stent implantation, N/tota l (%) 
Length of stented segment, mm 
Diameter of stented segment, mm 
I ntra-aortic ba l loon pump, N/total (%) 
Postprocedura l  TIMI flow g rade 3, N/total (%) 
l ntraprocedura l  compl ications, N/tota l (%) 
Side-branch occlusion 




1 02/526 ( 1 9.4) 
1 36/526 (25.9) 








3.0± 1 . 1 
23/479 (4.8) 
43 1 /501 (86.0) 
5/502 ( 1 .0) 
0 
1 /502 (0.2) 
Conventional  PCI 
(N=536) 
85/53 1  ( 1 6.0) 














1 /503 (0.2) 
P-value 
0. 1 4  
0.92 
0.64 









Plus-minus values are means ±SD. Data for total ischemic time were avai lable for 492 patients i n  the thrombus­
aspirationgroup and 488 patients in the conventional percutaneous-coronary-intervention (PCI) group; for body­
mass index, 488 and 490 patients, respectively; for systol ic and diastol ic blood pressures, 5 1 4  and 522; for heart 
rate, 5 1 2  and 522; for time from hospital entry to first bal loon inflation or aspiration, 502 and 503; for duration of 
fluoroscopy, 490 and 495; and for length and diameter of stented segment, 479 and 476. CABG denotes coronary­
a rtery bypass grafting, and TIMI  Thrombolysis in Myocardia l  I nfarction. 
t The body-mass index is the weight in k i lograms divided by the square of the height in meters. 
segmentson the postprocedu ra l ECGwerecompared with thoseon the ECG at presentation. 
The degree of resol ution of ST-segment e levation was categorized as complete (> 70%), 
partial (30 to 70%), or none (<30%).8 Persistent ST-segment deviation, defined as the sum 
of the ST-segment depression and the ST-segment e levation, was categorized as les s  than 
2 mm, 2 to 1 0  mm, and more than 1 0  mm. The presence or absence of pathologic Q waves 
was a lso recorded. 
Fi ltered, aspirated material was fixed i n  formal in for 24 hours. H istologic sections  were 
cut and sta ined with hematoxyl in and eosin for examination with a l ight microscope 
(magnification, x1 00). lmmunosta in ing was performed to optimize the visual ization of 




not effective on the basis of the presence of atherothrombotic material in  the aspirate 
samples. The material was classified as from a thrombus conta in ing only platelets, a 
thrombus with an eryth rocyte component, or a th rombus with plaque, as wel l  as according 
to length :  smal l  (<0.5 mm), moderate (0.5 to 2 mm), or large (>2 mm). 
Fol low-up data at 30 days were obta ined from hospita l records and th rough telephone 
interviews. Major bleeding was defined as symptomatic bleeding i n  a critica l a rea or 
organ, b leed ing causing a decrease in hemog lobin level of 2.0 mmol or more per l iter, or 
b leed ing that led to blood transfusion. Reinfarction was defined as recu rrent symptoms 
with new ST-segment e levation and elevation of the levels of cardiac markers to at least 
twice the upper l imit of the normal range. Target-vessel revascularization was defined as 
ischemia-driven revascularization of the i nfarct-related artery, performed by means of PCI 
or surgery (e.g., coronary-artery bypass g rafting) during the fol low-up period. A major 
adverse card iac event was defined as death, rei nfa rction, or ta rget-vessel revascu la rization. 
Statistical Analysis 
We estimated that we would have to enro l l  1 080 patients to ach ieve a power of 80%, 
with a twosided significance level of 0.05, to detect a 25% reduction in the primary end 
point i n  patients who underwent thrombus aspiration as compared with those who 
underwent conventional PCI, assuming a 30% rate of myocard ial blush g rade of 0 or 1 
in the conventional-PC! group.25 The study committee (see the Appendix) performed a 
planned interim ana lysis after 300 patients had been enrol l ed .  The stopping l imit was a 
d ifference of more than 25% in the primary end point between the two groups, with a P 
va lue of l ess than 0.0 1 . 
Categorical variables were compared with the use of the ch i-square test or Fisher's exact 
test. Continuous va riables were compared with the use of a two-ta i led Student's t-test. 
Prespecified subgroup ana lyses were performed by means of log istic-regression ana lyses 
with formal tests for interaction.28 We ana lyzed data for a l l  patients who were randomly 
assigned to a treatment g roup and for whom outcome data were avai lab le. Exploratory 
ana lyses of the association between the surrogate and c l in ica l  end points were performed 
by means  of logistic-regression ana lysis. Two-sided s ignificance tests were used. P va lues 
of less than 0.05 were considered to indicate statistica l s ignificance. SPSS software, version 
1 2.0. 1 , was used in al l statistica l ana lyses. 
Data management and statistical ana lyses were performed by staff of the data coord inating 
center (see the Appendix) and the principal i nvestigator, who vouches for the accuracy 
and completeness of the data . 
RESULTS 
Study Population 
During the study period, 1 1 61  patients were considered for i nclusion, and 1 07 1  patients 
were en rol led accord ing to the el ig ibi l ity criteria (Fig. 1 ) . Before coronary angiography, 
patients were randomly assigned to undergo either th rombus aspiration during PCI 
(535 patients) or conventional  PCI (536 patients) . The base l ine c l in ica l and angiographic 
characteristics were s imi lar in the two groups (Table 1 ) . 
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Thrombus aspiration during primary PCI 
Figure 2. Myocardial Reperfusion 
Data on Angiography and 
Electrocardiography, According 
to Treatment Group. 
The percentages of patients are 
shown according to myocardial 
blush grade on the angiogram 
(A) and the degree of resolution 
of ST-segment elevation (B) and 
persistent ST-segment deviation 
(C) on the electrocardiogram. PCI 






On the basis of the in it ia l  angiographic findings, 33 patients (approximately 6%) in each 
group did not undergo PCI. In  the thrombus-aspiration g roup, aspiration and d i rect stent 
implantation were performed in 295 patients (55 . 1  %), ba l loon d i lation was performed 
before stent implantat ion in 1 53 patients (28.6%), and conventional  PCI was performed in  
54 patients ( 1 0 . 1 %) i n  whom the operator judged the target artery to be too sma l l  or too 
tortuous to permit use of the aspi ration catheter (Fig. 1 ). 
Data about the procedu res and intraprocedu ra l  compl ications a re shown in Table 1 .  None 
of the compl ications were thought to be related to the aspiration device used. There were 
no intraprocedura l  deaths or strokes. 
Thrombus Conventional 
Aspiration PCI 
Baseline Characteristic no./total no. 
All patients 84/490 1 29/490 
Sex 
Male 52/337 9 1/356 
Female 32/1 53 38/134 
Age 
>65yr 52/202 78/223 
s65yr 32/288 51 /267 
Total ischemic time 
;ie 180 min 58/256 75/243 
< 180 min 20/222 46/231 
Infarct-related vessel 
RCA 1 8/1 77 42/199 
Other 66/3 1 3  87/291 
Infarct-related segment 
Proximal lesion 41 /290 72/307 
No proximal lesion 43/200 57/183 
TIMI flow grade before PCI 
O ar 1 62/275 96/306 
2 or 3 22/2 1 0  3 1 / 179 
Thrombus seen on angiography 
Yes 39/236 60/221 
No 44/241 68/262 
0.1 















1 .0 2.0 5.0 
Conventional 
PCI Better 
0.65 (0.5 1 -0.83) 
0.60 (0.44-0.82) 
0.74 (0.49-1 .1 1 )  
0.74 (0.5 5-0.99) 
0.58 (0.3 9-0.88) 
0.73 (0.5 5-0.99) 
0.45 (0.2 8-0.74) 
0.48 (0.2 9-0.81) 
0.71 (0.5 3-0.93) 
0.60 (0.4 3-0.85) 
0.69 (0.4 9-0.97) 
0.72 (0.5 5-0.95) 
0.60 (0.3 6-1 .0 1 }  
0.61 (0.43-0.87) 










Figure 3. Risk Ratios for the Primary End Point, According to Prespecified Clinical or Angiographic 
Subgroup 
Myocardial Reperfusion 
The postprocedura l  myocardia l b lush grade cou ld be assessed i n  980 (490 i n  each g roup) 
of the 1 005 patients (97.5%) who underwent PCI. A myocard ia l  b lush grade of O or 1 
occurred in 84 of the 490 patients ( 1 7 . 1  %) i n  the thrombus-aspiration group and i n  1 29 
of the 490 patients (26.3%) in the conventional-PC! group (ri sk ratio, 0.65; 95% confidence 
interva l [Cl], 0.5 1 to 0.83; P<0.00 1 )  ( Fig. 2A). 
The ECGs obta ined at basel ine and after the procedu re were analyzed in 982 of the 
1 005 patients (97.7%) who underwent PCI. The median time from treatment to the 
postprocedura l  ECG was 44 minutes (interquarti le range, 25 to 63) in the thrombus­
aspiration group and 43 minutes ( interquart i le range, 25 to 6 1 ) in the conventional-PC! 
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group (P = 0.40). Complete ST-segment resolution occurred in 275 of the 486 patients 
(56.6%) in the thrombus-aspiration group and 219 of the 496 patients (44.2%) in the 
conventional-PC! group (risk ratio, 1.28; 95% Cl, 1. 13 to 1 .45; P<0.001) (Fig. 2B). Similarly, 
258 of the 486 patients (53. 1 %) in the thrombus-aspiration group had no persistent ST­
segment deviation, as compared with 201 of the 496 patients (40.5%) in the conventional­
PCI group (risk ratio, 1.31; 95% Cl, 1. 14 to 1 .50; P<0.001) (Fig. 2C). In the thrombus­
aspiration group, 119 of 486 patients (24.5%) did not have pathologic Q waves on the 
ECG, as compared with 79 of 496 patients (15.9%) in the conventional-PC! group (risk ratio, 
1 .54; 95% Cl, 1. 19 to 1 .99; P = 0.001 ). 
There was no evidence that the benefit with regard to the primary end point was 
heterogeneous among the baseline levels of the prespecified covariates. There were no 
significant interactions for any subgroups (Fig. 3). 
Histopathological Features 
Table 2 shows the rate of retrieval and the histopathological characteristics and size of 
the aspirate, according to initial angiographic findings in the patients who underwent 
aspiration. Histopathological examination was performed in 454 patients, which in 331 
patients (72.9%) showed atherothrombotic material. 
Clinical Outcome at 30 Days 
In the thrombus-aspiration group and the conventional-PC! group, there was major 
bleeding in 20 of 529 patients (3.8%) and 18 of 531 patients (3.4%), respectively (risk ratio, 
1.11; 95% Cl, 0.60 to 2.08; P = 0.11); death in 11 of 529 (2.1%) and 21 of 531 (4.0%) (risk 
ratio, 0.52; 95% Cl, 0.26 to 1 .07; P = 0.07); reinfarction in 4 of 529 (0.8%) and 10 of 531 
(1.9%) (risk ratio, 0.40; 95% Cl, 0. 13 to 1 .27; P = 0.11 ); target-vessel revascularization in 24 
of 529 (4.5%) and 31 of 531 (5.8%) (risk ratio, 0.77; 95% Cl, 0.46 to 1 .30; P = 0.34); and major 
adverse cardiac events at 30 days in 36 of 529 (6.8%) and 50 of 531 (9.4%) (risk ratio, 0.72; 
95% Cl, 0.48 to 1 .08; P = 0. 12). The rates of death and major adverse cardiac events at 30 
days were both significantly related to myocardial blush grade, resolution of ST-segment 
elevation, and ST-segment deviation (P = 0.003 for the association between death and 
myocardial blush grade; P<0.001 for all other associations) (Fig. 4). 
DISCUSSION 
The results of our randomized trial show that effective manual aspiration of 
atherothrombotic material is feasible in a large majority of patients presenting with 
myocardial infarction with STsegment elevation. As compared with balloon angioplasty 
as an initial step in primary PCI, aspiration before stenting results in improved myocardial 
reperfusion, documented by a clear improvement in the myocardial blush grade, 
increased resolution of ST-segment elevation, and reduced residual ST-segment deviation. 
This beneficial effect of aspiration was consistently present in all patients, irrespective of 
baseline clinical or angiographic characteristics such as age, sex, infarctrelated coronary 
artery, preprocedural TIMI flow, or visible thrombus on the angiogram. Atherothrombotic 




the ma in constituent of the retrieved materia l  was platelets. 
Our data confirm the prognostic va l ue of the myocard ia l  b lush g rade and degree of 
resolution of the ST-segment elevation  after reperfusion therapy, si nce these variables 
were strongly related to the 30-day rates of death and major adverse cardiac events.7·8 
The trends we found for these rates were expected from the d ifferences between the 
two groups in va riables reflecting myocardia l  reperfusion. S ince a la rger proportion of 
patients in the thrombus-aspiration g roup than in the conventiona l-PC! g roup did not 
have pathologic Q waves on the postprocedura l  ECG, this benefit may be mediated, at 
least in part, by myocard ial sa lvage. 
Table 2. Histopathological characteristics of coronary-artery thrombi from initial findings on 
coronary angiography in patients undergoing thrombus aspiration* 
Characteristic 
Total patients, N 
Aspirate col lected, N (%) 
Composition of aspirate 
Platelet, N (%) 
<0.5 mm, % 
0.5-2.0 mm, % 
>2.0 mm, % 
Erythrocyte, N (%) 
<0.5 mm, % 
0.5-2.0 mm, % 
>2.0 mm, % 
Plaque, N (%) 
<0.5 mm, % 
0.5-2.0 mm, % 
>2.0 mm, % 
I nfa rct-Related Vessel TIMI F low Grade Thrombus seen Patients, 
N LAD Cx RCA Other O or 1 2 or 3 Yes No 
454 
331 (72.9) 
201 75 1 7 1 7 
1 38 49 1 40 4 
(68.7) (65.3) (8 1 .9) (57. 1 )  
224 (67.7) 1 0 1  3 3  8 8  2 
70.5 72.3 72.7 67.0 1 00 
24. 1 2 1 .8 1 8.2 29.6 0 
5.4 5.9 9.1 3 .4 0 




57 ( 1 7.2) 
33.3 
45.6 
2 1 . 1  
7.7 
42.9 25.0 1 1 .5 
0 
0 
57 . 1  75.0 80.8 1 00 
23 8 26 0 
39.1  25.0 30.8 
34.8 62.5 50.0 
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* The 454 patients undergoing thrombus aspiration were 448 patients in the thrombus-aspiration g roup and 6 
patients in the conventional percutaneous-coronary-intervention group. Data are reported for the patients who 
had coronary angiographic data at baseline. "Platelet" was defined as a thrombus composed only of platelets, 
"erythrocyte" as a thrombus with bands of erythrocytes, and "plaque" as a thrombus with any fragment of vessel wal l ,  
cholesterol crysta ls, inflammatory cel ls, or col lagen tissue. Al l mi l l imeter measurements refer to length. Cx denotes 
left circumflex artery, LAD left anterior descending a rtery, and RCA right coronary artery. 
The c l in i ca l  importance of embo l ization of atheroth rombotic materia l  from unstable 
plaques in patients with myocard ia l  i nfarction with ST-segment elevation has been 
recogn ized, 1 2•1 3 and embolic protection during PCI in such patients has been tested with 
va rious devices in smal l  or med ium-sized tria ls, with d iverse resu lts. 1 6-24 This va riation 
in resu lts may be in part related to the device used, s ince tria ls involving manual­
aspiration devices have a l l  shown favorable effects of aspiration on myocard ial-perfusion 
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variables.20-22 Most of the previous trials have enrolled patients who were selected on 
the basis of angiographic features, 1 6-1 9•21 -24 since it was assumed that patients with a large 
thrombotic burden are identified on angiography and will particularly benefit from the 
treatment. Our data show that angiographic variables such as TIMI flow or the presence 
of a visible thrombus are not predictors of patients in whom aspiration will be effective. 
Our findings therefore support the concept that the presence of a thrombus plays an 
important role in the pathophysiological characteristics of most patients with myocardial 
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Figure 4. Rates of Death and Major Adverse Cardiac Events, According to Myocardial Blush Grade and 
ST-Segment Variables 
We powered our trial on the assumption of a 25% reduction in the frequency of myocardial 
blush grade of O or 1 in the thrombus-aspiration group. Our data confirm a benefit of 
this magnitude, albeit with a somewhat lower incidence of myocardial blush grade of 0 
or 1 in the conventional-PC! group than expected: 26.4% instead of 30%. This may be 
explained by the administration of pharmacotherapy immediately after the diagnosis 
of myocardial infarction with ST-segment elevation was made, followed by the use of 
abciximab at the start of the PCI procedure. Our trial provides a systematic analysis of the 
role of coronary thrombi in a representative, contemporary population with myocardial 
infarction with ST-segment elevation, since aspiration was performed soon after the 
onset of symptoms in a large cohort of patients who were not selected on the basis of 
angiographic characteristics and were randomly assigned to a treatment group. The rate 
of retrieval of atherothrombotic material (73%) is somewhat lower than that reported 
in smaller, nonrandomized pathological thrombectomy studies of patients who had 
myocardial infarction with ST-segment elevation, 1 3•29 possibly because of the selection of 





Our histopathological findings confirm earlier observations that thrombi predominantly 
composed of platelets are common in patients who have myocardial infarction with ST­
segment elevation.1 3•29•30 Platelets are thought to play an importantrole in embolization 
and microvascular dysfunction. 1 2•3 1  Mechanical removal of a thrombus before PCI reduces 
the existing source of embolization but does not address platelet aggregates generated 
after PCI. These can be abolished with the use of platelet inhibitors.32 It is therefore 
possible that the combined use of aspiration and glycoprotein lib/Illa inhibitors will have 
a synergistic effect. 
The platelet thrombi were mostly small or moderate in size, whereas the erythrocyte-rich 
thrombi were moderate or large in size. This may reflect the process whereby a platelet 
thrombus forms by means of the adherence and aggregation of platelets on a disrupted 
lesion, followed by the development of thrombus through the deposition of erythrocytes 
in the stagnant blood flow over the platelet thrombus.1 •33•34The association between large 
erythrocyte-rich thrombi and a TIMI flow grade of O or 1 before PCI is consistent with this 
mechanism. 
We could not identify atherothrombotic material in 27% of patients in whom aspiration 
was performed. This may be due to a variety of mechanisms. First, a thrombus may 
be dissolved by endogenic or pharmacologic antithrombotic or fibrinolytic agents. 
Second, a thrombus may break off and embolize before PCI or during PCI, owing to the 
guidewire or aspiration device. In some patients in our trial, mechanical resistance at the 
site of occlusion prevented passage of the aspiration device through the infarct-related 
segment. It seems likely that, in some patients who have myocardial infarction with ST­
segment elevation, a high-grade, nonthrombotic, unstable atherosclerotic plaque causes 
the coronary obstruction (e.g., a plaque with hemorrhage).33•34 The patients who did not 
have a response to aspiration might also not have shown reperfusion after thrombolytic 
therapy. Third, within hours after formation, a thrombus may be covered by mononuclear 
cells that stop the deposition of platelets.35 Finally, fragile material may disintegrate while 
passing through the catheter or filter or in the collection bottle. 
Ou rtrial has several Ii mitations. First, it represents a sing le-center experience using surrogate 
end points. However, the fact that the surrogate end points of myocardial blush grade and 
the electrocardiographic variables of reperfusion were clearly associated with the rates of 
death and major adverse cardiac events supports the validity of using such end points in 
studies of patients who have myocardial infarction with ST-segment elevation. Second, 
to prevent selection bias, we performed randomization before coronary angiography. As 
a consequence, some patients did not undergo PCI or received the alternative therapy. 
This may have diluted to some extent the positive effects of aspiration, but it makes our 
findings applicable to a general population with myocardial infarction with ST-segment 
elevation. Third, it cannot be ruled out that extractable thrombi differ from thrombi in 
situ. Finally, it has been suggested that primary stenting without balloon predilation in 
patients who have myocardial infarction with ST-segment elevation results in improved 
distal flow and reduced embolization. Our study was not designed to evaluate the effect 
of dilation before stenting. This issue needs further investigation in a randomized setting. 
-------------------- Thrombus aspiration during primary PCI 
In conclusion, we found that manual thrombus aspiration can be performed in a large 
majority of patients presenting with myocardial infarction with ST-segment elevation, 
irrespective of their clinical and angiographic features (e.g., a visible thrombus on 
angiography) and results in improved myocardial reperfusion and clinical outcome 
as compared with conventional PCI. The significant relationship we found between 
myocardial and electrocardiographic variables of reperfusion and the rates of death 
and major adverse cardiac events supports the validity of these reperfusion variables 
as surrogate end points in patients who have myocardial infarction with ST-segment 
elevation. The histopathological findings in the aspirate specimens underline the 
importance of antiplatelet therapy in improving the outcome after primary PCI. 
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Percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction can be 
complicated byspontaneous or angioplasty-induced embolisation of atherothrombotic 
material. Distal blockage induces microvascular obstruction and can result in less 
than optimum reperfusion of viable myocardium. The Thrombus Aspiration during 
Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) found 
that thrombus aspiration resulted in improved myocardial reperfusion compared with 
conventional PCI, but whether this benefit improves clinical outcome is unknown. We 
aimed to investigate whether the early efficacy of thrombus aspiration seen in TAPAS 
translated into clinical benefit after 1 year. 
Methods 
Patients with ST-elevation myocardial infarction enrolled at the University Medical 
Centre Groningen were randomly assigned in a 1 :1 ratio to either thrombus aspiration or 
conventional treatment, before undergoing initial coronary angiography. Exclusion criteria 
were rescue PCI after thrombolysis and known existence of a concomitant disease with 
life expectancy less than 6 months. Of the 1071 patients enrolled between January, 2005, 
and December, 2006, vital status at or beyond 1 year after randomisation was available for 
1060 (99%). The primary endpoint was cardiac death or non-fatal reinfarction after 1 year, 
and analysis was by intention to treat. The TAPAS trial is registered with Current Controlled 
Trials number ISRCTN16716833. 
Findings 
Cardiac death at 1 year was 3.6% (19 of 535 patients) in the thrombus aspiration group 
and 6.7% (36 of 536) in the conventional PCI group (hazard ratio [HR] 1 .93; 95% Cl 1. 11-
3.37; p=0.020). 1-year cardiac death or non-fatal reinfarction occurred in 5.6% (30 of 
535) of patients in the thrombus aspiration group and 9.9% (53 of 536) of patients in the 
conventional PCI group (HR 1 .81; 95% Cl 1. 16-2.84; p=0.009). 
Interpretation 
Compared with conventional PCI, thrombus aspiration before stenting of the infarcted 
artery seems to improve the 1-year clinical outcome after PCI for ST-elevation myocardial 
infarction. Funding Medtronic and the Thorax Centre of the University Medical Centre 
Groningen. 
Card iac death and reinfarction after 1 year i n  the TAPAS 
INTRODUCTION 
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion therapy 
for ST-elevation myocardial infarction. Spontaneous or PCl-induced embolisation of 
atherothrombotic material from the culprit lesion into the distal vasculature occurs 
in most patients. Distal blockage induces microvascular obs truction and can result in 
suboptimum reperfusion of viable myocardium.1 In several randomised controlled trials, 
thrombus aspiration has improved myocardial reper fusion compared with conventional 
PCl .2-6 The Thrombus Aspiration during Percutaneous coronary intervention in Acute 
myocardial infarction Study (TAPAS)2 found that thrombus aspiration resulted in improved 
myocardial reperfusion, indicated by the myocardial blush grade and ST-segment analysis 
on the 12-lead electrocardiogram (ECG), compared with conventional PCI. However, data 
from randomised trials that have assessed clinical outcomes are scarce, and several meta­
analyses have shown conflicting results.7•8 The aim of our study was to investigate whether 
the early efficacy of thrombus aspiration translates into clinical benefit after 1 year. 
I 1 1 61 assessed for eligibility I 
... I 90 did not meet eligibility criteria I .. , 
,, 
1 071 STEMI patients randomised I 
+ + 
535 assigned to thrombus aspiration 536 assigned to conventional PCI 
+ + 
Treatment Treatment 
33 no PCI 33 no PCI 
502 primary PCI 503 primary PCI 
295 thrombus aspiration followed 485 bal loon dilation followed 
by direct stenting by stenting 
1 53 thrombus aspiration with 1 2  conventional PCI with additiona l  
additional bal loon dilation thrombus aspiration 
54 crossed over to conventional PCI 6 crossed over to thrombus aspiration 
+ + 
1 -year follow-up 1 -year follow-up 
530 completed follow-up 530 completed follow-up 
5 lost to follow-up 6 lost to follow-up 
4 thrombus aspiration followed by 5 bal loon dilation followed by 
direct stenting stenting 
1 thrombus aspiration with additional 1 no PCI 
balloon dilation 
Figure 1 .  Trial profile 
97 
Chapter 6 
Table 1 .  Baseline clinical and angiographic characteristics 
Thrombus aspiration Conventional PCI P-value 
(N=535) (N=536) 
Basel ine characteristics 
Age in years, mean±SD 63± 1 3 63± 1 3 
Male sex, N/total (%) 363/535 (67.9) 392/536 (73. 1 )  
R isk factors, N/total (%) 
Diabetes 56/530 ( 1 0.6) 67 /532 ( 1 2.6) 
Hypertension 1 7 1 /5 1 7  (33. 1 )  1 95/526 (37. 1 ) 
Hypercholesterolemia 1 1 5/485 (23.7) 1 30/480 (27. 1 )  
Previous myocardia l infarction 50/528 (9.5) 57 /533 ( 1 0.7) 
Previous PCI 39/526 (7.4) 38/53 1  (7.2) 
Previous CABG 1 7  /529 (3.2) 22/533 (4. 1 )  
Fami ly history 235/509 (46.2) 229/5 1 4  (44.6) 
Body mass index, mean ± SD 27±4 27±4 
Cu rrent smoking, N/tota l (%) 2 1 3/463 (46.0) 225/469 (48.0) 
Tota l ischemic time in min, med ian (IQR) 1 90 ( 1 1 0-270) 1 85 ( 1 07-263) 
Hemodynamics pre-procedure, mean ± SD 
Systolic blood pressure 1 28±26 1 30±26 
Diastol ic  blood pressure 74±1 5 75± 1 6  
Heart rate in beats/min 78±1 8 78± 1 9  
Diseased vessels, N/total (%) 
0 1 3/533 (2.4) 1 0/534 ( 1 .9) 
1 66/533 (3 1 . 1 ) 1 57 /534 (29.4) 
2 1 75/533 (32.8) 1 74/534 (32.6) 
3 1 78/533 (33.4) 1 93/534 (36. 1 ) 
Infarct related vessel, N/total (%) 
Left anterior descending artery 22 1 /5 1 5  (42.9) 223/5 1 7  (43. 1 ) 
Left circumflex artery 93/5 1 5  ( 1 8. 1 ) 79/5 1 7  ( 1 5.3) 
Right coronary artery 1 89/5 1 5  (36.7) 204/5 1 7  (39.5) 
Other 1 2/5 1 5  (2.3) 1 1 /5 1 7  (2. 1 )  
I n itial TIMI  flow, N/tota l (%) 
0/1 288/526 (54.7) 3 1 6/53 1  (59.5) 
2 1 02/526 ( 1 9.4) 85/53 1 ( 1 6.0) 
3 1 36/526 (25.9) 1 30/53 1  (24.5) 
(Continued) 
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Table 1 .  Continued 
Thrombus aspiration Conventional PCI P-va l ue 
(N=535) (N=536) 
Procedural characteristics 
Fina l  TIMI  flow 3, N/total (%) 43 1 /501 (86.0) 409/496 (82.5) 0. 1 2  
Dista l epicardia l  vessel obstruction after PCI 25/446 (5.6) 
Peak creatine kinase in total, Median (IQR) N=42 1 ,  N=41 8, 0.24 
565 (247 - 1 506) 637 (291 - 1 420) 
Time to creatine kinase in total hr, Median ( IQR) 8 (5 - 1 2) 7 (5 - 1 2) 0.84 
Peak creatine kinase-MB, Median (IQR) N=406, N=405, 0.46 
58 (24 - 1 1 8) 63 (30 - 1 1 4) 
Time to peak creatine kinase-MB in hr, Median (IQR) 7 (5 - 1 0) 7 (5 - 1 0) 0.80 
CABG=coronary artery bypass grafting. PCl=percutaneous coronary TIMl=thrombolysis in myocardial infarct ion flow 
grade. IQR=lnterquartile range. 
METHODS 
The study design, methods, and first results of the TAPAS trial have been reported 
previously.2•9 TAPAS investigated whether thrombus aspiration was better than 
conventional treatment of angioplasty without thrombus aspiration during primary PCI in 
patients with myocardial infarction. The trial was a single-centre, randomised open study 
with blinded assessment of endpoints. 
Patients 
1 07 1  consecutive patients were enrolled at the University Medical Centre Groningen 
between January, 2005, and December, 2006. Inclusion criteria were symptoms 
suggesting acute myocardial ischaemia of more than 30 min, time from symptom onset 
of less than 1 2  h, and ST-segment elevation of more than 0· 1 mV in two or more leads on 
the ECG. Exclusion criteria were rescue PCI after thrombolysis and known existence of 
a concomitant disease with life expectancy less than 6 months. The institutional review 
board approved the study and all patients included in the trial provided written informed 
consent. 
Treatment 
Before initial coronary angiography, patients were randomly assigned in a 1 :1 ratio to 
either thrombus aspiration or conventional treatment. In patients randomly assigned to 
thrombus aspiration, the Export Aspiration Catheter (Medtronic Corporation, California, 
USA) was used to establish antegrade flow before stenting. When necessary for stent 
delivery, balloon dila tion was done before stenting. In patients who received conventional 
treatment, balloon angioplasty was followed by stent placement (figure 1 ). All patients 
were pretreated with aspirin (500 mg followed by 80-1 00 mg per day), heparin (5000 IU), 
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and clopidogrel ( load ing dose of 600 mg fol lowed by 75 mg per day), which was admin 
istrated di rectly after electrocard iograph ic confirmation of ST-elevation myocardia l  
infarction.  Un less contra ind icated, patients received weig ht-adjusted g lycoprotein l l b/ 
I l la-inhibitor (abciximab) during the procedure and additiona l  heparin gu ided by activated 
clotting time. Standard therapies after PCI incl uded � b lockers, l ipid-lowering agents, 
and angiotensin-converting-enzyme inh ibitors or angiotensin-1 1 receptor antagonists, 
according to cu rrent gu idelines. 1 0  
Table 2.  Medication at  a median of 438 (402-486) days follow-up 
Thrombus aspiration 
Questionnaires send in total, N 1 99 
I nformation on medication, N/total (%) 1 49/1 99 (7 4.9) 
Du ration of fol low-up in days, median (IQR) 443 (400 - 493) 
No medication, N/total (%) 1 /1 49 (0. 1 )  
Aspirin, N/total (%) 1 26/1 49 (84.6) 
Clopidogrel, N/tota l (%) 1 3/1 49 (8.7) 
Coumarine derivates, N/total (%) 28/1 49 ( 1 8.8) 
Statins, N/total (%) 1 34/1 49 (89.9) 
Beta-blocker 1 30/1 49 (87 .9) 
Metro po lo I 96/1 30 (73 .8) 
Carved i lol 4/1 30 (3. 1 )  
Bisoprolol 25/1 30 ( 1 9.2) 
Sota lol 1 /1 30 (0.8) 
Nebivolol 4/1 30 (3. 1 )  
Ca lcium channel blockers, N/total (%) 23/1 49 ( 1 5 .4) 
Nitrates, N/total (%) 1 1 / 1 49 (7.4) 
Angiotensin-converting-enzyme inh ibitor, N/total (%) 77/1 49 (5 1 .7) 
Ang iotensin-I I  receptor antagonists, N/total (%) 30/ 149 (20. 1 )  
Diuretics, N/total (%) 37/1 49 (24.8) 
Outcome measures and follow-up 
Conventional  PCI 
1 93 
1 40/1 93 (72.5) 
43 1 (402 - 486) 
0/1 40 (0.0) 
1 1 7 /1 40 (83.6) 
2 1 /1 40 ( 1 5.0) 
25/1 40 ( 1 7.9) 
1 28/1 40 (91 .4) 
1 20/1 40 (85.7) 
83/1 1 9  (69.7) 
5/1 1 9  (4.2) 
28/1 1 9  (23.5) 
1 /1 1 9  (0.8) 
2/1 1 9  ( 1 .7) 
2 1 / 140 ( 1 5 .0) 
1 0/1 40 (7. 1 )  
80/1 40 (57. 1 )  
29/1 40 (20.7) 














The primary efficacy endpoint of TAPAS was post-procedural  frequency of myocardia l  
blush grade 0 or 1 .  Secondary endpoints included post-procedura l  Th rombolysis in  
Myocard ial  I nfarction (TIMl )-flow 3, complete ST-segment elevation resolution, no 
persistent ST-segment deviation, and 30-day and 1 -yea r major adverse cardiac events.9 
Death was regarded as cardiac unless an unequivocal non-cardiac cause of death was 
establ ished. Reinfarction was defined as recurrent symptoms with new ST-segment 
elevation and elevation of cardiac markers to at least twice the upper l imit of normal.  
Angiograph ica l ly proven stent thrombosis was defined as  a complete or partia l  occlusion 
with in the stented segment, with evidence of thrombus and reduced antegrade flow 
1 00 
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1 0  Conventional PCI 
















0 60 1 20 1 80 240 300 360 
Number at risk 
Time (days) 
Conventional PCI 536 506 501 499 495 494 489 
Thrombus aspiration 535 5 1 9  5 1 7  5 1 4  5 1 0  506 505 
Total 1 07 1  1 025 1 0 1 8  1 0 1 3  1 005 1 000 994 
Figure 2. Kaplan-Meier curve for all-cause mortality at 1 -year follow-up 
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Number at risk 
Time (days) 
Conventional PCI 536 506 501 499 495 494 489 
Thrombus aspiration 535 5 1 9  5 1 7 5 1 4  5 1 0  506 505 
Total  1 07 1  1 025 1 0 1 8  1 0 1 3  1 005 1 000 994 
Figure 3.  Kaplan-Meier curve for cardiac death at 1 -year follow-up 
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(TIMI flow <3) with a concurrent acute c l in ical ischaemic event. 1 1  Dista l embol isation after 
PCI was defined as a fi l l i ng defect with abrupt cutoff in the vessel located dista l ly of the 
culprit lesion. 
Information on vita l status, reinfarction, and coronary revascu larisation procedures were 
assessed using hospita l records, written questionnaires, a nd telephone interviews at 
or beyond 1 year after randomisation. Written questionna i res were a lso used to obtain  
information on medical therapy during fol low-up. Vita l status was a lso obta ined from a 
centra l  popu lation registry. A l l  major adverse cardiac events were assessed and classified 
by an interventional card io logist who was unaware of the treatment a l location. 
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Log-rank p=0-008 
0 60 1 20 
Number at risk 
Conventional PCI 536 495 489 
Thrombus aspiration 535 5 1 2  508 
Total 1 07 1  1 007 997 
1 80 240 300 360 
Time (days) 
484 482 479 472 
504 500 495 494 
988 982 974 966 
Figure 4. Kaplan-Meier curve for the combined endpoint of cardiac death or non-fatal reinfarction at 
1 -year follow-up. 
Statistical analysis 
Categorical variables were compa red using the x2 test or Fisher's exact test. Continuous 
variables were compared using a two-ta i led Student's t-test or Mann Whitney U test. 
Fol low-up ana lysis was done us ing time-to-event data (for which patients were censored 
at the time of last fol low-up) .  Hazard ratios and 95% Cls were estimated with a Cox's 
proportional hazard model, with treatment 
as the on ly covariate. 1 -yea r c l i n ical outcomes were d isp layed us ing Kaplan Meier 
methodo logy and were compared with log-rank test pooled over strata. The relation 
between reperfusion pa rameters (myocard ia l  b lush g rade and ST-segment elevation 
resolution) and c l in ical outcome were ca lcu lated us ing x2 tests. Un ivariate and mu ltivariate 
1 02 
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logistic-regression analyses were used for identifying risk factors for the combined 
endpoint of cardiac death or non-fatal reinfarction at 1 year follow-up. Baseline variables 
of the TIMI risk score1 2  and treatment assignment were tested for their predictive value. 
These variables were age, diabetes, hypertension, systolic blood pressure at admission, 
heart rate at admission, weight, anterior myocardial infarction, total ischaemic time, 
and randomisation to thrombus aspiration. Significant variables at univariate analysis 
(p<0.075) were included in the multivariate model. Analyses were done according to 
the intention-to-treat principle. All p values were 2-tailed. Analyses were done with SPSS 
software version 14.0.2 (SPSS, Chicago, USA). 
Table 3. Adverse clinical events at 1 -year follow-up 
Thrombus aspiration Conventional PCI 
N=535 N=536 
Al l-cause morta lity, N (%) 25 (4.7) 41 (7.6) 
Cardiac death 1 9  (3.6) 36 (6.7) 
Reinfarction 1 2  (2.2) 23 (4.3) 
Target vessel revascularization 60 ( 1 2.9) 69 ( 1 1 .2) 
Second PCI target-vessel 37 (6.9) 51 (9.5) 
CABG target-vessel 25 (4.7) 20 (3.7) 
Cardiac death or Non-fatal reinfarction 30 (5.6) 53 (9.9) 
Major Adverse Cardiac Events 89 ( 1 6.6) 1 09 (20.3) 
Angiographica l ly proven stent-thrombosis 6 ( 1 . 1 )  1 2  (2.2) 
Acute (24 hrs) 1 (0.2) 1 (0.2) 
Subacute (> 1 -30 days) 1 (0.2) 3 (0.6) 
Late (>30-365 days) 4 (0.7) 8 ( 1 .5) 
CABG=coronary artery bypass grafting. PCl=percutaneous coronary intervention. 
Role of funding source 
Hazard Ratio P-va l ue 
(95% CI) 
1 .67 ( 1 .02 - 2.75) 0.042 
1 .93 ( 1 . 1 1 - 3 .37) 0.020 
1 .97 (0.98 - 3.96) 0.05 
1 . 1 9  (0.84 - 1 .68) 0.34 
1 .8 1  ( 1 . 1 6  - 2.84) 0.009 
1 .26 (0.95 - 1 .67) 0. 1 0  
2.05 (0.77 - 5.47) 0. 1 5  
The study was supported by an unrestricted grant from Medtronic (for angiographic 
analyses by the corelaboratory). All other costs were covered by the Thorax Centre of 
the University Medical Centre Groningen. Medtronic had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had final responsibil ity for the 
decision to submit for publication. 
RESULTS 
Vital status 1 year after randomisation was available for 530 (99. 1 %) patients in the 
thrombus aspiration group and for 530 (98.9%) in the conventional PCI group (figure 1 ). 
54 patients (10%) in the thrombus aspiration group were crossed over to the conventional 
group because of a tortuous or distal infarct-related segment, and six patients (1 %) in the 
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conventional group were crossed over to thrombus aspiration because of angiographic 
evidence of thrombus. Baseline clinical and angiographic characteristics were well 
balanced between the treatment groups (table 1 ). 
Written questionnaires to obtain information on vital status, hospital admissions, and 
current medical therapy were sent to 392 patients at 1 year or more after randomisation. 
In 289 (73.7%) cases the questionnaire was sent back with information on current medical 
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Figure 5. Relation between parameters for myocardial reperfusion and total mortality, cardiac 
death, and the combined endpoint of cardiac death or non-fatal reinfarction at 1 -year follow-up 
66 patients died during 1-year follow-up. The number of deaths of cardiac origin was 55 
(83.3%), of whom 30 died during the first 30 days and 25 between 30 days and 1 year. Of 
the 25 cardiac deaths after 30 days, ten occurred in the thrombus aspiration group and 
15 in the conventional PCI group. Kaplan-Meier estimates for cardiac death after 30 days 
were 1 .95% for thrombus aspiration and 3.00% for conventional PCI (log-rank p=0.284). 
Causes of definite non-cardiac deaths were malignancy (n=8, including pulmonary cancer 
[3], hepatobiliary cancer [2], non-Hodgkin lymphoma [1 ], acute leukaemia [1 ], and prostate 
cancer [1 ]), septicaemia (n=1 ), trauma (n=1 ), and myelodysplastic syndrome (n=1 ). The 
Kaplan-Meier curves revealed a significant diff erence for 1-year all-cause mortality (log­
rank p=0.040), cardiac death (log-rank p=0.018), and the combined endpoint of cardiac 
death or non-fatal reinfarction (log-rank p=0.008; figures 2, 3, and 4). The hazard ratios of 
adverse clinical events at 1-year follow-up are shown in table 3. 
The primary endpoint of TAPAS was myocardial blush grade O or 1. Myocardial blush 
grade was associated with all-cause mortality (p=0.001 ), cardiac death (p=0.003), and the 
combined endpoint of cardiac death or non-fatal reinfarction (p=0.004) at 1-year follow­
up. Moreover, the occurrence of clinical events at 1 year was also significantly related to ST-
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segment elevation resolution (p<0.0001 for all associations; figure 5). Also, after exclusion 
of patients who died during the first 30 days, there was still a significant difference in 
distribution of cardiac death after 30 days according to myocardial blush grade: 4.4% (9 
of 204) in myocardial blush grade O or 1, 1.6% (6 of 375) in grade 2, and 1.3% (5 of 377) in 
grade 3 (p=0.032). 
Treatment assignment and variables of the TIMI-risk score were tested for their univariate 
and multivariate predictive value (table 4). Significant multivariate risk factors for cardiac 
death or nonfatal reinfarction were: assignment to thrombus aspiration (odds ratio 0.54; 
95% Cl 0.33-0.93; p=0.025); age (1.04; 1.02-1.06; p=0.001); diabetes (3.22; 1.80-5.74; 
p<0.0001 ); and heart rate at admission (1.02; 1.00-1.03; p=0.027). 
Table 4. TIMI risk score variables of the combined endpoint of cardiac death or non-fatal reinfarction 
Univariate analysis Multivariate analysis* 
Odds Ratio 95% (1 p-va lue Odds Ratio 95% (1 p-va lue 
Thrombus-aspiration 0.54 0.34 - 0.86 0.0 1 0  0.54 0.33 - 0.93 0.025 
Age in  yr 1 .05 1 .03 - 1 .07 <0.0001 1 .04 1 .02 - 1 .06 0.001 
Diabetes 3.62 2. 1 5  - 6.07 <0.0001 3.22 1 .80 - 5.74 <0.0001 
Weight in  kg 0.98 0.96 - 0.99 0.0 1 0  0.98 0.96 - 1 .00 O.D7 
Anterior myocardial infarction 1 .69 1 .07 - 2.67 0.026 1 .6 1  0.97 - 2.66 0.06 
Heart rate at admission 1 .0 1  1 .00 - 1 .03 0.02 1 1 .02 1 .00 - 1 .03 0.027 
Systol ic blood pressure at admission 1 .00 0.99 - 1 .0 1  0.50 
Hypertension 1 . 1 8  0.74 - 1 .87 0.49 
Tota l ischemic time in hr 1 .04 0.97 - 1 . 1 1  0.32 
* Multivariate analysis of s ignificant univariate risk factors p<0.075. 
DISCUSSION 
The main finding of this study is that a strategy of thrombus aspiration before stenting 
during primary PCI results in a lower cardiac mortality and a lower incidence of the 
combined endpoint of cardiac death or non-fatal reinfarction than does normal therapy 
alone. 
Previous studies have reported that visually assessed myocardial blush is an important 
parameter for myocardial reperfusion after primary PCI and is strongly associated with 
infarct size, recovery of ventricular function, and mortality. 1 • 1 3  Additionally, resolution of ST­
segment elevation has proven to be an independent predictor of long-term mortality. 1 4 In 
line with these previous studies, we noted a strong association between these parameters 
for myocardial reperfusion and clinical events at both 30 days and 1 year in TAPAS. Also, 
after exclusion of patients who died during the first 30 days, there was still a significant 
association between cardiac death and myocardial blush grade. The benefit in improved 
parameters for myocardial reperfusion seen in the thrombus aspiration group resulted in 
less clinical events at 30 days.2 Our study shows that this beneficial effect on reperfusion 
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trans lates into a sign ificant improvement of c l in ical outcome at 1 year. 
The effect of manua l  thrombus aspiration on pa rameters for myocard ia l  reperfusion has 
been widely investigated. However, randomised data for c l in ical outcome are scarce. 
Two smal l  randomised tria l s  have been publ ished i nvestigating the effect of thrombus 
aspiration on left ventricu lar remodel l ing. The myocard ia l  contrast echocardiography 
substudy of the REMEDIA Tria ls enrol led 50 patients randomly assigned to thrombus 
aspiration or standard PCI. Thrombus aspiration was associated with a s ignificant reduction 
in severity and extent of myocard ia l  obstruction at 24 h, wh ich was susta ined at 1 week 
and 6 months. Additiona l ly, end-diastol ic and end-systo l ic l eft ventricular volumes were 
s l ightly, but not sign ificantly, smal ler in patients undergoing th rombus aspiration.  De Luca 
and col leagues6 showed that, in 76 patients with anterior myocardia l  infarction, thrombus 
aspiration was associated with s ignificantly lower end-diastol ic and end-systol ic left 
ventricu lar vol umes at 6 months than  with conventional  PCI. Although these tria ls show 
promising resu lts, sample sizes were sma l l  and accuracy of echocardiography i n  assessing 
left ventricular function i s  relatively moderate compared with contrast-enhanced MRI .  
I n  TAPAS, the morta l ity benefit and the reduced reinfa rction rates in the thrombus 
aspiration group were probably associated with less thrombotic compl ications associated 
with the treatment. Less d ista l embol isation wi l l  result in improved myocard ia l  perfusion2-4 
and left ventricu lar function,5•6 and in a surviva l benefit at fo l low-up. 1 5 Thrombus aspiration 
reduced the source of d ista l embol isation by removing the c lots as wel l  as atherosclerotic 
plaque materia l  exposed to the l umina l  su rface after p laque ruptu re. H istopathological 
ana lysis of aspirated clots i n  TAPAS showed both so-ca l led white clots, composed main ly 
of plate lets, and red c lots composed of fibrin and red blood cel ls.2 Thrombus aspiration is 
therefore of additional  va lue du ring primary PCI, s ince cu rrently used antiplatelet agents 
main ly ta rget white platelet clots. Fu rthermore, in TAPAS there were less reinfarctions in 
the thrombus aspiration g roup, contributing to the surviva l benefit. Th is lower reinfarction 
rate seems to be at least in part caused by a reduction in thrombotic compl ications, 
such as stent thrombosis, after thrombus aspiration. The presence of thrombus, i n  
particu lar a large thrombus-load, has  been associated with incomplete stent apposition, 1 6 
reinfarction, 1 7  and stent-thrombosis at fol low-up.11 Therefore, a reduction i n  thrombus­
load by thrombus aspiration cou ld be expected to resu lt in less reinfarction at fol low-up. 
Other elements contributing to the favourable outcome of manual  th rombus aspiration 
are its s impl icity ( ind icated by s imi lar duration of fluoroscopy and door-to-ba l loon times 
as the control g roup) and safety (no flow-l imiting d issections or other device-related 
compl ications occurred during the procedure).2 1 -year  ta rget vessel revascu larisation did 
not show an eff ect of thrombus aspiration on c l in ical recurrence. Therefore, our  resu lts do 
not ind icate an  eff ect of th rombus aspiration on neointima hyperplasia compared with 
conventional PCI .  
TAPAS was designed to  detect d iff erences in myocard ia l  reperfusion and-with 1 07 1  
patients, 66  deaths, and 35 reinfarctions-had l imited power to  investigate the  magnitude 
of the eff ect of thrombus aspiration on c l inical outcome. Another l imitation of our study 
was that no systematic measurement of infarct size and l eft ventricular function was 
done. These data cou ld  have offered additional  information on the mechanism behind 
the c l in ica l benefit seen i n  the thrombus aspiration g roup. 
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In conclusion, compared with conventional PCI, thrombus aspiration before stenting of 
the infarct-related artery results in improved myocardial perfusion and seems to improve 
clinical outcome 1 year after PCI for ST-elevation myocardial infarction. 
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To investigate which patient characteristics are independent predictors of thrombus 
retrieval and whether manual thrombus aspiration should be recommended for use in all 
patients or in a more selected population with ST-elevation myocardial infarction (STEMI). 
Background 
Manual thrombus aspiration devices are increasingly used during primary percutaneous 
coronary intervention (PCI) for STEMI. This in an attempt to reduce the incidence and 
amount of PCl-induced distal embolisation by removing atherothrombotic material 
exposed to the lumen. 
Methods 
We performed an analysis on all patients with STEMI treated with routine manual thrombus 
aspiration between January 2005 and May 2010 in our center. Thrombus aspiration was 
defined as effective when atherothrombotic material was seen in the aspirate. 
Results 
A total of 171 2  patients underwent thrombus aspiration, which was effective in 82.6%. 
Multivariate independent predictors of effective thrombus aspiration were reference 
vessel diameter >3mm, angiographic visible thrombus and total ischemic time >3hours. 
However, the discriminative value of these predictors together was low, with an area under 
the ROC-curve of 0.60 (Cl 0.56-0.64, p<0.0001 ). The institutional and individual learning 
curves showed that improvement of efficacy occurred with increasing volume, indicating 
that thrombus aspiration may also be operator related. 
Conclusion 
This analysis demonstrates that routine manual thrombus aspiration in STEMI patients is 
feasible and results in successful thrombus retrieval in the majority of the patients. The 
high efficacy rates across all patient subgroups support a strategy of routine thrombus 
aspiration over a more selective approach. 
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INTRODUCTION 
Thrombus aspiration devices are increasingly used in the setting of primary percutaneous 
coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). This in an 
attempt to reduce the incidence and amount of PCl-induced distal embolisation by 
removing atherothrombotic material exposed to the lumen. 1 •2 Besides that thrombus load 
can be a source of distal embolisation, it also has been associated with the occurrence of 
other adverse events such as stent undersizing, malapposition and stent thrombosis.3•5 
Recent randomized controlled trials6·1 1 and meta-analyses1 2•1 3  demonstrated that manual 
thrombus aspiration results in improved myocardial reperfusion and clinical outcome. 
The efficacy rate of thrombus aspiration (as defined as retrieval of atherothrombotic 
material) ranges between 73 and 95 percent in published randomized controlled 
trials.9•1 0  However, current trials investigated thrombus aspiration in a routine setting 
and not in selected patients groups. In addition, study sizes were often too small to 
perform adequate subgroup analyses.6•1 1 It is therefore currently unclear which patient 
characteristics are independent predictors of effective thrombus aspiration and whether 
thrombus aspiration should be recommended for use in all patients or in a more selected 
population. 
In the present analysis, we investigated the feasibility and efficacy of routine thrombus 
aspiration in an all-comers population treated between 2005 and 201 0  in our center. 
Analyses were performed to identify independent predictors of effective thrombus 
aspiration, which were subsequently tested for their discriminative and clinical value. 
In addition, institutional and individual learning curves for thrombus aspiration were 
analysed. 
METHODS 
In the University Medical Center Groningen all patients undergoing primary PCI for STEMI 
were included in a prospective registry. In the year 2005 and 2006 thrombus aspiration 
was performed in the setting of the Thrombus Aspiration during Percutaneous coronary 
intervention in Acute myocardial infarction Study (TAPAS).8•9 After the trial was finished, 
thrombus aspiration became the preferred strategy for patients with STEMI in our center. 
Patients 
All patients treated with primary PCI for STEMI between January 2005 and May 2010 in our 
center were enrolled in the present analysis. Inclusion criteria were: onset of symptoms 
<12 hours or in case of persisting symptoms due to ongoing ischemia <24 hours, ST­
segment elevation >0.1 mV in 2 or more leads on the electrocardiogram and a culprit 
lesion suitable for PCI. We compared patients characteristics of those in which thrombus 
aspiration was attempted with those who did not undergo thrombus aspiration. Patients 
in who thrombus aspiration as initial intervention was attempted were used in analyses to 
identify independent predictors of effective thrombus aspiration. Patients randomized to 
conventional PCI in the TAPAS trial were excluded. No other exclusion criteria were used. 
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between January 2005 and May 201 0 
Randomized to conventional PCI in 
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'� .,_ _______________ � 
TA was the preferred treatment strategy in 
2079 patients 
367 ( 1 7.7%) No TA attempted 
Treatment: 
� 1 9.6% Bal loon di latation 
57.5% Predilatation + stenting 
22.9% Direct stenting 
TA attempted in 1 7 1 2  (82.3%) patients 
Treatment: 
1 .6% TA only 
4.0% TA + bal loon di latation 
3 1 .9% TA + predi latation + stenting 
61 .9% TA + direct stenting 
0.6% unknown 
Data on aspect of aspirate avai lable in 1 505 (87.9%) patients 
262 ( 1 7.4%) No effective TA 
Treatment: 
0.8% TA only 
7.3% TA + ba l loon di latation 
43. 1 % TA + predilatation + stenting 




1 243 (82.6%) Effective TA 
Treatment: 
1 .7% TA only 
3.2% TA + ba l loon d i latation 
28.5% TA + predi latation + stenting 
66.0% TA + direct stenting 
0.6% unknown 
Figure 1. Flow diagram. PCI= Percutaneous coronary intervention, STEMI= ST-elevation myocardial 
infarction, TA= Thrombus aspiration, TAPAS= Thrombus Aspiration during Percutaneous coronary 
intervention in Acute myocardial infarction Study. 
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Treatment 
All patients were pre-treated with asprnn, heparin and clopidogrel, which was 
administered directly after electrocardiographic confirmation of STEMI. Patients received 
weight-adjusted glycoprotein ! lb/Illa-inhibitor (Abciximab) during the procedure and 
additional activated clotting time-guided heparin, unless contraindicated. The Export 
Aspiration Catheter (Medtronic Corporation, California, USA) was used in the majority 
of the patients to establish antegrade flow before stenting. From January 2007 to March 
2007 the Diver Clot Extraction (lnvatec, Roncadelle, Italy) was also used.1 4  When necessary 
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Figure 2. ROC curve for effective thrombus aspiration 
Definitions and endpoints 
0.8 1 .0 
Attempted thrombus aspiration included all cases in which thrombus aspiration was 
performed as initial strategy to establish coronary flow. Aspiration was defined as 
effective when atherothrombotic material was seen in the aspirate by the treating 
interventional cardiologist or by histopathological examination in a selection of the 
patients. For histopathological examination, aspirated material during thrombus 
aspiration was placed in formalin, and fixed for 24 hours. Histological sections were cut 
and stained with hematoxylin-eosin for examination with a light microscope (x100) 
performed by independent pathologists.8 All coronary angiographic data were analysed 
by an independent core laboratory (Cordinamo, Wezep, the Netherlands) or 2 experienced 
observers blinded to all clinical data. Thrombolysis In Myocardial Infarction (TIMI) flow 
grade and angiographic visible thrombus were scored as previously described.1 5•1 6  
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Table 1. Baseline, angiographic and procedural characteristics 
Thrombus aspiration attempted Effective thrombus aspiration 
No Yes P-va lue No Yes P-value 
Patients, N/total (%) 367 /2079 ( 1 7.7) 1 7 1 2/2079 (82.3) 262/1 sos ( 1 7.4) 1 243/1 505 (82.6) 
Age in yr, mean±SD 67.8 ± 1 2.7 63.3 ± 1 2.9 <0.0001 64.2 ± 1 2.9 62.6 ± 1 2.7 NS 
Male sex, N/total (%) 256/367 (69.8) 1 235/1 7 1 2  (72. 1 )  NS 1 83/262 (69.8) 9 1 9/1 243 (73.9) NS 
Risk factors 
Diabetes 57 /326 ( 1 7.5) 1 78/1 685 ( 1 0.6) <0.0001 37 /260 ( 1 4.2) 1 22/1 228 (9.9) 0.042 
Hypertension 1 32/296 (44.6) 624/1 644 (38.0) 0.G3 1 1 08/254 (42.5) 444/1 205 (36.8) NS 
Previous CABG 1 5/366 (4. 1 )  38/1 704 (2.2) 0.040 7/260 (2.7) 24/1 238 ( 1 .9) NS 
Previous Ml 64/341 ( 1 8.8) 1 50/1 689 (8.9) <0.0001 23/258 (8.9) 1 1 1  /1 232 (9.0) NS 
Previous PC! 45/366 ( 1 2.3) 1 20/1 706 (7.0) 0.001 1 4/261 (5.4) 90/1 239 (7.3) NS 
Three vessel disease 1 34/367 (36.5) 474/1 7 1 0  (27.7) 0.001 82/261 (3 1 .4) 33 l /1 242 (26.7) NS 
Systolic BP :-;;90 mm Hg at admission 43/246 ( 1 7.5) 1 29/1 6 1 1 (8.0) <0.0001 1 5/249 (6.0) 92/1 208 (7.6) NS 
Total ischemic time 
Median (IQR) 2 1 1 ( 1 45 - 350) 1 85 ( 1 30 - 286) <0.0001 1 95 ( 1 39 - 320) 1 80 ( 1 27 - 279) 0.Q28 
>3 hrs 1 77 /286 (61 .9) 842/ 1 59 1  (52.9) 0.005 l 47 /249 (59.0) 608/1 1 93 (5 1 .0) 0.020 
>6 hrs 70/286 (24.5) 280/1 59 1  ( 1 7.6) 0.006 48/249 ( 1 9.3) 1 96/1 1 93 ( 1 6.4) NS 
Location culprit lesion <0.0001 NS 
LAD 1 40/367 (38. 1 )  733/1 7 1 2  (42.8) 1 20/262 (45.8) 533/1 243 (42.9) 
LCx 68/367 ( 1 8.5) 265/1 7 1 2  ( 1 5 .5) 47 /262 ( 1 7.9) 1 83/1 243 ( 1 4.7) 
RCA 1 28/367 (34.9) 687/1 7 1 2  (40. 1 ) 9 1 /262 (34.7) 5 1 2/1 243 (4 1 .2) 
Left main artery 23/367 (6.3) 1 4/ 1 7 1 2  (0.8) 1 /262 (0.4) 9/1 243 (0.7) 
Graft 8/367 (2.2) 1 3/1 7 1 2  (0.8) 3/262 ( 1 . 1 )  6/1 243 (0.5) 
AHN ACC lesion characteristic C 1 86/363 (5 1 .2) 682/1 672 (40.8) <0.0001 1 03/262 (39.3) 504/1 243 (40.5) NS 
Proximal location 1 5 1 /367 (4 1 . 1 )  70 1 /1 7 1 2  (40.9) NS 1 03/262 (39.3) 562/1 243 (45.2) NS 
Thrombus visible pre 305/357 (85.4) 1 478/1 709 (86.5) NS 202/262 (77 . 1 )  1 09 1 /1 243 (87.8) <0.0001 
TIMI flow 0/1 pre 2 1 9/362 (60.5) 1 073/ 1 708 (62.8) NS 1 40/261 (53.6) 794/1 240 (64.0) 0.002 
Reference vessel diameter >3mm 235/308 (76.3) 1 044/1 242 (84. 1 )  0.00 1 1 99/257 (77.4) 1 036/1 229 (84.3) 0.008 
Number of stents implanted 1 .3 ± 1 .0 1 .3 ± 0.7 NS 1 .3 ± 0.7 1 .3 ± 0.7 NS 
Mean stent diameter 3.3 ± 0.5 3.3 ± 0.5 0.029 3.3 ± 0.5 3.4 ± 0.4 0.003 
Mean stent length 1 9.6 ± 6.7 1 9.9 ± 6.5 NS 20.5 ± 6.6 1 9.8 ± 6.5 NS 
Glycoprotein  l ib/I l la inhibitor 250/367 (68. 1 )  1 57 1 /1 7 1 2 (9 1 .8) <0.0001 238/262 (90.8) 1 1 6 1  /1 243 (93.4) NS 
Intra aortic balloon pump 73/355 (20.6) 1 24/1 687 (7.4) <0.0001 1 0/261 (3.8) 80/1 224 (6.5) NS 
BP = blood pressu re, CABG = coronary artery bypass g rafting, LAD = left anter ior descending artery, LCx = left 
c i rcumflex artery, M l = myocard ia l  infarction, RCA = Right coronary a rtery, TIM I  flow = thro mbolysis in myocard ia l  
infarction flow grade. 
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Statistics 
Data are presented as frequency (percentage), mean ± standard deviation or as median 
(i nterquarti le range). Categorical variables were compared with the use of the chi­
square test or Fisher's exact test. Continuous va riables were compared with the use of 
two-tai led Student's t-test or Mann Whitney U-test. Un ivariate and multivariate log istic 
regression ana lyses were used to detect independent predictors of effective thrombus 
aspiration and retrieva l of  thrombi > 1 mm. The fol lowing eighteen variables were tested 
for thei r predictive va lue: gender (male), diabetes, cu rrent smoking, hypertension, 
hypercholesterolemia, body mass index >30, previous myocard ia l  infarction, previous PCI, 
previous CABG, culprit vessel location, systol ic blood pressure �90mmHg at admission, 
age, tota l ischemic time, angiographic visible thrombus pre, TIMI flow pre, reference 
vessel diameter, AHA/ACC lesion type, three vessel d isease. Significant un ivariate 
predictors (p<0. 1 5) were tested for their multiva riate predictive va lue. To investigate the 
d iscriminative va lue of the multiva riate predictors, receiver operating characteristic (ROC) 
cu rves were drawn using predictive probabi l ities of each patient. Goodness-of-fit of the 
mu ltiva riate models were tested using the Hosmer-Lemeshow chi-square test. I n  add ition, 
ana lyses of institutiona l and individual  lea rning cu rves were performed. The institutional  
learning curve was investigated between January 2005 and Ju ly 2009, as in this period the 
same six interventional cardiologists performed a l l  procedures in  our center. To correct for 
d ifferences in patient popu lation, the categorical variable"Time" (subgroups of 1 year, with 
2009 as reference year) was adjusted for s ign ificant multivariate predictors of effective 
thrombus aspiration. Ind ividual  learning cu rves were analysed of the six operators which 
performed a l l  procedures between January 2005 and Ju ly 2009, and were calculated by 
d ividing the patients of each operator into subgroups of 1 5  consecutive patients. Al l  
p-va lues were 2-ta i led, with statistica l s ignificance set at <0.05 . Ana lyses were performed 
using SPSS software version 1 6.0.2 (SPSS, Ch icago, I l l i nois). 
RESULTS 
A tota l of 26 1 5  patients underwent primary PCI for STEMI between January 2005 and May 
201 0 (see figure 1 ) .  Of these patients, 536 (20.5%) were randomized to conventional  PCI in 
the context of the TAPAS trial and therefore excluded from this ana lysis. 
Thrombus aspiration attempted 
Thrombus aspiration was attempted in 1 7 1 2/2079 (82.3%) patients (Table 1 a nd Figu re 
1 ). The group in which thrombus aspiration was not attempted was older (67.8 vs. 63.3yr), 
had longer total ischemic times (median 21 1 vs. 1 85 min) and more often three vessel 
d isease (36.5 vs. 27.7%) and left main disease (6.3 vs. 0.8%) . Although in itial TIM I  flow 
rate and incidence of visible thrombus before PCI were s imi lar  in both groups, patients 
in which thrombus aspiration was not attempted had a higher rate of additiona l ba l loon 
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In 1 712 patients thrombus aspiration was attempted as initial strategy to establish coronary 
flow. In 1 505/1712 (87.9) patients data was available on efficacy. Thrombus aspiration 
was effective in 1 243/1505 (82.6) patients (table 1 ). In these patients atherothrombotic 
material was retrieved, confirmed by either histopathological analysis and/or the operator. 
As compared with those without effective thrombus aspiration, these patients had less 
often diabetes, shorter total ischemic times, more often angiographic visible thrombus 
and larger reference vessel diameters. No significant differences were found regarding 
baseline variables such as age, sex and other cardiovascular risk factors. 
Nine variables were significant at univariate analyses and were tested for their predictive 
multivariate value (see table 2). Total ischemic time >3 hours, a reference diameter of 
>3mm and angiographic visible thrombus were significant predictors in the multivariate 
model. However, the area under the ROC curve of this multivariate model was only 0.60 
(Cl 0.56 - 0.64, p<0.0001) (figure 2). The poor discriminative value of univariate and 
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multivariate predictors of effective thrombus aspiration is supported by figures 3A-D, 
which illustrate high efficacy rates across all subgroups. 
Institutional and individual learning curves 
Between January 2005 and July 2009 all interventions were performed by the same six 
interventional cardiologists. During these years, the efficacy rate of thrombus aspiration 
increased from 66% in 2005 to 95% in 2009 (figure 4A). The relation between time (years 
after introduction) and efficacy rate remained significant after adjusting for multivariate 
predictors of effective thrombus aspiration (p<0.0001 ). Also the individual learning curves 
of the six operators during the first 105 aspiration procedures demonstrated that higher 
efficacy rates were achieved with increasing number of patients treated with thrombus 
aspiration (figure 4B). 
Table 2. Predictors of effective thrombus aspiration 
Univariate predictors, p<0. 1 5 Multivariate predictors, p<0.05 
OR 95% CI p OR 95% CI p 
Age >65yrs 0.78 0.60 - 1 .02 0.07 0.88 0.66 - 1 . 1 8  0.40 
Hypertension 0.79 0.60 - 1 .04 0.09 0.8 1 0.60 - 1 .09 0. 1 6  
Diabetes 0.67 0.45 - 0.99 0.043 0.77 0.50 - 1 .2 1  0.26 
Total ischemic time >3 hrs 0.72 0.55 - 0.95 0.02 1 0.73 0.54 - 0.98 0.033 
Three vessel d isease 0.79 0.59 - 1 .06 0.1 2 0.84 0.62 - 1 . 1 6  0.29 
Culprit location - RCA 1 .32 1 .00 - 1 .74 0.05 1 .2 1  0.89 - 1 .64 0.23 
Reference vessel d iameter >3mm 1 .57 1 . 1 2  - 2. 1 8  0.008 1 .45 1 .02 - 2.08 0.041 
TIMI flow pre 0/1 1 .54 1 . 1 8  - 2.02 0.002 1 .28 0.91 - 1 .8 1  0. 1 6  
Angiographic visible thrombus 2. 1 7  1 .56 - 3.03 <0.0001 1 .87 1 .22 - 2.86 0.004 
Cl = Confidence interval, OR = Odds Ratio, RCA = Right coronary artery, TIMI flow = thrombolysis in myocard ial 
infarction flow grade. 
Histopathological analyses 
Histopathological analyses were performed in 490/1505 (32.6) of patients who underwent 
thrombus aspiration. Histopathological analyses demonstrated thrombi larger than 1 mm 
in 128/490 (26.1) of patients. Regression analyses identified the following multivariate 
independent predictors for retrieval of thrombi larger than 1 mm: angiographic visible 
thrombus (OR 2.92, Cl 1.22 - 6.99, p=0.016), reference diameter of >3mm (OR 2.23, Cl 1.04 -
4.76, p=0.039), three vessel disease (OR 0.38, Cl 0.22 - 0.67, p=0.001 ), age >65jrs (OR 0.51, Cl 
0.31 - 0.84, p=0.009), diabetes (OR 0.34, Cl 0.12 - 0.94, p=0.037) and hypercholesterolemia 
(OR 0.52, Cl 0.29 - 0.94, p=0.031 )). The discriminate value of this multivariate model was 
low, given an area under the ROC of 0.72 (Cl 0.67 - 0.77, p<0.0001) 
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DISCUSSION 
This analysis demonstrated that thrombus aspiration in STEMI patients is feasible and 
effective in the majority of the patients. Independent predictors for effective thrombus 
aspiration were vessel diameter, presence of angiographic visible thrombus and total 
ischemic time. Nevertheless, high efficacy rates were achieved across all patient subgroups, 
which support a strategy of routine thrombus aspiration in STEMI patients undergoing 
primary PCI over a more selective approach. 
Recent randomized studies demonstrated that manual thrombus aspiration results in 
improved myocardial reperfusion as compared with conventional PCl.6- 1 1  These findings 
have driven the use of thrombus aspiration devices in routine clinical practice. However, 
the discussion about which subgroups will benefit more from thrombus aspiration and 
which less is still ongoing. 1 7• 1 8  As a result patients undergoing thrombus aspiration are 
often selected on baseline or angiographic characteristics, both in daily clinical practice as 
in setting of prospective studies. However, evidence supporting the exclusion of specific 
patient subgroups is lacking. This study offers more insight on which patient characteristics 
influence efficacy rates of thrombus aspiration and to which extend. 
In the present analyses routine thrombus aspiration resulted in a high efficacy rate of 
82.6% in an all-comers STEMI population. Also when we define cases in which the operator 
decided not to attempt thrombus aspiration as not effective thrombus aspiration, the 
efficacy rate is still very acceptable (68%). This rate is comparable with most previous 
studies, such as the TAPAS trial (73%),8 EMERALD trial (73%), 1 1  and the study of Kramer 
et al (74%) 1 9• These high efficacy rates are likely to be related to the good, all-round 
applicability of current manual thrombus aspiration catheters. In addition, although in 
some patients no angiographic visible thrombus was present, aspiration may still be 
successful and effective due to the presence of mural thrombus. 1 9-2 1 
We found that the efficacy rate of thrombus aspiration is mainly influenced by coronary 
anatomy characteristics (vessel diameter) and presence of thrombus on the initial 
angiogram. Furthermore, total ischemic time longer than 3 hours was associated with 
a lower efficacy rate. This is most likely explained by more organised thrombi, which 
are less friable and more difficult to aspirate.1 9  Further, the institutional and individual 
learning curves showed that improvement of efficacy occurred with increasing volume, 
indicating that effective thrombus aspiration may also be operator related.22•23 This 
operator dependence of thrombus aspiration could be related to increased experience 
in performing the procedure or better selection of patients who would benefit from 
thrombus aspiration. Further, it could also be explained by an increased focus of operators 
on retrieval of atherothrombotic material after the positive results of the TAPAS trial in 
2007. Nevertheless, the TAPAS trial performed between 2005 and 2006, demonstrated 
that thrombus aspiration can be safely performed during this possible learning curve, as 
during this period no complications were observed related with thrombus aspiration.9 
Reduction of thrombus load is likely to reduce the incidence and amount of distal 
embolisation and improve myocardial reperfusion. However, in the present study no 
analyses were performed on myocardial reperfusion or outcome, as thrombus aspiration 
was performed in a routine fashion without a large conventional PCI control group. In the 
TAPAS study, subanalyses did not demonstrate significant differences in clinical benefit 
1 20 



















cu 0 a: 
2005 2006 2007 
Year 
Figure 4A. Institutional learning curve 



























1 -15  
+ 




\ I  









- - - Mean 
61-75 76-90 91-105 
Number of procedures performed 
Figure 4B. Individual learning curves 
of thrombus aspiration across prespecified subgroups (TIMI flow, age, sex, total ischemic 
time, infarct related vessel, proximal lesion and thrombus seen on initial angiogram).9 
Also in a recent meta-analysis of individual patient data of most thrombus aspiration trials 
(n=2686), no differences were found across these subgroups or other baseline patient 
characteristics.1 2  Further, although several independent predictors for effective thrombus 
aspiration were found in the present analyses, the discriminative value of these predictors 
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together were low. In addition, efficacy rates remained high in all patient subgroups. These 
results support the routine application of thrombus aspiration in all patients undergoing 
primary PCI for STEMI. 
This large single-center retrospective study on predictors of effective thrombus 
aspiration suffers from several limitations. Only a part of aspirated material underwent 
histopathological analyses and the majority was scored by the interventional cardiologist. 
Further, although thrombus aspiration was performed routinely in our center, and 
no exclusion criteria were used, it was not attempted in all patients. In some high risk 
subgroups thrombus aspiration was less often performed; for example, in patients with an 
IABP or a culprit lesion in a graft. This may indicate that some selection by the operators 
may have been performed, however, also in these high risk patients thrombus aspiration 
was still attempted in the majority of the cases (IABP 63% and culprit in graft 62%). 
In conclusion, this analysis demonstrates that routine thrombus aspiration in STEMI 
patients is feasible and effective in the majority of the patients. The high efficacy rates 
across all patient subgroups support a strategy of routine thrombus aspiration in STEMI 
patients undergoing primary PCI over a more selective approach. 
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The objective of this study was to compare 2 manua l  thrombus aspiration catheters 
i nunselected patients with ST-segment e levation myocard ia l  infarction. 
Background 
Dista l embol ization is common during percutaneous coronary intervention in STsegment 
e levation myocard ial infarction and can induce impa i red myocard ia l  perfusion. Severa l 
aspiration thrombectomy devices have been i ntroduced to prevent d ista l embol ization, 
however, withconfl icting c l in ica l resu lts. Cu rrently, it is u nclear to what extent this variance 
in outcome can be explained by device-re lated factors, such as i nternal l umen size. 
Methods 
We performed a prospective cohort study i n  which patients undergoing primary 
percutaneous coronary intervention were treated with a large-internal- l umen catheter 
(Diver, l nvatec, Roncadel le, Italy). Outcomes were compared with a matched population of 
the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocard ia l  
infarction Study (TAPAS) tria l ,  in  which patients were treated with a med ium-sized catheter 
(Export, Medtronic, Minneapol is, Minnesota). A h istopathologica l a na lysis was performed 
of retrieved material . 
Results 
A tota l of 1 60 patients, treated with the Diver (n = 80) or Export (n = 80) aspiration catheter, 
were enro l led. Effective thrombus aspiration was seen in 70.3% of the patients treated 
with the Diver catheter versus 8 1 .8% with the Export catheter (p = 0. 1 0) No s ignificant 
d ifference was found i n  myocard ial blush g rade or electroca rd iographic outcome between 
the 2 devices. Size d istribution of retrieved thrombotic partic les was s imi lar  per device. 
Erythrocyte-rich thrombi were found in 34.8% of the cases and were predominately seen 
in patients with low in itia l Th rombolysis In Myocard ia l  I nfarction flow grade (p = 0.008) .  
Conclusions 
A larger i nternal l umen diameter does not resu lt i n  retrieva l of la rger thrombotic particles, 
nor in improved angiographic or electrocardiograph ic outcomes. 
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INTRODUCTION 
Distal embolization is common during percutaneous coronary intervention (PCI) in ST­
segment elevation myocardial infarction (STEMI) and can induce impaired myocardial 
perfusion,1 ,2 Several aspiration and thrombectomy devices have been introduced to 
prevent distal embolization. These include the Diver (lnvatec, Roncadelle, Italy), Export 
(Medtronic, Minneapolis, Minnesota), Probing (Boston Scientific, Natick, Massachusetts), 
Pronto (Vascular Solutions, Minneapolis, Minnesota), and Rescue catheters (Boston 
Scientific, Natick, Massachusetts).3-8 The ideal aspiration catheter should be rapidly 
exchangeable, good deliverable (also in small diameter and tortuous culprit vessels), 
and at the same time have sufficient lumen size to aspirate thrombus material. Based on 
internal lumen diameter, aspiration catheters can be subdivided into 3 size groups: large 
(Diver, 0.062 inch; Pronto, 0.065 inch), medium (Export, 0.041 inch; Rescue, 0.042 inch), 
and small (Probing, 0.018 inch). Currently, it is unknown whether large-lumen-diameter 
catheters are able to aspirate larger thrombotic components when compared with 
smaller sized ones. Retrieval of larger particles could improve the efficacy of thrombus 
aspiration, leading to better myocardial perfusion after primary PCI. On the other hand, a 
larger lumen diameter could influence handling characteristics and device safety. 
To test the hypothesis that a large-lumen-diameter catheter is capable of aspirating larger 
thrombotic components, we performed a prospective cohort study in which patients 
undergoing primary PCI were treated with a large-diameter catheter (Diver catheter). 
Further, because histopathological analysis of aspirated debris has only been performed 
in small and selected study populations,8-1 0 we also performed a histopathological 
assessment of retrieved material. 
Histopathological, angiographic, and clinical outcomes were compared with a matched 
population of the TA PAS (Thrombus Aspiration during Percutaneous coronary intervention 
in Acute myocardial infarction Study), in which patients were treated with a medium-sized 
catheter (Export catheter).3 
M ATERI ALS AND METHODS 
Enrollment in the TAPAS trial ended December 2006.3 From January 2007 to March 2007, all 
patients who underwent PCI in a native vessel for STEMI were included in this prospective 
study. Inclusion and exclusion criteria were similar to that for the TAPAS trial. In summary, 
patients were considered eligible for inclusion when they had symptoms suggesting 
acute myocardial ischemia >30 min, time from symptom onset was <12 h, and STsegment 
elevation >0.1 mV in �2 contiguous leads was present on the electrocardiogram (ECG). 
Patients were excluded when they underwent rescue PCI after thrombolysis, had known 
existence of a disease with life expectancy <6 months, or no informed consent was given. 
Consecutive patients treated with the Diver catheter were matched with patients included 
in the TA PAS study, in which thrombus aspiration with the Export catheter was attempted.3 
Matching was based on the following variables: gender, initial Thrombolysis In Myocardial 
Infarction (TIMI) flow grade ±1, age ±5 years, and segment culprit lesion. 
The primary end point is incidence of aspirated thrombotic components > 1 mm. Secondary 
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end points a re myocard ia l  b lush g rade, ST-segment e levation resolution, persistent ST­
segment elevation, enzymatic infarct size, postprocedura l  d ista l embol ization, and major 
adverse card iac events at 30 days. 
The angiograph ic, h i stopathological ,  and electrocardiographic methods used in this study 
were s imi lar to those used in the TAPAS tria l .3 
Description of the thrombusaspiration catheters 
The PCI was performed using standard percutaneous techniques. The Export aspiration 
catheter (Medtronic) and the Diver Clot Extraction ( l nvatec) are both 6-F compatib le 
th rombus aspiration catheters. The Export has an obl ique aspiration tip design, with 
an aspiration l umen of 0.041 inch. The Diver has a d ista l aspiration lumen of 0.062. I n  
both aspiration catheters, suction i s  provided by h and  with a lockable 20-ml syri nge. 
Al l interventiona l  card io logists were experienced i n  the usage of manual thrombus 
aspiration catheters. I n  addition, because the usage of both aspiration catheters is s imi lar, 
no learning curve was expected in the Diver g roup. 
Medication 
Before PCI, the patient was treated with aspir in (a bol us of 500 mg), i ntravenous heparin 
(5000 IU), and clopidogrel (a load ing dose of 600 mg) .  Adjunctive therapy i ncl uded 
n itrog lycerin intravenously and g lycoprotein ! l b/I l l a  i nh ibitors. During PCI, additional  
heparin is admin istered gu ided by activated clotti ng t ime measurements. Standard 
therapies after PCI inc l uded aspir in 80 mg, clopidogrel 75 mg, beta-blockers, l ipid-lowering 
agents, and angiotensin-converti ng enzyme inh ibitors or angiotensin I I  receptor blockers. 
Angiographic, electrocardiographic, and clinical outcome 
I ntravenous n itrog lycerin was given after the procedu re and before the fina l  ang iogram 
in  a l l  patients. The TIM I  flow grades wi l l  be  estimated as previously described: g rade 0 :  
no perfusion, g rade 1 :  penetration without perfusion, g rade 2: partial perfusion, g rade 
3 :  complete perfus ion.11 The eva l uation of myocard ia l  blush g rades wi l l  be performed as 
described by van't Hof et a l .1 : grade 0: no myocardia l b l ush, g rade 1 :  min ima l  myocard ia l  
b lush or contrast density, grade 2, moderate myocard ia l  b lush or contrast density but 
less than that obta ined during angiography of a contra latera l  or ips i latera l non-infarct­
related coronary a rtery, and g rade 3, normal myocard ia l  b lush or contrast density 
comparable with that obta ined during angiography of a contra latera l or ips i latera l non­
infarctrelatedcoronary artery. Pers isting myocard ial b lush (sta i ning) suggests leakage of 
contrast med ium into the extravascu lar  space and is g raded 0. Dista l embol ization was 
considered to have occurred if new circumscribed fi l l ing defects and/or abrupt cut-off 
of the vessel distal to the target lesion appears. Th rombus was assessed accord ing to the 
criteria summarized by Mabin et a l .12 The coronary angiograms were ana lyzed offl ine by 2 
experienced observers. 
A 1 2-lead ECG was acquired at presentation and after the PCI procedure. The post­
procedu ra l  ECG was ana lyzed by compa rison to the ST-segments of the ECG at 
presentation .  ST-segment elevation resolution was categorized as complete (�70%), 
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partial (30% to 70%), or absent (<30%). Persistent ST-segment deviation, defined as the 
sum of ST-segment depression and ST-segment elevation, was categorized into <2 mm, 2 
to 10 mm, and � , o  mm. 
Clinical status (death, reinfarction, and ischemia-driven target vessel revascularization) 
was collected from hospitalrecords as well as by telephone interviews at 30 dayspost­
procedure. 
Histopathological analysis 
Filtered material obtained during aspiration was analyzed using the same method as used 
in the TAPAS trial. In short, material was placed in formalin and fixed for 24 h. Thereafter, 
filtered material was pelleted by centrifugation in liquid agar 65°C in an Eppendorf tube. 
After the agar pellet was solidified at 4°C, it was embedded in paraffin using an automated 
tissue processor. Paraffin sections were cut at 4 µm and stained with hematoxylin-eosin 
for microscopical examination (x100). lmmunostaining was performed to optimize 
visualization of endothelial cells, smooth muscle cells, and macrophage foam cells. 
Samples were classified into effective or no effective aspiration based on the presence 
of thrombotic material. Identified material was classified into 4 types: thrombus with 
only platelets, thrombus with an erythrocyte component, thrombus with atheromatous 
plaque, and thrombus with both erythrocyte and atheromatous plaque and in 5 size 
groups: residue (very small filter casts of loosely cohesive platelets), well-formed thrombi 
smaller than 0.5 mm, 0.5 to 1 mm, 1 to 2 mm, and >2 mm. 
Statistical methods 
The primary end point of this study is the incidence of aspirated thrombotic components 
> 1 mm. Based on earlier experience with the Export catheter,3 it was estimated that we 
needed to enroll 160 patients to achieve a power of 80% (with a 2-sided significance level 
of 0.05) to detect a increase from 35% to 55% with the Diver catheter. 
Values are shown as means ± standard deviations, median (inner quartile range [IQR]), 
or numbers of patients (percentages). Differences in baseline characteristics and 
outcomes were tested using either paired sample t test or Wilcoxon signed-rank test. 
Nonpaired, univariate, and multivariate logistic regression analysis were used to assess 
independent predictors associated with effective thrombus aspiration and histological 
subsets. Significant variables at univariate analysis (p < 0. 15) were included in multivariate 
models. The following variables were evaluated: gender, catheter, age, ischemic time, 
hyperlipidemia, diabetes, current smoking, pre-angina pectoris, body mass index, 
3-vessel disease, TIMI flow grade beforehand, thrombus visible beforehand, and severe 
calcification. 
All p values were 2-tailed, with statistical significance set at 0.05. Analyses were performed 
using SPSS software version 12.0. 1 (SPSS Inc., Chicago, Illinois). 
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Table 1 .  Baseline and procedural characteristics 
Diver (n = 80) 
Age, years (mean ± SD) 62.4 ± 1 2.0 
Male gender 61  /80 (76.3) 
Body mass index (median, IQR) 26. 1 (24.2 -29.4) 
Risk factors 
Diabetes 6/79 (7.6) 
Hypertension 25/78 (32. 1 )  
Hyperl ipidemia 24/71 (33.8) 
Current smokers 40/79 (50.6) 
Family history 43/78 (55. 1 ) 
Previous CABG 1 /80 ( 1 .3) 
Previous Myocardial infarction 7/80 (8.8) 
Previous PCI 3/80 (3.8) 
Pre-infarct angina 42/77 (54.5) 
Symptom duration, hr  (median, IQR) 3.3 (2.0 - 5.3) 
Hemodynamics pre-procedure 
Systolic blood pressure (mean ± SD) 1 23.5 ± 25.6 
Diastolic blood pressure (mean ± SD) 74.7 ± 1 4.8 
Pulse pressure (mean ± SD) 8 1 .6 ± 23.9 
Three vessel disease 24/78 (30.8) 
Peri-procedura l  GP l i b/I l la inh ibitors 71 /80 (88.8) 
Treated vessel 
LAD 31 /80 (38.8) 
RCA 34/80 (42.5) 
Severely calcified lesion 1 4/80 ( 1 7.5) 
B irfucation lesion 31 /80 (38.8) 
T IMI  flow pre procedure 
0/1 57 /80 (71 .3) 
2 1 3/80 ( 1 6.3) 
3 1 0/80 ( 1 2.5) 
Th rombus visible pre 43/80 (53.8) 
TIM I  flow 3 post PCI 70/80 (87.5) 
Stent diameter, m m, (mean ± SD) 3.3 ± 0.4 
Stent length, mm, (mean ± SD) 1 9.9 ± 6.6 
Peak CK-MB (median, IQR) 72.8 (28 . 1  - 1 30.0) 
Time to peak CK-MB, hr  (med ian, IQR) 6.6 (4.3 - 9.9) 
Peak CK-total (median, IQR) 686.2 (244.4 - 1 283.4) 
Time to peak CK-total, hr (median, IQR) 7.2 (4.2 - 1 0.9) 
Export (n = 80) 
62.5 ± 1 1 .5 
61 /80 (76.3) 
26.2 (24.2 - 29.3) 
1 5/79 ( 1 9.0) 
26/75 (34.7) 
1 8/67 (26.9) 
40/73 (54.8) 
44/79 (55.7) 
1 /79 ( 1 .3) 
9/79 ( 1 1 .4) 
7/79 (8.9) 
30/77 (39.0) 
3.2 (2.2 - 5.6) 
1 29.7 ± 28. 1 
75 . 1  ± 1 5.4 
76.6 ± 1 8.8 
26/77 (33.8) 
77 /80 (96.3) 
31 /80 (38.8) 
34/80 (42.5) 
1 2/80 ( 1 5.0) 
24/80 (30.0) 
54/80 (67.5) 
1 6/80 (20.0) 
1 0/80 ( 1 2.5) 
40/75 (53.3) 
67 /80 (83.8) 
3.4 ± 0.5 
2 1 .3 ± 7.3 
68.0 (27.6 - 1 23.0) 
6.8 (5 . 1  - 8.8) 
764.1 (29 1 .6 - 1 45 1 .8) 
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CABG = Coronary Artery Bypass Grafting, CK = Creatine kinase, IQR = I nterquarti le range, PCI = Percutaneous 
Coronary I ntervention, SD = standard deviation, TIMI = Thrombolysis I n  Myocardia l  Infarction flow grade. 
1 32 
--------------- A comparison of two thrombus aspiration devices in STEM/ 
RESULTS 
A total of 82 consecutive patients were included. Two very young patients had no 
matching control patient within 5 years and were therefore excluded from the analysis. 
Baseline characteristics of the 80 enrolled patients are shown in Table 1. 
Angiographic and electrocardiographic outcome 
No serious complications, such as flow-limiting dissections or air embolization, occurred in 
the Diver or the Export group. A stent was placed in 91.3% (73 of 80) of the Diver patients 
and in 93.8% (75 of 80) of the Export patients. Direct stenting (stenting after thrombus 
aspiration without balloon pre-dilatation) was performed in 42.5% (31 of 73) of the 
patients treated with the Diver catheter and in 53.3% (40 of 75) treated with the Export (p 
= 0.39). Distal embolization post PCI was seen in 6.3% (5 of 80) of the patients in the Diver 
group and in 5.8% (4 of 70) in the Export group (p = 0.74). TIMI flow grade post-procedure 
and myocardial blush grade were similar in both groups (Table 1, Fig. 1 ). 
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Myocardial Blush Grade 
Figure 1 .  Myocardial blush grade after percutaneous coronary intervention 
The ECGs for persistent ST-segment deviation analysis were available in 92.5% (148 of 160) 
of the patients and for ST-segment elevation resolution analysis in 91.3% (146 of 160). 
Median (IQR) time between balloon angioplasty and post-PCI ECG was 0.7 (0.5 to 0.9) h in 
the Diver group and 0.7 (0.6 to 1. 1) h in the Export group (p = 0.37). Persistent ST-segment 
deviation <2 mm and > 70% STsegment elevation resolution was seen in the majority of 
the patients treated with thrombus aspiration, respectively 52.0% (77 of 148) and 64.4% 
(94 of 146). No differences were seen in rates of persistent ST-segment deviation <2 mm, 
2 to 10 mm and > 10 mm between the Diver (49.3%, 39.7%, and 11 .0%) and Export group 
(54.7%, 33.3%, and 12.0%) (p = 0.38) (Fig. 2). Incidences of ST-segment elevation resolution 
<30%, 30% to 70% and >70% were also similar in patients treated with the Diver (15.5%, 
16,9%, and 67.6%) and the Export patients (14.7%, 24.0%, and 61.3%) (p = 0.97) (Fig. 3). 
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Short-term clinical outcome 
Fol low-up was completed in 1 00% of the patients. Occurrence of death, reinfarction, and 
ta rget vessel revascularization within 30 days were s imi lar in both groups. One death 
occurred in the Export g roup (0% vs 1 .3%, p = 0.32). In the Diver g roup 2 reinfarctions 
occurred, compared with 1 in the Export g roup (2.5% vs 1 .3%, p = 0.57). Five patients 
underwent target vessel revascu larizations in the Diver group, compared with 4 in the 
Export g roup (6.3% vs 5.0%, p = 0.74). The i ncidence of the combined end point of death, 
reinfarction, or target vessel revascularization was 7.5% (6 of 80) in the Diver group versus 
6.3% (5 of 80) i n  the Export g roup (p = 0.76). 




ST-segment elevation resolution 








Figure 2. Persistent ST­
segment deviation 
Figure 3. ST-segment 
elevation resolution 
Effective th rombus aspiration was seen in 70.3% (52 of 74) of the patients treated with 
the Diver catheter versus 8 1 .8% (63 of 77) of the Export patients (p = 0.1 0) . Aspi rated 
th rombotic components > 1 mm were found in 44.4% (28 of 63) of the Export patients 
and in 34.6% ( 1 8 of 52) of the Diver patients (p = 0.5 1 ). The size d istribution of retrieved 
thrombotic pa rticles was a lso s imi lar for the 2 devices (p = 0.61 ) (Fig. 4) . 
Eryth rocyte-rich thrombi and thrombi with p laque components were found in respectively 
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26.9% (14 of 52) and 7.7% (4 of 52) of the patients treated with the Diver and in 22.2% 
(14 of 63) and 14.3% (9 of 63) of the patients treated with the Export catheter. Thrombi 
with both plaque and erythrocytes components were seen in 13.5% (7 of 52) of the Diver 
patients and in 7.9% (5 of 63) of the Export patients. Distribution of histological subsets 
was similar in the 2 groups (p = 0.47). 
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Residue <0,5mm 0,5-1mm 1-2mm >2mm 
Size aspirated material 
Figure 4. Size distribution of aspirated material 
The relationship between histopathological findings and baseline characteristics was 
investigated using logistic regression (Table 2). Thrombus was visible on the initial 
angiogram in the majority of the patients; however, this was not associated with retrieval 
of material at univariate logistic regression (p = 0.70). Multivariate analysis showed that 
thrombus aspiration with the Export catheter was not an independent predictor of 
effective thrombus aspiration (p = 0.09). Independent predictors for erythrocyte-rich 
thrombi at multivariate analysis were low initial TIMI flow grade (p = 0.008) and absence 
of 3-vessel disease (p = 0.026). 
DISCUSSION 
This prospective cohort study shows that the Export and Diver catheters are both safe 
and effective in removing thrombus in an unselected population with ST-segment 
elevation myocardial infarction. The larger internal lumen diameter of the Diver catheter 
did not result in retrieval of larger thrombotic particles, nor in improved angiographic or 
electrocardiographic outcomes. 
Primary PCI does not always result in successful reperfusion of the myocardium, 
despite a patent epicardial vessel. Mechanical crushing and fragmentation of the 
thrombuscontaining lesion during primary PCI is thought to be at least partly responsible 
for myocardial dysfunction after PCl.13-15 Several devices have been introduced to facilitate 
removal of thrombus and plaque material, thereby protecting the microvasculature 
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and improving myocardia l  blood flow. I n  saphenous vein graft PCI, dista l embolic 
protection devices have proven to be very effective in preventing d ista l embol ization 
(class I recommendation, level of evidence A).16 In primary PCI for native coronary lesions, 
aspiration thrombectomy devices may be most usefu l because their size a l lows access to 
the lesion over a routine wire. The DEAR-M l (Dethrombosis to Enhance Acute Reperfusion 
in Myocardia l  I nfa rction) tria l randomized 1 55 patients to thrombus aspiration with the 
Pronto catheter or to primary PCI a lone.5 Thrombus aspiration in  this tria l  was associated 
with sign ificantly better ST-segment resol ution, better myocardia l  b lush grade, and less 
dista l embol ization compared with primary PCI. The resu lts of the TAPAS tria l  (Export 
aspiration catheter) and the REM ED IA (Randomized Eva luation of the Effect of Mechanica l 
Reduction of Dista l Embol ization by Thrombus-Aspiration in Primary and Rescue 
Angioplasty) tria l (Diver aspiration catheter), which compared thrombus aspiration with 
primary PCI, reported also feasibi l ity and appl icabi l ity of this approach.3•6 Confl icting 
resu lts came from the tria l  of Ka ltoft et a l .,7 which enro l led 2 1 5 patients to thrombus 
aspiration with the Rescue catheter or primary PCI. This study reported larger fina l  i nfarct 
size and a trend toward less myocardia l  salvage associated with thrombus aspi ration. I n  
the abovementioned stud ies, 4 d ifferent aspiration devices were used. I t  i s  unclear t o  what 
extent these conflicti ng resu lts can be expla ined by device-related factors. One major 
difference between these devices is i nterna l  l umen d iameter. An aspiration catheter with 
insufficient capacity to aspi rate can theoretica l ly manipulate and dis lodge the th rombus, 
causing an adverse effect on myocardia l  perfusion. Th is present study shows that both 
medium-lumen and large-l umen th rombus aspiration catheters are safe and effective in 
terms of hig h  rates of myocardia l  blush grades 2 to 3 and ST-segment norma l ization. 
Table 2. Multivariate logistic regression analysis of significant baseline characteristics (p<0. 1 5) on 
effective thrombus aspiration and erythrocyte-rich thrombi 
Dependent variable Co-variable Exp (B) (95% Cl) P-value 
Effective thrombus aspiration 
Catheter (Export) 2.07 (0.90 to 4.76) 0.09 
Diabetes 0.39 (0. 1 3 to 1 . 1 4) 0.08 
Hyperl ipidemia 0.48 (0.2 1 to 1 . 1 1 ) 0.09 
Erythrocyte-rich thrombi 
lschemic time (hrs) 1 .07 (0.98 to 1 . 1 8) 0. 1 5  
Three vessel d isease 0.32 (0. 1 2 to 0.87) 0.026 
TIMI flow pre 0.54 (0.34 to 0.85) 0.008 
Cl = confidence interval; Exp (B) = exponentiation of the B coefficient; TIMI = Thrombolysis In Myocardia l  I nfa rction 
flow grade, pre = pre angioplasty procedu re. 
The size distribution of retrieved particles d id not d iffer s ign ificantly between the 2 
catheters; however, especia l ly in the range 1 to 2 mm, some d ifference cou ld be detected 
in favor of the Export catheter. These d ifferences can be caused by d ifferences in d istal tip 
design between the 2 catheters. The nonsuperiority of a la rger- lumen catheter may be 
explained by the fact that freshly formed thrombi are easi ly friab le. Whether a larger-l umen 
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catheter has a benefit in the context of older occlusions and degenerated saphenous vein 
grafts, in which particles are less friable, is currently unclear. 
Previous angioscopic studies in patients with acute coronary syndromes suppose 
erythrocyte-rich thrombi to be present in the majority of the patients with acute 
myocardial infarction. 1 7•1 8 Our study found a lower incidence of erythrocyte-rich thrombi 
(34.8%, 40 of 115). Erythrocyterich thrombi were predominantly seen in patients with low 
initial epicardial flow in combination with a trend for longer ischemic time. This supports 
the thought that erythrocyterich thrombi are formed mainly during stasis of blood flow, 
whereas white thrombi are predominately seen in patients with TIMI flow grade 1 to 3 
at presentation. 1 7-20 The lower incidence of erythrocyte-thrombi in our study can be 
explained by the fact that most previous observations date from the thrombolytic era, 
whereas nowadays patients are pretreated with heparin, aspirin, and clopidogrel during 
transportation to a PCI facility. These antithrombotic agents can induce enhancement 
of lysis and dissolvement of thrombus, causing pharmacological reperfusion before the 
initial angiogram.21•22 
In our study we compared 2 manual thrombus-aspiration catheters. However, there are 
several types of adjunctive mechanical devices for reducing distal embolization. Recently 
a meta-analysis has been published combining the results of 21 randomized trials 
investigating the impact of adjunctive mechanical devices to prevent distal embolization.4 
In this analysis, the benefit in terms of better myocardial perfusion and less distal 
embolization was more apparent in studies investigating the impact of thrombectomy as 
compared with distal protection devices. Whether there is a difference in efficacy between 
different types of adjunctive mechanical devices (for example, mechanical thrombectomy 
vs manual thrombus aspiration) is currently unclear in the context of STEMI, because no 
direct comparisons have been performed. 
This study has several limitations. Both study groups were followed up prospectively 
and matched for age, gender, initial TIMI flow grade, and infarct-related segment, but 
bias of unknown confounders still might exist. Our histopathological analysis provides 
information on aspiration capacity in terms of presence of thrombotic material and size of 
aspirated particles. However, no analysis was performed on the total volume of retrieved 
debris. A distal embolic protection device may be useful for investigating differences in 
the volume ratio of aspirated versus distal embolic debris, but these devices are only 
feasible in a selected group of patients. 
CONCLUSION 
The present study shows that manual aspiration catheters are safe and effective in 
removing thrombus in patients with ST-segment elevation myocardial infarction. A larger 
internal lumen diameter did not result in retrieval of larger thrombotic particles, nor in 
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To investigate the feas ib i l ity and safety of manual th rombus aspiration in patients 
undergoing percutaneous coronary intervention (PCI) for non-ST-elevation myocard ia l  
i nfa rction (NSTEMI) . 
Background 
Myocardia l necrosis in patients with acute coronary synd romes may be a s ign of 
m icrovascular obstruction, owing to spontaneous or PCl-induced embol ization of 
atherothrombotic materia l .  Manua l  thrombus aspiration resu lts in improved myocard ia l  
reperfusion in patients undergoing PCI for ST-elevation myocard ia l  infarction. Currently, 
no  publ ished data on th rombus aspi ration i n  patients with NSTEMI are ava i lable. 
Methods 
As part of a prospective cohort study, 70 patients undergoing PCI for NSTEMI were treated 
with thrombus aspi ration (Export Aspi ration  Catheter, Medtronic, Minneapol is, MN) .  
H istopathological ana lysis was performed on aspirated materia l .  
Results 
Thrombus aspiration was effective in 58 patients (83%) and resu l ted in a marked reduction 
ofTIM l-thrombus score 4/5 (40% pre- versus 7% postth rombus aspiration) and increase of 
the rate of TIMI-flow 3 (36% pre- versus 66% postthrombus aspiration). The incidence of 
myocard ial b lush grade 2 and 3 were 39 and 45%, respectively. Dista l embol ization was 
visib le in three patients (4%) on the fi na l  ang iogram. 
Conclusion 
This study demonstrates that thrombus aspiration in most NSTEMI patients is feasib le and 
safe and is associated with a high rate of retrieva l of thrombotic materia l .  
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INTRODUCTION 
Acute coronary syndromes (ACS) are initiated by an eroded, fissured, or ruptured 
atherosclerotic plaque, leading to subsequent platelet aggregation and thrombus 
formation. Myocardial necrosis occurs when the resultant thrombus induces (transient) 
epicardial occlusion, but may also be a sign of microvascular obstruction, owing to 
spontaneous or percutaneous coronary intervention (PCl)-induced embolization of 
atherothrombotic material.1 -3 Recently, we have demonstrated that manual thrombus 
aspiration is effective in patients undergoing PCI for ST-elevation myocardial infarction 
(STEMl).4•5 At the present time, no published data on thrombus aspiration in patients with 
non-ST-elevation myocardial infarction (NSTEMI) are available. 
In this prospective cohort study, we have investigated the feasibility and safety of 
thrombus aspiration (Export Aspiration Catheter, Medtronic, Minneapolis, MN) in patients 






NSTEM I  patients meeting el ig ibi l ity criteria 
1 3 ( 1 6%) 
Thrombus aspiration not attempted * 
70 (84%) 
Thrombus aspiration attempted 
58 (83%) retrieval of thrombus 
TA followed by d irect stenting 
TA with additional bal loon d i latation 





1 2  ( 1 7%) no retrieval of thrombus 
TA fol lowed by d irect stenting 
TA with additional bal loon di latation 
TA followed by only bal loon d i latation 
Figure 1 .  Study flow diagram 
* The operator decided that thrombus aspiration was not feasible because of left main stenosis (N=2) 




MATERI ALS AND METHODS 
Patients who underwent PCI for NSTEMI were included in this prospective study. NSTEMI 
was defined as chest pain at rest, time from last chest pain to angiography less than 24 hr, 
an ECG with ST-segment shifts and/or T-wave changes, and a positive cardiac troponin T. 
No angiographic subsets of patients were excluded. 
Device and Procedure Characteristics 
The Export Aspiration Catheter (Medtronic, Minneapolis, MN) is a 6F compatible thrombus 
aspiration catheter with an aspiration lumen of 0.041 in. and a crossing profile of 0.068 in. 
Suction is performed by hand with lockable 20-ml syringes. 
After crossing the ischemia-related lesion with a guide wire, the Export Aspiration 
Catheter was advanced into the target segment during continuous aspiration. The 
number of passages, necessary to achieve an optimal result, was left over to the judgment 
of the operator, but at least 2 x 20 ml was aspirated in multiple passages. Additional 
balloon angioplasty was performed when necessary for stent delivery. All interventional 
cardiologists were experienced in performing manual thrombus aspiration.4 
Medication 
Before PCI, the patient was treated with aspirin (a bolus of 500 mg), intravenous heparin 
(5,000 IU), and clopidogrel (a loading dose of 600 mg). Adjunctive therapy included 
nitroglycerin and glycoprotein (GP) llb/llla inhibitors. During PCI, additional heparin 
was administered guided by ACT measurements. Standard therapies after PCI included 
aspirin 80 mg, clopidogrel 75 mg, beta-blockers, lipid-lowering agents, and angiotensin­
converting enzyme inhibitors or angiotensin II receptor blockers. 
Risk Stratification, Angiographic, and Clinical Outcome 
The risk for in-hospital mortality was calculated using the GRACE-risk score6 and divided in 
low (probability in-hospital death <1 %), intermediate (1- 3%), and high (>3%). Coronary 
angiograms were analyzed off-line by an experienced interventional cardiologist. 
lntracoronary nitroglycerin was given after the procedure and before the final angiogram 
in all patients. Thrombolysis in myocardial infarction (TIMI) flow grades and myocardial 
blush grades (MBG) were estimated as previously described.2 Distal embolization was 
defined as circumscribed filling defects and/or abrupt cut off of the vessel distal to the 
target lesion on the final angiogram after the PCI procedure. Thrombus was assessed 
according to the criteria summarized by Mabin et al.7 and thrombus load was graded from 
O to 5 according to the TIMl-thrombusscore.8 
Clinical status (death, reinfarction, and ischemia driven target vessel revascularization) 
was collected from hospital records as well as by telephone interviews at 30 days 
postproced u re. 
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Table 1 .  Baseline and procedural characteristics 
Age, years (mean ± SD) 
Male gender 








Previous Myocardia l  infarction 
Previous PCI 
Hemodynamics pre-procedure 
Systol ic blood pressure (mean ± SD) 
Diastolic blood pressure (mean ± SD) 
Heart rate, beats/min (mean ± SD) 
Peri-procedural  GP l i b/I l la inh ibitors 
Severely calcified lesion 
Bifurcation lesion 




TIMI flow 3 post procedure 











Stent diameter, mm, (mean ± SD) 
Stent length, mm, (mean ± SD) 
PeakTroponin T (median, IQR) 
Time to peak Troponin T ,  hr  (median, IQR) 
Peak CK-total (median, IQR) 
Time to peak CK-total, hr  (median, IQR) 
Peak CK-MB (median, IQR) 
Time to peak CK-MB, hr (median, IQR) 
N = 70 
6 1 . 1  ± 1 1 .9 
55/70 (78.6) 
26.2 (24.8 - 28.7) 
4/70 (5.7) 
32/68 (47. 1 )  
33/62 (53 .2) 
27 /69 (39. 1 )  
4 1  /68 (60.3) 
4/70 (5.7) 
7/70 ( 1 0.0) 
8/70 ( 1 1 .4) 
1 26.8 ± 23.3 
75.6 ± 1 2.0 
76.3 ± 1 6.4 
55/70 (78.6) 
1 4/70 (20.0) 
30/70 (42.9) 
23/70 (32.9) 
22/70 (3 1 .4) 
25/70 (35.7) 
6 1 /70 (87. 1 )  









3.3 ± 0.5 
1 8.6 ± 5.8 
1 .0 (0.2 - 2.7) 
4.8 ( 1 .6 - 4.8) 
3 1 7.0 ( 1 04.5 - 1 1 20.5) 
4.4 (0.3 - 8.7) 
52.5 (20.3 - 1 3 1 .5) 
2.9 (0.3 - 9.9) 
CABG = Coronary Artery Bypass Grafting, IQR = I nterquarti le range, PCI = Percutaneous Coronary Intervention, SD = 




Filtered materia l  obta ined duri ng aspiration was ana lyzed us ing the same method as 
used in the TAPASstudy.4•9 Effective th rombus aspiration was defined as the presence 
of atherothrombotic materia l  in  the aspi rate samples. Identified materia l  was classified 
based on the composition (white platelet thrombus vs. red eryth rocyte-rich th rombus) 
and size of aspirated and fi ltered atherothrombotic material , as wel l  as on the presence of 
plaque components. Material was d ivided in three size g roups: sma l l  (very sma l l  fi lter casts 
of loosely cohesive platelets and th rombi smal ler than 0.5 mm), med ium (thrombi 0.5-2 
mm), and large (th rombi >2 mm). 
Statistical Analysis 
Uni- and mu ltivariate reg ression analyses were performed to identify pred ictors of effective 
thrombus aspiration and improved TIMI flow (d ifference between pre- and postthrombus 
aspiration TIMI  flow). The fol lowing variables were tested: age (years), sex (ma le), tota l 
ischemic time (hr), hypertension, diabetes, hypercholesterolemia, current smoking, 
previous Ml, heart rate at admission, systol ic blood pressu re, body mass index, anterior Ml ,  
periprocedura l  GPl l b/l l l a, number of vessels diseased, prox ima l  i nfarctrelated segment, 
thrombus vis ible pre, stent diameter (as estimate of vessel d iameter) .  S ignificant variab les 
at un ivariate ana lysis (P < 0 . 1 5) were inc luded in the mu ltiva riate model. All P-va lues were 
two-ta i led, with statistica l s ign ificance set at <0.05. Ana lyses were performed using SPSS 
software version 1 4.0.2 (SPSS, Ch icago, IL) .  
RESULTS 
Between January 2007 and August 2007, 83 patients met the e l ig ib i l ity criteria. I n  1 3/83 
patients ( 1 6%), the operator decided not to attempt thrombus aspiration because of 
left main stenosis (N = 2) and smal l  and/or tortuous vessel (N = 1 1  ). In 70/83 patients 
(84%), th rombus aspiration was attempted. The characteristics and outcomes of these 70 
patients a re described in deta i l  in  this ana lysis (see Fig. 1 ) .  
Baseline Characteristics 
The mean age was 61 ± 1 2  years (see Table I ) .  The GRACE-risk scores for in-hospita l 
morta l ity were low in 26%, intermediate i n  32%, and h igh i n  42% of the patients. The 
ischemia-related artery was the right coronary artery in 43%, left anterior descending 
artery in 29%, left circumflex artery in 23%, and a venegraft i n  4%. Mu ltivessel disease was 
present in 56% of the patients. 
Angiographic and Clinical Outcomes 
Thrombus was visible on the in itia l ang iogram in 36 patients (5 1 %) . No compl ications 
such as flow l im iting d issections or a i r  embo l ization occu rred duri ng thrombus aspiration. 
Th rombus aspiration was associated with a marked reduction ofTIMl-thrombus score 4/5 
(40% pre- versus 7% postthrombus aspiration) and increase of the rate ofTIMl-flow 3 (36% 
pre- versus 66% postthrombus aspiration) .  Di rect stenting was performed in  39 patients 
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(55.7%) (see Fig. 1 and Table I). Incidence of post-PCI TIMI-flow 3 was 87%. The incidence of 
myocardial blush grade (MBG) 2 and 3 were 39 and 45%, respectively. Distal embolization 
was visible in three patients (4%) on the final angiogram. 
At 30-days follow-up, two patients underwent target vessel revascularization (a re-PCI and 
a CABG) and no deaths or reinfarctions occurred. 
Multivariate linear regression analysis demonstrated that "thrombus visible on initial 
angiography" was the only significant variable associated with increase in TIMI flow after 
thrombus aspiration (see Table 1 1 ). 
Table 2. Analysis of aspirated material 
Age Gender MVD In itial TIMI Thrombus 
(yrs) (Men) flow CAG* 
Total <60 �60 no Yes no yes 0/1 2/3 no yes 
Tota l , N 70 3 1  39 1 5  55 28 36 23 47 34 36 
Effective thrombus aspiration, N (%) 58 (83%) 29 29 1 1  47 23 30 2 1  3 7  26 3 2  
(94%) (74%) (73%) (85%) (82%) (83%) (91 % )  (79%) (76%) (89%) 
Thrombus 
White platelet thrombus 44 (76%) 72% 79% 82% 74% 70% 77% 57% 86% 92% 63% 
Red erythrocyte-rich thrombus 1 4 (24%) 28% 2 1 %  1 8% 26% 30% 23% 43% 1 4% 8% 38% 
Plaque 
Thrombus with plaque comp 1 4 (24%) 28% 2 1 %  9% 28% 22% 23% 33% 1 9% 1 5% 3 1 %  
Thrombus without plaque comp 44 (76%) 72% 79% 9 1 %  72% 78% 77% 67% 8 1 %  85% 69% 
Size 
Sma l l  37 (64%) 59% 69% 82% 60% 65% 63% 38% 78% 85% 47% 
Medium 1 0 ( 1 7%) 1 7% 1 7% 9% 1 9% 1 7% 1 3% 29% 1 1 % 8% 25% 
Large 1 1  ( 1 9%) 24% 1 4% 9% 2 1 %  1 7% 23% 33% 1 1 % 8% 28% 
*Thrombus visible on initial angiogram, Comp.= Component, MVD= Multivessel d isease. 
Histopathological Outcome 
Thrombus aspiration was effective (retrieval of atherothrombotic material) in 58/70 
patients (83%). With inclusion of the 13 patients in which thrombus aspiration was not 
attempted, the rate of effective thrombus aspiration is 58/83 patients (70%). Microscopic 
analysis of aspirated material showed white platelet thrombus in 44 patients (76%) and red 
erythrocyte-rich thrombus in only 14 patients (24%). Thrombi with plaque components 
were found in 14 patients (24%). The size of particles was small in 37 (64%), moderate in 
10 (17%), and large in 1 1  patients (19%). The outcomes of the histopathological analysis 
in subgroups are detailed in Table Ill. In particular, the presence of thrombus on the initial 
angiogram and lower initial TIMI flow were associated with retrieval of large, erythrocyte 




In summary, this prospective study demonstrates the following: thrombus aspiration in 
NSTEMI is a safe method to prepare the culprit lesion for stent implantation; associated 
with a high rate of retrieval of thrombotic material; decreases intracoronary thrombus 
burden; and results in improved flow in the ischemiarelated coronary artery. 
In high-risk ACS-patients with elevated troponin levels or ST-segment depression, an early 
invasive strategy has proven to be effective.1 0• 1 1  However, mobilization and subsequent 
embolization of thrombus and plaque material occurs in a majority of PCI procedures 
and plays a significant role in the pathogenesis of impaired reperfusion. 1 • 1 2  Especially 
in patients with non-ST-elevation ACS, PCl-induced distal embolization is of clinical 
importance, as reflected by the high incidence of periprocedural myocardial infarction in 
these patients. 13-1 5 
Recently, Galiuto et al. have demonstrated that thrombus aspiration in STEMI can 
significantly reduce the severity and extent of myocardial obstruction, as measured by 
contrast-enhanced echocardiography.2 Several trials have demonstrated that thrombus 
aspiration significantly improves myocardial perfusion after primary PCI as assessed by 
myocardial blush grade and ST-segment elevation resolution.4• 1 6•1 7 The largest trial to date, 
the TAPAS-trial, evaluated the efficacy of thrombus aspiration compared with convention 
angioplasty in 1 ,071 patients undergoing PCI for STEMI. In this trial, thrombus aspiration 
resulted in improved myocardial perfusion and clinical outcomes.4•5 
Table 3. Multivariate regression analysis of significant variables at univariate analysis (p<0.1 5) 
Thrombus visi ble pre 
Number of vessels diseased 
Heart rate at admission 
Body Mass Index 
Thrombus visi ble pre 
Heart rate at admission 
Sex (ma le) 
Systol ic B lood Pressure 
Anterior M l  
Effective thrombus aspiration 
OR 95% (1 p 
1 1 .76 0.69 to 201 .75 0.09 
2.04 0.38 to 1 0.83 0.40 
1 . 1 4  1 .0 1  to 1 .28 0.040 
0.77 0.58 to 1 .02 O.o? 
Delta pre and post aspiration TIMI flow 
ARD 95% (1 p 
0.89 0.39 to 1 .39 0.00 1 
0.0 1 -0.Q l to 0.03 0.1 9 
0.26 -0.36 to 0.87 0.4 1 
-0.01 -0.Q2 to 0.00 0.09 
-0.30 -0.8 1 to 0.20 0.24 
ARD = absolute risk difference, Cl = confidence interval ,  GP = Glycoprotein l l b l l la i nh ibitor, Ml = Myoca rd ia l  
I nfarction, n/a = not appl icable, OR = Odds Ratio. 
In this study, comparison of pre- and postthrombus aspiration angiograms demonstrated 
a marked improvement of coronary blood flow and reduction of thrombus load, indicating 
that thrombus aspiration is an effective method to prepare the culprit lesion for stent 
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implantation. The efficacy of thrombus aspiration was also indirectly confirmed by a high 
incidence of MBG 2/3, a low incidence of distal embolization, and a high rate of direct 
stenting. 
Thrombus aspiration in NSTEMI was effective in a large majority of patients, comparable to 
the rate found in STEMI patients treated with this aspiration catheter.4 Aspirated material 
contained predominantly white thrombi, as can be expected in patients with high initial 
epicardial flow (77% had TIMI-flow 1-3), in a pattern that shows remarkable similarity 
to findings in STEMI patients.4 The presence of thrombus on the initial angiogram and 
lower initial TIMI flow were associated with retrieval of large, erythrocyte rich, thrombotic 
particles. 
Compared with earlier reports on conventional PCI in non-ST-elevation ACS, the 30 
days incidences of death, reinfarction, and revascularization in our study on thrombus 
aspiration are low.1 3-15 For example, in the TACTICS-TIMl-18 study,14 2,220 patients with 
unstable angina (63%) or NSTEMI (37%) were randomized to an early invasive strategy 
(catheterization within 4-48 hr and PCI as appropriate) or to a more conservative 
treatment (catheterization only if the patient had objective evidence of recurrent 
ischemia or an abnormal stress test). Standard medical therapy included aspirin, heparin, 
and glycoprotein llb/llla antagonists. The incidence of death or nonfatal reinfarction was 
4.7% in the early invasive group and 7.0% in the conservative strategy at 30 days. In the 
subgroup of patients in the early invasive group who underwent PCI (41 %) the incidence 
of death at 30 days was 1.9%. The TRITON-TIMl-38 study of Wiviott et al. randomized 
13,608 patients who underwent PCI for ACS (26% STEMI and 74% unstable angina or 
NSTEMI) to prasugrel or clopidogrel. The incidence of glycoprotein lib/I l la antagonists use 
was 54%. The incidence of cardiac death, nonfatal reinfarction, or nonfatal stroke was ±5% 
in the prasugrel group and 67% in the clopidogrel group at 30 days (percentages retrieved 
from Kaplan-Meier curves). lnaddition, the ICTUS trial1 3  randomized 1,200 patients with 
ACS without ST-segment elevation to an early invasive strategy or to a more conservative 
(selectively invasive) strategy. Patients received aspirin daily, enoxaparin for 48 hr, and a 
glycoprotein lib/Illa antagonist at the time of PCI. The mortality rate at 1 year was similar 
in the two groups (2.5%). Reinfarction rate at 1 year occurred in the 15% of the patients in 
early invasive management group and in 10.0% of the conservative group. 
Thrombus aspiration seems to be safe in patients with NSTEMI, as no complications 
associated with thrombus aspiration occurred in this study. As also observed in the TAPAS 
trial, thrombus aspiration was demonstrated to be safe (no flow-limiting dissections) and 
a straightforward therapy (similar duration of fluoroscopy and door-to-balloon times as 
the control group).4 
This single-center prospective cohort study on the impact of thrombus aspiration in 
NSTEMI suffers of several limitations, including a small sample size and absence of control 
group. In addition, thrombus aspiration was not attempted in 13 patients. With inclusion 
of these 13 patients in the analysis of the rate of effective thrombus aspiration, our success 
rate is 58/83 patients (70%). Randomized controlled trials are necessary to investigate if 
thrombus aspiration in NSTEMI results in improved angiographic and clinical outcomes 
when compared with conventional PCI. 
In conclusion, this study demonstrates that thrombus aspiration in most NSTEMI patients 
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Chapter 1 0  
ABSTRACT 
Aim 
To evaluate the additional effect of thrombus aspiration in ST-Elevation Myocardial 
Infarction (STEMI) patients who are eligible for direct stenting. 
Methods and Results 
Data were obtained from all consecutive STEMI patients treated with primary PCI from 
January 2004 to December 2007 in our hospital. Patients treated with direct stenting were 
compared to patients who received thrombus aspiration prior to stenting. 
Of the 1 992 STEMI patients, 751 /1992 (37.7%) were eligible for direct stenting. Direct 
stenting was performed in 245/751 (32.6%) and thrombus aspiration prior to stenting in 
506/751 (67.4%) patients. Despite worse angiographic baseline characteristics, thrombus 
aspiration prior to stenting was associated with significant improved primary endpoint 
Myocardial blush Grade (p=0.002) and TIMI flow grade (p=0.013) as compared with the 
direct stenting group. The beneficial contribution of thrombus aspiration prior to stenting 
to myocardial reperfusion remained after correction for well-known prognostic factors. 
Conclusion 
This study indicates that thrombus aspiration is of additional benefit in STEMI patients 
who are eligible for direct stenting. 
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INTRODUCTION 
Several randomized controlled trials and meta-analyses have demonstrated that manual 
thrombus aspiration is associated with improved myocardial reperfusion as compared 
with conventional percutaneous coronary intervention (PCI) in patients with ST-Elevation 
Myocardial Infarction (STEMl).1-4These studies demonstrated that in patients with sufficient 
antegrade coronary flow after thrombus aspiration, balloon predilatation before stenting 
was often not necessary. This resulted in a higher rate of stenting without predilatation 
compared with conventional PCI. Since some studies suggest that direct stenting is 
superior compared with balloon predilatation followed by stenting,5•6 the beneficial 
effect of thrombus aspiration could (partly) be related to the effect of direct stenting. 
It is currently unclear what the value is of direct stenting in the context of primary PCI, 
and whether thrombus aspiration is still beneficial in patients who are eligible for direct 
stenting. 
In the present analysis, we compared STEM! patients who underwent direct stenting with 
patients who underwent thrombus aspiration prior to stenting in routine clinical practice. 
1 992 consecutive STEMI patients treated with primary PCI between January 
2004 and December 2007 
� 1 24 1  patients not eligible for 
direct stenting 
V 
751 patients eligible for direct stenting 
l L 
245 treated with 506 treated with thrombus 
direct stenting aspiration prior to stenting 





Patients treated with primary PCI for STEMI in the University Medical Center Groningen 
were included. Inclusion criteria were: ST-segment elevation >0.1 mV in 2 or more leads 
on the ECG, onset of symptoms less than 1 2  hours or less than 24 hours with persisting 
symptoms due to ongoing ischemia, and eligible for direct stenting. Eligible for direct 
stenting included those patients in whom the operator decided that balloon predilatation 
was not necessary before stent implantation. 
To investigate the additional benefit of thrombus aspiration prior to stenting in patients 
eligible for direct stenting, we compared patients undergoing direct stenting with 
patients receiving only thrombus aspiration prior to stenting. To limit selection bias, these 
two groups were selected from 2 different populations. The direct stenting group was 
selected from a population in which conventional PCI was the preferred strategy; patients 
treated from January 2004 until January 2005 and those randomized to conventional PCI 
in the context of the TAPAS7 between January 2005 until December 2006. The thrombus 
aspiration group was selected from a population in which thrombus aspiration was the 
preferred strategy; patients treated after January 2007 (when thrombus aspiration became 
the preferred treatment) untill December 2007 and those randomized to thrombus 
aspiration in the context of the TA PAS. 
Angiographic analysis 
All coronary angiograms were analyzed by an independent core laboratory or by two 
experienced observers blinded to all clinical data. The sequence of intervention during 
PCI was determined on coronary angiogram. The myocardial perfusion was determined 
by the contrast density of the myocardial region of the infarct-related artery and classified 
as MBG 0: no myocardial blush or persisting blush (staining), 1: minimal myocardial blush, 
2: moderate myocardial blush or 3: normal myocardial blush, all compared to the MBG of 
myocardial regions of non-infarct-related arteries.8 Thrombolysis In Myocardial Infarction 
(TIMI) flow grade was classified as 0: no antegrade flow, 1: minimal antegrade flow into the 
obstructed segment, 2: slow antegrade flow into the distal bed, 3: normal antegrade flow 
into the distal bed.9 Large thrombus burden was defined as TIMI thrombus grade 4 or 5. 1 0 
Endpoints 
Primary endpoint of this study was MBG. Secondary endpoints were TIMI flow grade after 
PCI and all-cause mortality at 30 days and 1 year. Mortality was collected in all patients 
using municipal civil registries, which has completeness of vital status of all residents 
registered in The Netherlands. 
Statistical analysis 
Normally distributed continuous variables are presented as mean with standard 
deviation (SD) and were compared using a two-tailed Student's t-test. Skewed distributed 
continuous variables are presented as median with interquartile range ( IQR) and were 
compared using a Mann Whitney U test. Categorical variables are presented as number 
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Table 1.  Baseline characteristics 
Direct Stenting Thrombus aspiration P-va lue 
prior to stenting 
n=245 n=506 
Genera l  characteristics 
Age, years (mean±SD) 6 1 .0±1 3 6 1 .9±1 2 0.37 
Male sex 1 69/245 (69) 364/506 (72) 0.40 
History 
Hypertension 82/201 (41 )  1 5 1 /479 (32) 0.020 
Diabetes mel l itus 26/2 1 7  ( 1 2) 45/492 (9) 0.25 
Hypercholesterolem ia 65/206 (32) 95/41 6 (23) 0.0 1 9 
Myocard ial infarction 1 6/227 (7) 36/494 (7) 0.9 1 
PCI 1 0/245 (4) 36/506 (7) 0. 1 0  
CABG 8/245 (3) 1 9/506 (4) 0.74 
Current smoking 1 1 4/1 95 (58) 230/455 (5 1 )  0.06 
lschemic time, minutes (median ( IQR)) 1 77 ( 1 25-245) 1 75 ( 1 30-255) 0.44 
Angiographic characteristics 
Culprit location 0. 1 5  
Right coronary artery 95/245 (39) 205/506 (41 )  
Left anterior descending artery 1 08/245 (44) 1 99/506 (39) 
Left circumflex artery 35/245 ( 1 4) 89/506 ( 1 8) 
Other 7/245 (3) 1 3/506 (3) 
Mu ltivessel d isease 1 45/242 (60) 3 1 5/505 (63) 0.50 
TIMI flow grade pre <0.00 1 
0 58/242 (24) 228/504 (45) 
2 1 /242 (9) 59/504 ( 1 2) 
2 or 3 1 63/242 (67) 2 1 7/504 (43) 
Visible thrombus 1 82/242 (75) 4 l 7 /505 (83) 0.0 1 8 
Large thrombus burden 1 07 /240 (45) 3 1 8/502 (63) <0.001 
Reference vessel diameter <3mm 2 1 /236 (9) 54/460( 1 2) 0.25 
Number of stents implanted (mean±SD) 1 .2±0.6 1 .3±0.6 0.40 
Mean stent diameter (mean±SD) 3.3±0.6 3.3±0.7 0.93 
Data are number (%) un less otherwise indicated. PCI = percutaneous coronary intervention, CABG = coronary a rtery 
bypass grafting, TIMI = Thrombolysis In Myocard ial I nfarction, SD = standard deviation, IQR = interquarti l e  range. 
and percentage and were compared using the x2 test. Multivariab le regression ana lysis  
was used to eva luate the i ndependent contribution of th rombus aspiration pr ior  to 
stenting to MBG 3 after correction for basel ine d ifferences and wel l-known predictive 
variables. Statistica l significance was defined as a two-sided p-va lue  of l ess than 0.05. 
Statistica l ana lysis was performed using SPSS software version 1 6.0 (SPSS, Ch icago, USA). 
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RESU LTS 
Study population 
In total, 1992 STEMI patients were treated with primary PCI in our hospital in the 4 year 
period. Of these patients 751 (37.7%) were eligible for direct stenting and were included 
in the present analysis. Direct stenting was performed in 245/751 (32.6%) patients and 
thrombus aspiration prior to stenting was performed in 506/751 (67.4%) patients (Figure 
1 ). Patients who received thrombus aspiration prior to stenting had worse angiographic 
baseline characteristics, including lower TIMI flow grade and larger thrombus burden 
before PCI (Table 1 ). 
Outcome 
There was an significant increase of the primary endpoint MBG in the group of thrombus 
aspiration prior to stenting (MBG 0, 1, 2 and 3: 2%, 15%, 38% and 45%) compared to the 
group of direct stenting (7%, 14%, 41 % and 38%) (p=0.002) (Table 2 and Figure 2). TIMI 
flow grade after PCI was also significant higher in the group of thrombus aspiration prior 
to stenting (TIMI 0, 1, 2 and 3: 0%, 1 %, 9% and 91 %) compared to the group of direct 
stenting (1 %, 3%, 9% and 87%) (p=0.013)) (Table 3 and Figure 3). Multivariable analysis 
showed that thrombus aspiration prior to stenting was an independent predictor of MBG 
3 after correction for age, ischemic time, anterior infarction, TIMI flow O or 1 and visible 
thrombus before PCI (Table 3). All-cause mortality at 30 days and 1 year was available in all 
patients and showed a trend in favour of thrombus aspiration prior to stenting (Table 2). 
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Figure 2. Incidence of the primary endpoint 
Myocardial Blush Grade after the procedure. 
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Figure 3. Incidence of TIMI flow grade after the 
procedure. 
This study indicates that thrombus aspiration prior to stenting has additional benefit 
compared with direct stenting in STEMI patients undergoing primary PCI. Despite the 
worse TIMI flow grade and more visible thrombus before PCI, patients treated with 
thrombus aspiration prior to stenting had significant increased myocardial reperfusion. 
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Table 2. Outcome characteristics 
Direct Stenting Thrombus aspiration P-va lue 
prior to stenting 
n=245 n=506 
Post procedural  characteristics 
MBG n=220 n=49 1 0.002 
0 1 5  (6.8) 8 ( 1 .6) 
30 ( 1 3.6) 74 ( 1 5 . 1 ) 
2 91 (4 1 .4) 1 89 (38.5) 
3 84 (38.2) 220 (44.8) 
TIMI flow grade n=243 n=504 0.01 3 
0 2 (0.8) 0 (0) 
7 (2.9) 3 (0.6) 
2 22 (9. 1 )  4 3  (8.5) 
3 2 1 2  (87.2) 458 (90.9) 
Follow-up 
30 days mortal ity 9 (3.7) 1 2  (2.4) 0.3 1 0  
1 -year mortality 1 6  (6.5) 21 (4.2) 0. 1 58 
Data are number (%). MBG = Myocardia l Blush Grade, TIMI  = Thrombolysis In Myocardial Infarction. 
Furthermore, increased restoration of blood flow was observed in this study. Several 
suggestions can be made to explain the additional benefit of thrombus aspiration 
prior to stenting. Firstly, distal embolization occurs frequently in patients undergoing 
primary PCI and is associated with impaired myocardial reperfusion and poor clinical 
outcome.1 1 It is likely that when thrombus burden is present, despite sufficient antegrade 
coronary flow, distal embolization is still at risk in patients treated with direct stenting. As 
thrombus aspiration reduces the atherothrombotic burden, it reduces the risk of distal 
embolization.1-2 Further, the risk of distal embolization is thought to be highest during this 
first intervention, whether this is balloon dilatation or stent implantation. Therefore, also 
in patients eligible for direct stenting, a PCI strategy starting with thrombus aspiration 
before stenting is likely to result in less distal embolization as compared with those who 
undergo direct stenting. 
Secondly, sufficient antegrade flow through the infarct-related segment is necessary for 
selection and positioning of the stent. As thrombus aspiration results in the majority of 
the patients in sufficient antegrade flow, balloon predilatation before stenting is often 
not necessary. In contrast, stenting in patients without sufficient antegrade flow has the 
risk of undersized stenting or inaccurate positioning of the stent, which are predictors for 
restenosis and stent thrombosis. 1 2• 1 3  
Finally, the remaining fractured atherothrombotic burden after the PCl-procedure exposes 
thrombogenic contents. Restenosis and stent thrombosis are partly induced as a response 
to these contents.1 4•1 5 
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To the best of our knowledge, this study i s  the first that compares direct stenting with 
and without prior manual thrombus aspiration in routine clinical practice. Several studies 
have compared direct stenting with predilatation mainly in elective patients with variable 
findings.5•6 In selected patients, direct stenting appears to be safe and possibly associated 
with improved clinical outcome. However, in unselected STEMI patients no improved 
myocardial perfusion or clinical outcome was detected.1 6 In a recent randomized trial 
with selected STEMI patients, mechanical thrombus aspiration prior to stenting did not 
improve myocardial perfusion, but did improve longterm clinical outcome compared to 
direct stenting. 1 7  
Table 3.  Contribution of thrombus aspiration prior t o  stenting t o  myocardial blush grade 3 
Univariate ana lysis Multivariate ana lysis 
Odds ratio (95%CI) p-val ue Odds ratio (95%CI) p-va lue 
Age (yr) 0.98 (0.96-0.99) <0.00 1 0.98 (0.97-0.99) 0.001 
lschemic time 1 .00 ( 1 .00-1 .00) 0.05 1 1 .00 ( 1 .00-1 .00) 0.060 
Anterior infarction 0.55 (0.45-0.68) <0.00 1 0.54 (0.39-0.76) <0.001 
TIMI  pre-PCI O or 1 0.62 (0.46-0.84) 0.002 0.72 (0.50-1 .06) 0.093 
Vis ible thrombus 0.54 (0.37-0.78) 0.00 1 0.62 (0.39-0.97) 0.037 
TA prior to stenting 1 .3 1  (0.95- 1 .82) 0.099 1 .50 ( 1 .05-2. 1 4) 0.026 
TA = thrombus aspiration, TIMI = Thrombolysis In Myocard ia l  Infarction. 
As described in these trials, patient selection in both interventions is inevitable. Stenting 
alone is not favourable in patients with large thrombus burden or low TIMI flow grade, for 
example. Because both angiographic characteristics are associated with worse prognosis, 
population bias for the choice of direct stenting or thrombus aspiration before stenting 
will always influence the benefit. 
The main limitation of this study is the fact that direct stenting was not studied in a 
randomized fashion. However, we wanted to evaluate the treatment of patients who 
were eligible for stenting alone according to the operator in routine clinical practice. 
Furthermore, the size of the study is too small to detect significant differences in clinical 
outcome. We used myocardial blush grade as the surrogate end point, which is strongly 
associated with clinical outcome.3•7•1 8  
CONCLUSION 
This is the first study that evaluated the difference in outcome of STEMI patients treated 
with direct stenting compared to manual thrombus aspiration prior to stenting in 
routine clinical practice. Our study shows that thrombus aspiration prior to stenting has 
additional benefit compared with stenting alone on procedural outcome, despite the 
worse antegrade flow and thrombus burden before PCI. 
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ABSTRACT 
Aims 
Primary percutaneous coronary intervention (PCI) is a widely practised therapeutic 
procedure to treat ST-elevation myocardial infarction (STEMI). However, a significant 
proportion of patients undergoing primary PCI suffers from adverse events, such as 
incomplete myocardial reperfusion. It is currently unknown to which degree these adverse 
events are operator related. 
Methods and results 
We investigated inter-operator variation using objective safety and efficacy endpoints 
during primary PCI for STEMI. All PCl's were performed by six experienced interventional 
cardiologists as part of a randomised single centre trial. The primary endpoint of this study 
was optimal myocardial reperfusion (myocardial Blush grade 3 [MBG]). All 1,071 patients 
enrolled in the Thrombus Aspiration during Percutaneous coronary intervention in Acute 
myocardial infarction Study (TAPAS) were included in this analysis. In the six operator 
groups, the rate of the primary endpoint MBG3 ranged between 29.2% and 55.5%. The 
variable for operators remained significantly associated with MBG3 after adjustment for 
baseline and procedural differences. There were no statistical differences observed with 
regard to safety endpoints. 
Conclusions 
This study illustrates the observation that even in a controlled setting significant inter­
operator variation may exist in the efficacy of primary PCI. This study supports the 
routine collection of high-quality datasets to evaluate and improve individual operator 
competence and skills. 
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INTRODUCTION 
Percutaneous coronary intervention (PCI) is a widely practised therapeutic procedure 
to treat coronary heart disease. In Europe, more than 1 ,100,000 PCls are performed 
yearly, while in the United States that number is more than 1,300,000Y Due to rapid 
improvement and innovation of catheter techniques, devices and co-medication, PCI is 
nowadays considered safe and suitable as reperfusion therapy for patients with acute 
ST-elevation myocardial infarction (STEMl). 1 -5 This is mainly based on the low incidence 
of major adverse cardiac and cerebral events (death, reinfarction, revascularisation and 
stroke) during and after primary PCl.5•6 
However, a significant proportion of patients treated with primary PCI for STEMI suffer 
from more hidden, but nevertheless serious adverse events, such as bleeding requiring 
blood transfusion,7-9 distal embolisation, 1 0-1 4 and incomplete myocardial reperfusion.1 0• 1 1 • 1 5  
Although, patient related factors play a major role in the occurrence of these adverse 
events,7-1 5 it is currently unknown to which degree these adverse events are also operator 
related. 
Previous published studies and medical audits have investigated operator dependence of 
outcome after primary PCI with rates of inhospital mortality and/or other major adverse 
events as endpoints, and found almost no differences across operators.6• 1 6-21 As the 
incidences of these events are low, the analyses had limited statistical power to conclude 
whether there is significant operator dependence of outcome in the context of primary 
PCI. In addition, interpreting individual outcome data requires stratification of outcomes 
based on operator versus other factors, such as system of care, hospital quality, temporal 
factors, patient related factors, procedural characteristics and adjunctive therapies. 
Because of incomplete data sets, studies were often not able to fully adjust their data for 
possible confounders.6•1 6• 1 7•22 Finally, data collection and analyses were often not done by 
independent investigators, which may have induced bias in the reported results.6•1 6-2 1 
We therefore thought to investigate inter-operator variation using objective safety and 
efficacy endpoints during primary PCl forSTEMI. AII PCl's were performed by six experienced 
interventional cardiologists as part of a large randomised controlled single centre trial.23•24 
All endpoints were analysed by a core laboratory or independent investigators.25 The 
primary hypothesis was that even in the controlled setting of a randomised controlled 
trial with experienced interventional cardiologists, significant inter-operator performance 
variation exists in terms of efficacy and safety. 
METHODS 
The University Medical Center Groningen (UMCG) is a large tertiary referral centre in the 
northern part of The Netherlands. The UMCG has a high volume PCI centre with a 24-hour 
on-call duty schedule. Annually, around 2,000 PCls (1,250 elective and 750 emergency PCls) 
are performed by six interventional cardiologists: R.L. Anthonio, A.F.M. van den Heuvel, 
G.A. Jessurun, B.J. de Smet, E.S. Tan and F Zijlstra. All operators had a total individual case 
load of > 1500 PCls before the start of the study period. During the study period they all 
performed an annual number of >250 PCls. 
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1 1 61  
patients assessed for el igibi l ity 
1 071  
90 patients not meeting el ig ibi l ity criteria 
61 had a diagnosis other than STEM! 
1 1  underwent rescue PCI 
9 had a know life expectancy of <6m 
5 did not provide informed consent 
4 died before entry in to cath lab 
STEM!  patients randomized 
535 assigned to thrombus aspiration 536 assigned to conventional PCI 
1 071  interventions (d iagnostic ang iograms +/- PCI) performed by 6 
operators 
Endpoints 
1 .  Myocardial Blush Grade 
2. TIMI flow grade post PCI 
3. l ntraprocedura l  compl ications 
4. Delta Hemoglobin 
5 .  Blood transfusion 
6. Effective TA 
Data ava i lable in :  
980 pts 
997 pts 
1 071  pts 
971 pts 
1 047 pts 
454 pts 
Figure 1 .  Trial Flow Diagram. 
Patients 
We included all 1,071 patients who were enrolled in the Thrombus Aspiration during 
Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS). The 
study design, methods and results of theTAPAS-trial have been reported.21 -23 TheTAPAStrial 
was a single-centre, prospective randomised open trial with blinded evaluation of 
endpoints, which investigated whether thrombus aspiration was superior to conventional 
treatment during PCI in patients with STEMI who were candidates for primary PCI. The 
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primary endpoint of the trial was post PCI myocardial blush grade (MBG). 
All patients admitted to the UMCG during the study period were assessed for eligibility. The 
inclusion criteria were, symptoms suggesting acute myocardial ischaemia >30 minutes, 
time from symptom onset <12 hours, and ST-segment elevation >0. 1 mV in two or more 
leads on the ECG. Exclusion criteria were rescue PCI after thrombolysis, known existence 
of a concomitant disease with life expectancy <6 months, and no informed consent. 
Randomisation 
Before initial coronary angiography, patients were randomly assigned in a 1 :1 ratio to 
either thrombus aspiration or conventional treatment. Randomisation was done using a 
computerised voiceresponse system. The randomisation code was developed by means 
of a number generator used to select randomly permuted blocks of three to six patients. 
Randomisation was stratified by interventional cardiologists to achieve a balanced group 
assignment with regard to both treatment group and operator performing the PCI. All 
included patients were treated by one of the six interventional cardiologists. The name of 
the interventional cardiologist performing the procedure was prospectively registered in 
the main database. 
Treatment 
In patients randomised to thrombus aspiration, the Export Aspiration Catheter (Medtronic 
Corporation, Minneapolis, MN, USA) was used to establish antegrade flow before stenting. 
When necessary for stent delivery, balloon dilatation was performed before stenting. In 
conventional patients, balloon angioplasty was followed by stent placement. However, 
in both groups, the use of balloon dilatation as well as the use of (additional) stents was 
finally left over to the operators decision. 
All patients were pre-treated with aspirin (a loading dose of 500 mg), heparin (5000 IU) and 
clopidogrel (loading dose of 600 mg), all administered directly after electrocardiographic 
confirmation of STEMI. Unless contraindicated, patients received weight-adjusted 
glycoprotein ! lb/Illa-inhibitor (GPI) abciximab) during the procedure and additional ACT­
guided heparin. Arterial sheaths were removed with manual compression after PCI, no 
arterial puncture closing devices were used during the study period. Therapy after PCI was 
performed according to current guidelines.4 
Quality evaluation and improvement programme 
Our programme for quality evaluation and improvement was according to the 
guidelines of the American College of Cardiology/American Heart Association/Society 
for Cardiovascular Angiography and Interventions (ACC/AHA/SCAl).18 Quality of care 
was assessed in weekly meetings in which interventional cardiologists and research 
fellows reviewed and evaluated all performed primary PCl's during that week (including 
all patients included in the TAPAS-trial). Two times a year, all complications occurring 
during PCI were discussed and evaluated. In addition, clinical follow-up of all patients 
undergoing PCI (STEMI and non-STEMI) in the UMCG were collected on a per operator 
basis and evaluated. 
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Endpoints 
The primary endpoint was optimal myocardial reperfusion assessed by MBG. Secondary 
endpoints were effective thrombus aspiration, TIMI 3 flow post PCI, delta haemoglobin, 
the use of blood transfusions and intraprocedural complications. All endpoints were 
analysed by the core laboratory or independent blinded investigators. 
MBG is a well established surrogate endpoint for myocardial reperfusion and is strongly 
related with death and other major adverse events after primary PCl.1 5•23•24 Retrieval 
of thrombotic material after thrombus aspiration is an objective marker for efficacy of 
thrombus aspiration. Delta haemoglobin and the use of blood transfusions reflect 
bleeding complications during PCI. Bleeding complications are associated with longer 



















Figure 2, Control chart for odds ratio per operator for optimal myocardial perfusion after adjustment 
for baseline and procedural differences. Dotted lines represent 99.8% confidence intervals. 
Endpoint assessment 
MBG and TIMI flow grade were assessed as previously described.1 5•26 All coronary 
angiographic data were analysed at an independent core laboratory (Cordinamo, Wezep, 
the Netherlands). Effective thrombus aspiration was determined by histopathological 
examination, performed by pathologists unaware of PCl-operator and clinical data.25 
Aspirated material during thrombus aspiration was placed in formalin, and fixed for 24 
hours. Histological sections were cut and stained with hematoxylin-eosin for examination 
with a light microscope (x100). Samples were classified into effective or no effective 
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aspiration based on the presence of atherothrombotic material. Delta haemoglobin was 
calculated using the haemoglobin level at admission and one day after admission in 
patients who did not receive blood transfusions or underwent revascularisation (rePCI or 
CABG) within this period. The use of blood transfusions was defined as any gift of packed 
red blood cells given at the day of admission or one day after. Bleeding was subdivided 
in major and minor bleeding according the TIMI Bleeding Score.26 Major Bleeding was 
defined as a reduction of haemoglobin of 5 g/dl or more from study entry to the time of 
the lowest haemoglobin level within 10 days. Minor Bleeding was calculated similar and 
was defined as a reduction of haemoglobin of 3 to 5 g/dl. lntraprocedural complications 
included intraprocedural deaths, strokes, CABG within 24 hours after diagnostic 
angiography, flow limiting dissections and side branch occlusions. We re-analysed all 
coronary angiograms and hospital records of patients who underwent CABG within seven 
days after diagnostic angiography, to investigate whether they were possibly related or 
caused by complications occurred during the index procedure. 
Statistical analysis 
Data are presented as frequency / number of patients with available data on the specific 
variable (percentage), mean ±SD or as median (interquartile range [IQR]). Comparisons 
across the six operator groups were performed by the Pearson chi-squaretest forcategorical 
variables, one-way ANOVA for normal distributed continuous variables and Kruskal-Wallis 
test for not-normal distributed continuous variables. Multivariate regression analyses were 
used to correct for possible confounders. The following baseline variables were introduced 
in the multivariate analysis: age, gender, total ischemic time, diabetes, three vessel vessel 
disease, TIMI flow, previous myocardial infarction, systolic blood pressure and heart rate 
at admission, anterior myocardial infarction and off hour arrival at cathlab (to correct for 
differences in temporal factors, system of care before arrival and level of catheterisation 
lab staff occupation). In addition, the following procedural variables were used to correct 
for possible procedural differences: number of stents implanted, balloon used (both pre­
and postdilatation), effective thrombus aspiration, GPI used and TIMI flow 3 post PCI. In 
the regression analyses, the categorical variable operator was coded using the simple 
contrast method; each operator (except the reference operator) was compared to the 
reference operator. The operator with the best performance for the primary endpoint was 
chosen as the reference operator. Predicted probabilities per patient after multivariate 
analysis were used to draw a control chart for the primary endpoint. All p-values were 
2-tailed. Statistical significance was set at <0.002 (X3SD), because several studies have 
demonstrated that in the setting of comparing performance, a threshold of X3SD limits 
is more adequate to find special-cause variation in practice.27•28 Analyses were performed 
using SPSS software version 16.0.1 (SPSS, Chicago, 1 1 , USA). 
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Table 1 .  Baseline clinical and angiographic characteristics 
Operator #1 #2 #3 #4 #5 #6 p 
Patients, N 209 1 52 1 58 1 69 233 1 50 
Age in years, mean ± SD 63.9 ± 1 2.9 63.5 ± 1 3.0 6 1 .3 ± 1 2.4 64.0 ± 1 2.8 62.9 ± 1 2.5 62.3 ± 1 3.3 0.34 
Male gender 1 47/209 1 07/1 52 1 1 9/1 58 1 1 4/1 69 1 60/233 1 08/1 50 
(70.3) (70.4) (75.3) (67.5) (68.7) (72.0) 
Body mass index, median 26.2 (24.4 - 26.8 (24.5 - 26. 1 (24.3 - 26.2 (24.0 - 26.3 (24. 1 27.0 (24.9 - 0.40 
( IQR) 29.0) 29.2) 28.5) 29.0) 28.8) 29.4) 
Risk factors 
Diabetes 26/205 ( 1 2.7) 22/1 52 ( 1 4.5) 1 7  / 1 58 ( 1 0.8) 1 5/1 66 (9.0) 2 1 /232 (9. 1 )  22/ 149 ( 1 4.8) 0.35 
Hypertension 73/205 (35 .6) 58/1 49 (38.9) 46/1 56 (29.5) 57 /1 62 (35.2) 77 /224 (34.4) 55/ 147 (37.4) 0.62 
Hyperl ipidemia 53/1 95 (27.2) 41 /1 26 (32.5) 36/1 54 (23.4) 31 / 149 (20.8) 46/1 97 (23.4) 38/1 44 (26.4) 0.29 
Fami ly history 92/1 92 (47.9) 68/1 46 (46.6) 70/1 57 (44.6) 74/1 60 (46.2) 97 /224 (43.3) 63/1 44 (43.8) 0.94 
Previous CABG 5/206 (2.4) 2/1 5 1  ( 1 .3) 8/1 58 (5 . 1 ) 1 0/1 66 (6.0) 7/232 (3.0) 7/1 49 (4.7) 0. 1 9  
Previous Myocard ia l  20/206 (9.7) 1 2/1 5 1  (7.9) 1 4/1 58 (8.9) 20/1 66 ( 1 2.0) 23/232 (9.9) 1 8/1 48 ( 1 2.2) 0.78 
infarction 
Previous PCI 1 3/206 (6.3) 8/1 49 (5 .4) 1 1  /1 58 (7.0) 1 8/1 66 ( 1 0.8) 1 4/23 1  (6. 1 )  1 3/1 47 (8.8) 0.38 
Hemodynamics pre-
procedure, mean ± SD 
Systolic BP 1 29.4 ± 25.5 1 30.7 ± 26.8 1 26.6 ± 26.8 1 30.4 ± 25.9 1 28.0 ± 25.5 1 28.2 ± 26.9 0.73 
Diastolic BP 74.6 ± 1 5 .9 74.5 ± 1 7. 1  74.8 ± 1 4.6 74.4 ± 1 5 .7 73.5 ± 1 3.9 74.6 ± 1 5.5 0.96 
Heart rate, beats/min 79.5 ± 1 9.3 78.6 ± 1 9. 1  76.3 ± 1 5 . 1  76.4 ± 1 7.3 78.0 ± 1 7.9 8 1 .9 ± 20.6 0,07 
Tota l  ischemic time in  1 80 ( 1 30 - 1 80 ( 1 30 - 1 82 ( 1 35 - 1 95 ( 1 35 - 1 95 ( 1 40 - 1 90 ( 1 50 - 0.46 
min, median (IQR) 273) 282) 283) 308) 323) 3 1 7) 
Time of arrival at cath lab 
Off hou rs* 49/209 (23.4) 3 1 /1 50 (20.7) 44/1 58 (27.8) 42/1 68 (25.0) 77/230 (33.5) 6 1 /1 50 (40.7) 0.00 1 
Three vessel d isease 64/206 (3 1 . 1 )  62/1 52 (40.8) 57 /1 57 (36.3) 61 /1 68 (36.3) 73/233 (3 1 .3) 54/1 50 (36.0) 
I nfarct-related vessel 
Left anterior 96/201 (47.8) 68/1 49 (45.6) 59/1 5 1  (39. 1 ) 62/1 65 (37.6) 1 0 1 /223 58/1 43 (40.6) 
descending artery (45.3) 
Left circumflex artery 26/201 ( 1 2.9) 27 /1 49 ( 1 8. 1 )  26/1 5 1  ( 1 7.2) 30/1 65 ( 1 8.2) 35/223 ( 1 5 .7) 28/1 43 ( 1 9.6) 
Right coronary artery 75/201 (37.3) 53/1 49 (35.6) 6 1 /1 5 1  (40.4) 69/1 65 (41 .8) 8 1 /223 (36.3) 54/1 43 (37.8) 
Other 4/201 (2.0) 1 /1 49 (0.7) 5/1 5 1  (3.3) 4/1 65 (2.4) 6/223 (2.7) 3/1 43 (2. 1 )  
0.38 
0.79 
TIMI  flow 0/1 pre 
procedure 
1 1 9/208 90/1 5 1  (59.6) 88/1 54 (57. 1 ) 92/1 66 (55.4) 1 42/232 73/1 46 (50.0) 0.39 
(57.2) (6 1 .2) 
Thrombus visible on 99/205 (48.3) 76/1 5 1  (50.3) 65/1 52 (42.8) 69/1 64 (42. 1 )  1 07 /23 1  69/1 45 (47.6) 0.65 
in itial angiogram (46.3) 
Data are presented as frequency / n umber of patients with ava i lable data on the specific variable (percentage). 
* Weekdays from 5 pm to 7 am and any time on weekends. CABG= Coronary Artery Bypass Grafting, IQR= 
I nterquarti le range, SD= standard deviation, TIMI= Thrombolysis In Myocardia l  I nfarction flow grade. 
1 72 
Operator dependence of outcome after primary PCI 
RESULTS 
Only a minority (7.8%) of the patients assessed for eligibility, were excluded. The six 
operators each performed between 150 and 233 primary PCls of the study. There were no 
differences in baseline clinical and angiographic characteristics across operator groups, 
except for the variable off hour arrival at catheterisation lab (Table 1 ). 
Procedural variation 
Procedural differences were present across operator groups with regard to the frequency 
of periprocedural GPI administration, use of balloon dilatation and stent implantation 
(Table 2). 
Efficacy endpoints 
Myocardial blush grade 
MBG3 was present in 381/980 (38.9%) of the patients in which post PCI MBG could be 
assessed. In the six operator groups the rate of MBG3 ranged between 29.2% and 55.5% 
(Table 3). After adjustment for baseline and procedural characteristics in multivariate 
analysis, the variable operator remained a strong predictor of the primary endpoint MBG 
(Table 4). 
Effective thrombus aspiration and TIMI flow 3 post PC/ 
Thrombus aspiration was effective in 331 /454 (72.9%) patients. There was a significant 
difference in rate of effective thrombus aspiration between operator groups, ranging from 
55.4% to 85.7%. No difference was found regarding post PCI TIMI flow 3 (Table 3). 
Safety endpoints 
lntraprocedural complications 
The incidence of intraprocedural complications was low (see Table 3). No deaths, strokes 
or flow-limiting dissections occurred during the primary PCI procedures. A total of 29 
patients underwent a CABG within seven days after diagnostic angiography. Thirteen 
(44.8%) of these CABGs were performed with 24 hours. None of the CABGs were caused by 
or related with intraprocedural complications. Side branch occlusions were visible in nine 
patients after stent implantation. No significant differences were present across operator 
groups with regard to these complications. 
Bleeding complications 
Data on delta haemoglobin was available in 971 patients. The median decrease in 
haemoglobin was 0.6 g/dl (IQR 0.2 to 1 .3) (Table 3). Blood transfusions were given to 
55/1 047 patients (5.3%). No inter-operator variation was present regarding bleeding 
complications. 
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Table 2. Operator depended procedural characteristics 
Operator #1  #2 #3 #4 #5 #6 p 
After diagnostic ang iography: 0. 1 3  
No PCI performed 9/209 (4.3) 9/1 52 (5.9) 1 3/1 58 (8.2) 4/1 69 (2.4) 1 9/233 (8.2) 1 0/1 50 (6.7) 
Primary CABG performed 
<24 hours 2/209 ( 1 .0) 3/1 52 (2.0) 1 / 1 58 (0.6) 0/1 69 (0.0) 1 /233 (0.4) 0/1 50 (0.0) 
<7 days 3/209 ( 1 .4) 4/1 52 (2.6) 3/1 58 ( 1 .9) 0/1 69 (0.0) 1 /233 (0.4) 2/1 50 ( 1 .3) 
Primary PCI performed 200/209 1 43/1 52 1 45/1 58 1 65/1 69 21 3/233 1 40/1 50 
(95.7) (94. 1 )  (91 .8) (97.6) (9 1 .8) (93.3) 
CABG performed after PCI 
<24 hours 1 /209 (0.5) 0/1 52 (O.O) 2/1 58 ( 1 .3) 1 /1 69 (0.6) 0/233  (0.0) 2/1 50 ( 1 .3) 
<7  days 3/209 ( 1 .4) 1 /1 52 (0.7) 5/1 58 (3.2) 3/1 69 ( 1 .8) 1 /233 (0.4) 3/1 50 (2.0) 
Procedural characteristics 
Thrombus aspiration 89/209 63/1 52 59/1 58 84/1 69 1 0 1 /233 58/1 50 0.27 
performed (42.6) (4 1 .4) (37.3) (49.7) (43.3) (38.7) 
Bal loon used 1 06/1 90 93/1 35 73/1 34 88/1 56 1 67/202 75/1 33 <0.0001 
(55.8) (68.9) (54.5) (56.4) (82.7) (56.4) 
Stent implanted 1 86/1 89 1 26/1 36 1 1 9/1 34 1 48/1 59 1 85/203 1 1 6/1 34 0.002 
(98.4) (92.6) (88.8) (93 . 1 ) (9 1 . 1 )  (86.6) 
Number of stents implanted, 1 .3 ± 0.6 1 .2 ± 0.7 1 .3 ± 0.9 1 .3 ± 0.7 1 .2 ± 0.7 1 . 1 ± 0.6 0.032 
mean ± SD 
Peri-procedu ral GPI  1 86/209 1 38/1 52  1 22/1 58 1 5 1 / 1 69 1 93/233 1 3 1 /1 50 0.003 
(89.0) (90.8) (77.2) (89.3) (82.8) (87.3) 
I ntra-aortic ba l loon pump 8/1 94 (4. 1 )  5/1 37 (3.6) 1 1  /1 25 (8.8) 1 4/1 54 (9. 1 )  8/202 (4.0) 1 2/1 37 (8.8) 0.07 
Data are presented as frequency / number of patients with avai lab le data on the specific variable (percentage). 
CABG= Coronary Artery Bypass Grafting, GPI= Glycoprotein l l b l l la inh ibitor, IQR= I nterquarti le range, PCI= 
Percutaneous Coronary I ntervention, SD= standard deviation, TIMI= Thrombolysis In Myoca rd ial I nfarction flow 
grade. 
DISCUSSION 
Th is analysis i l l u strates that even during primary PCI  performed by experienced operators, 
and despite strict adherence to cu rrent gu idel i nes in the setting of a randomised control led 
tria l , s ign ificant variation may exist with respect to the rate of optimal myocard ial 
reperfusion. These d ifferences remained s ignificant after multivariate adjustment. There 
were no statistica l d ifferences observed with regard to safety endpoints. 
It is cu rrently a matter of d iscussion whether individua l  outcome data should be used as 
method to eva l uate and improve the qua l ity of heathcare. Important for this d iscussion is 
the avai labi l ity of appropriate data to investigate the presence and impact of i nteroperator 
variation on procedura l  outcome. Our study setting a l lowed us to perform an accurate 
ana lysis on the impact of the operator on safety and efficacy. We investigated inter­
operator va riation i n  the setting of a randomised contro l led s ingle centre trial , therefore 
process of care, hospita l qua l ity and (co)therapy was comparable in a l l  inc luded patients. I n  
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addition, as a resu lt of the acute nature of primary PCI, operator specific outcome data was 
not influenced by operator dependent patient selection due to selective withho ld ing or 
referra l  of procedures in patients at h igher risk, this in contrast with previous ana lyses.6·29·30 
Previous studies investigated ind ividua l  operator performance in terms of d ifferences in 
morta l ity or other major adverse events.6•1 6-2 1 For example, the New York State Depa rtment 
of Hea lth reports risk adjusted morta l ity data for individua l  operators s ince 1 994.6 Given 
the low in-hospita l/30-day morta l ity rates (0.63% in non-emergency and 3 .27% for 
emergency PCls performed during 2003-2005) these ana lyses had often l im ited statistica l 
power to detect interoperator d ifferences. Fu rther, as previously mentioned, data 
col lection and ana lyses were often not done by independent investigators ( in th is  case, 
the operator h im or herself), which wi l l  have induced bias in the reported resu lts.6•1 6·21 
Table 3. Procedural outcomes and complications 
Operator #1 #2 #3 #4 #5 #6 p 
Efficacy endpoints 
Myocardia l  B lush Grade 0.008 
0 1 4/1 9 1  (7.3) 5/1 37 (3.6) 6/1 38 (4.3) 8/1 64 (4.9) 1 5/2 1 3  (7.0) 5/1 37  (3.6) 
28/1 91  ( 1 4.7) 32/1 37 (23.4) 25/1 38 ( 1 8. 1 )  27/1 64 ( 1 6.5) 35/2 1 3 ( 1 6.4) 1 3/1 37 (9.5) 
2 74/ 1 9 1  (38.7) 60/1 37 (43.8) 62/1 38 (44.9) 65/ 1 64 (39.6) 82/2 1 3 (38.5) 43/1 37 (3 1 .4) 
3 75/1 91  (39.3) 40/1 37 (29.2) 45/1 38 (32.6) 64/1 64 (39.0) 8 1 /2 1 3  (38.0) 76/1 37 (55 .5) 
Effective Thrombus 74/89 (83. 1 )  45/63 (71 .4) 40/59 (67.8) 72/84 (85.7) 56/1 01 (55.4) 44/58 (75.9) <0.0001 
aspiration 
TIMI 3 flow post PCI 1 63/1 97 1 23/1 42 1 2 1 /1 39 1 32/1 65 1 79/2 1 4  1 22/1 40 0.42 
(82.7) (86.6) (87. 1 )  (80.0) (83.6) (87. 1 )  
Safety endpoints 
Deaths 0/209 (0.0) 0/1 52 (0.0) 0/1 58 (0.0) 0/1 69 (0.0) 0/233 (0.0) 0/1 50 (0.0) 1 .00 
Strokes 0/209 (0.0) 0/1 52 (0.0) 0/1 58 (0.0) 0/1 69 (0.0) 0/233 (0.O) 0/1 50 (0.0) 1 .00 
Emergency CABG 0/209 (0.0) 0/1 52 (0.0) 0/1 58 (0.O) 0/1 69 (0.0) 1 /233 (0.4) 1 /1 50 (0.7) 0.57 
Flow l imiting d issections 0/209 (0.0) 0/1 52 (0.0) 0/1 58 (0.0) 0/1 69 (0.0) 0/233 (0.0) 0/1 50 (0.0) 1 .00 
Side-branch occlusions 0/209 (0.0) 1 /1 52 (0.7) 0/1 58 (0.0) 3/1 69 ( 1 .8) 1 /233 (0.4) 4/1 50 (2.7) 0.05 
B leeding compl ications 
Delta hemog lobin * 0.6 (0.0 - 1 . 1 )  0.6 (0.0 - 1 . 1 )  0.6 (0.0 - 1 . 1 )  0.6 (0.0 - 1 . 1 )  0.6 (0.3 - 1 .5) 0.6 (0.0 - 1 .4) 0.22 
[g/dl], median (IQR) 
Blood transfusion t 7 /207 (3.4) 9/1 5 1  (6.0) 1 0/1 50 (6.7) 7 / 1 63 (4.3) 1 4/230 (6. 1 ) 8/1 46 (5.5) 0.72 
Minor bleed ing * 1 3/1 56 (7.7) 6/1 1 8  (4.6) 6/1 1 8  (4.6) 7 / 1 30 (5. 1 )  1 3/1 84 (6.6) 6/1 1 2  (5. 1 )  0.86 
Major bleed ing * 2/1 67 ( 1 .2) l / 1 23 (0.8) l / 1 23 (0.8) 2/1 35 ( 1 .5) l /1 96 (0.5) l /1 1 7  (0.8) 0.97 
Data are presented as frequency / number of patients with ava i lable data on the specific variable (percentage). 
* patients who received blood transfusions or underwent rePCI / CABG were excluded. t patients who underwent 
rePCI / CABG within the first days were excluded. CABG= Coronary Artery Bypass Grafting, IQR= Interquarti l e  range, 
PCI= Percutaneous Coronary I ntervention, SD= standard deviation, TIMI= Thrombolysis In Myocardia l  I nfarction flow 
grade. 
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Analyses on c l in ical endpoints a re certa in ly mandatory, however they should be 
accompan ied with objective and sensitive surrogate endpoints. MBG and the secondary 
endpoints used in our study a re important markers for efficacy and safety during primary 
PCI, and were analysed by either a core lab or b l inded investigators. These endpoints are 
simple and not time consum ing to col lect and ana lyse, and therefore usefu l for eva luation 
of every day practice. In addition, the recent i ntroduction of software for computer­
assisted assessment of MBG and ST-segment resol ution, fu rther fac i l itates the routine use 
of these surrogate endpoints for assessi ng efficacy of reperfusion therapies.3 1 •32 
So what are the possible explanations of the observed inter-operator variation in efficacy? 
We adjusted for possib le d ifferences in patient case mix, tempora l factors and process 
of care (e.g., total ischaemic t ime; on- versus off-hours).22 The res idual  variation suggests 
difference in operator performance. Wel l  investigated is the idea that the experience of an  
interventional card iologist (operator volume) is inversely proportiona l to  the  incidence of 
procedure related compl ications during PCl. 1 8·2 1 However, it is not l ikely that "experience" 
played a major role in our study, as a l l  operators were experienced and performed >250 
PCls/year. Further, there can be d ifferences in opinions about the optima l  approach duri ng 
primary PCI . Th is may have caused inter-operator variation with regard to the use of co­
medication, bal loon d i latation  and coronary stents. Severa l stud ies have demonstrated 
that the extent and the complexity of the procedure (h igher number, duration, and 
pressure of bal loon inflations and stent implantations) is associated with the occurrence 
of dista l embol isation and impaired myocard ia l  reperfusion. 10· 14  The additional ana lyses 
performed in our study suggest that these procedura l  d ifferences may partly expla in the 
Table 4. The effect of the operator on the primary endpoint optimal myocardial reperfusion 
(Myocardial Blush Grade 3) 
Operator effect on optimal myocardial reperfusion 
Unadjusted Adjusted for Adjusted for Adjusted for both 
basel ine variablest procedu ra l  differences=!= basel ine and 
procedural differences 
OR 99.8%(1 OR 99.8%(1 OR 99.8%(1 OR 99.8%(1 
Operator 1 * 0.5 1 9  0.257 - 1 .046 0.483 0.2 1 9  - 1 .067 0.608 0.1 60 - 2.3 1 7 0.655 0. 1 45 - 2.960 
Operator 2 * 0.33 1  0 . 1 5 1 - 0.727 0.3 1 3  0. 1 30 - 0.753 0. 1 53 0.034 - 0.684 0. 1 94 0.039 - 0.977 
Operator 3 * 0.388 0 . 1 79 - 0.841 0.33 1 0. 1 39 - 0.787 0.433 0.1 04 - 1 .807 0.398 0.083 - 1 .9 1 5 
Operator 4 * 0.5 1 4  0.249 - 1 .062 0.445 0. 1 95 - 1 .0 1 6  0.426 0.1 1 1  - 1 .636 0.361  0.080 - 1 .638 
Operator 5 * 0.493 0.248 - 0.979 0.463 0.2 1 4  - 0.999 0.823 0.2 1 5  - 3 . 1 53 0.805 0. 1 84 - 3 .528 
Operator 6 (reference) 
* Versus operator 6. 
t Adjusted for the following basel ine variables: age, gender, total ischemic time, diabetes, th ree vessel vessels 
disease, TIMI  flow 0/1 pre, previous myocardial infarction, systol ic blood pressure at admission, heart rate at 
admission, Time of arrival at cath lab (on versus off hours) and anterior myocard ial infa rction. 
:j: Adjusted for the fol lowing procedura l  differences: number of stents implanted, bal loon used (yes/no), effective 
thrombus aspiration, GP l lb l l l a  inh ibitor used (yes/no), TIMI  flow 3 post procedure. 
OR is for the occurrence of optimal  myocardia l  reperfusion for the specific operator as compared with reference 
operator. 
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under/above performance of some operators. However, also after multivariate correction 
for procedural characteristics (including effective thrombus aspiration) there remained 
significant inter-operator variation with regard to impaired myocardial reperfusion. This 
suggest that differences in factors for which we were not able to account for, including 
most likely differences in technical skills, have contributed to the observed inter-operator 
variations. 
The ACCF/AHA/SCAI Clinical Competence Statement 2007 proposes interventionalists 
to participate in local, regional and/or national PCI registries to monitor and improve 
both hospital and individual operator performance.1 8  Our results strongly support 
this recommendation and demonstrate that the systematic collection, reviewing and 
reporting of data provides important feedback with regard to safety and efficacy of health 
care, and is mandatory even among experienced operators. Further, essential requisites 
for the investigation of inter-operator variation is the careful selection of endpoints and 
high quality data sets, col lected and analysed by independent investigators. 
Limitations 
Our study suffers from several limitations: With regard to the operator, we did not adjust 
for differences in physician characteristics (age, years of experience and total caseload). 
In our opinion this is not necessary, as all operators had a sufficient total case load and 
number of PCls performed per year to label them as experienced and assume that 
learning curves have flattened out. Secondly, we adjusted for important baseline and 
procedural characteristics. However, we can not rule out that our results were influenced 
by other confounders (such as quality of care before arrival at our hospital, experience 
of catheterisation staff, etc.). Thirdly, although all operators had trained with thrombus 
aspiration before the start of the study period - and we corrected for effective thrombus 
aspiration in additional analyses - the use of new devices such as thrombus aspiration 
may have augmented the observed inter-operator variation in this study. Finally, inter­
operator variation was investigated only in terms of functional endpoints. However, as 
the magnitude of the inter-operator variation in our study is comparable with the effect 
size of thrombus aspiration on myocardial reperfusion in TAPAS (MBG3 rate was 32.2% in 
conventional PCI versus 45.7% in the aspiration group),23 the impact of operator variation 
during primary PCI is certainly of clinical relevance. 
CONCLUSION 
Our study illustrates that even in a very controlled setting significant inter-operator 
variation may exist in the efficacy of primary PCI for STEMI. This study supports the routine 
collection, reporting and reviewing of high-quality datasets to evaluate and improve 
individual operator performance. 
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Part I Strategies for inducing and sustaining epicardial reperfusion 
Restenosis 
In chapter 2 the safety and efficacy of drug-eluting stents (DES) in patients undergoing 
primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction 
(STEM!) were investigated. In this registry study, the use of DES in a cohort of 552 STEMI 
patients was associated with an excellent event-free survival rate of 90. 1 % at 1 year post­
discharge. In comparison with a historical cohort of 577 STEM! patients treated with bare 
metal stents (BMS), DES implantation was associated with a significant lower rate of target 
lesion revascularisation at follow-up. No significant difference in death or reinfarction was 
observed between the two types of stents. 
These results and those of current published randomized controlled trials (RCT), indicate 
that DES are able to reduce in-stent restenosis and clinical recurrence at long term follow­
up in patients with STEM1 .1-5 However, do these results also indicate that DES should 
be used routinely in all STEM! patients? A subanalysis of the largest RCT on DES versus 
BMS in STEM! (n=3006) suggests that DES are mainly effective in patients with a small 
vessel diameter (<3mm), long lesion length (�30mm) and insuline-treated diabetes.5 In 
patients without one of these risk factors (n=947 /3006, 32.2%), no difference in target 
lesion revascularisation at 1 year was found between DES and BMS (3.3% versus 3.2%, 
p = 0.93). Further, there remain safety concerns, as DES in STEM! may be associated 
with an increased risk on late stent thrombosis. Several risk factors are identified for the 
occurrence of stent thrombosis, and the clinical presentation STEM! yields a considerable 
number of these.6-9 In addition, in the acute phase of STEM! it is often unclear if patients 
have contraindications for extended dual antiplatelet therapy. Although the baseline risk 
on stent thrombosis for DES in STEM! is likely to be increased, RCTs and meta-analyses did 
not find a higher incidence of stent thrombosis associated with DES.1 -5 
Current data indicate that DES should not be used routinely. For each patient the benefit of 
less restenosis should be carefully weighed against the increased risk on stent thrombosis 
and higher costs. Finally, current published RCTs on DES versus BMS in STEM! investigated 
mainly older generation DES. Numerous new types of stents are currently being tested, 
focussing on higher efficacy and better safety profiles.10 
Thrombotic complications 
In chapter 3 the incidence of initial coronary artery patency and short-term outcome 
was compared in treatment groups of RCTs in which patients received pretreatment with 
clopidogrel with those in which patients did not receive clopidogrel before initial coronary 
angiography. A total of 38 treatment groups comprising 8429 patients was included. Initial 
patency and clinical outcome (death or non-fatal reinfarction) were found to be improved 
in treatment groups that received pretreatment with clopidogrel. 
These findings are accordance with the experience of pretreatment with clopidogrel in 
elective patients, non-ST-elevation coronary syndromes, and thrombolytic studies.1 1 • 1 2  
Recently, the preliminary results o f  the first RCT on pretreatment of clopidogrel in patients 
undergoing primary PCI for STEM! were presented.1 3 This trial randomized 337 patients 
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to pretreatment (n=l 66) or post-angiography clopidogre l  600mg loading dose (n=l 7 1  ) .  
The pre l iminary resu lts showed an i ncrease in in itial patency in the pretreatment group 
and lower rate of death or non-fatal reinfarction ( 1 .2% versus 4.2%), without an  increase 
of major bleeding (8.6% versus 8.2%) or stroke (0.0% versus 0.0%) . These resu lts i ndicate 
that it is safe and effective to give a load ing dose of clopidogrel in patients as early as 
possible after ECG confirmation of STEMI .  The relative merits of new type ADP-inh ibitors 
a re currently being investigated in severa l  RCTs. 
Multivessel disease 
I n  Chapter 4 the composite publ ished data on the 3 current PCI strategies for mu ltivessel 
d isease in STEMI patients were studied. Pa i rwise and network meta-ana lyses were 
performed of a l l  publ ished data to summarize current evidence for these 3 PCI strategies. 
Eighteen publ ished studies, involving 40,280 patients, were i ncluded. Pa irwise meta­
ana lyses demonstrated that staged PCI was associated with sign ificant lower short­
and long-term morta l ity rates compared to culprit vessel only PCI and mu ltivessel PCI . 
I n  addition, cu lprit vessel on ly PCI was superior at both short- and long-term fol l ow-up 
compared to mu ltivessel PCI . I n  the network ana lysis, staged PCI was a lso consistently 
associated with lower morta l ity rates compared to culprit vessel only PCI and mu ltivessel 
PCI. 
These ana lyses suggest that the poss ib le benefits of mu ltivessel PCI do not outweigh the 
adverse effects associated with this aggressive strategy. As advised in current g u ide l ines, 
sign ificant non-cu lprit vessel lesions su itable for PCI should on ly be treated during staged 
PCI procedures. More prospective research should be performed to investigate which 
strategy is superior, in  both hemodynamic stable and unstable, STEMI patients (CABG 
versus cu lprit vessel only PCI versus staged PCI versus mu ltivessel PCI). 
Part II Strategies for improving microvascular reperfusion after primary PCI 
Manual thrombus aspiration in STEMI 
In chapter 5 the main resu lts of the Thrombus Aspiration during Percutaneous Coronary 
I ntervention i n  Acute Myocardia l  I nfarction Study (TA PAS) a re presented, which randomized 
1 07 1  patients to th rombus aspiration (n=535) or conventional  PCI (n=536). The primary 
endpoint was optimal myocardia l  reperfusion (measured by myocard ia l  b lush g rade 
[MBG] 2/3), which was s ignificantly h igher in the g roup treated with thrombus asp i ration. 
Th is RCT demonstrated that thrombus aspiration is safe and appl icable in a la rge  majority 
of STEMI patients, and resu lts in better myocardia l  reperfusion than conventiona l  PCI . I n  
chapter 6 i t  was investigated i f  the  improvement in myocard ia l  reperfusion associated with 
thrombus aspiration in the TAPAS, a l so trans lated into improved cl i nical outcome at one 
year fol low-up. Compared with conventiona l PCI ,  thrombus aspiration before stenting of 
the infarct related artery seems to improve the 1 -year  c l in ica l outcome after PCI for STEMI 
Currently, manua l  thrombus aspiration is increas ing ly used in routine c l in ica l practice 
as it is an  easy, relatively i nexpensive and safe method to reduce th rombus burden and 
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improve myocard ia l  reperfusion. Although several thrombus aspiration RCTs and meta­
ana lyses a lso found an improvement in c l in ica l outcome, 1 4-1 7 no RCT have been publ ished 
which was adequately powered on a c l in ica l  endpoint. Currently, a mu lticenter RCT on 
thrombus aspiration is being performed which wi l l  randomize 5000 STEMI patients to 
either th rombus aspiration or conventiona l  PCl .18 As it is powered on 30 day a l l-cause 
morta l ity, this RCT wi l l  be able to answer the q uestion if thrombus aspiration i s  a l so ab le 
to s ign ificantly improve survival .  
The study i n  chapter 7, i nvestigated what independent pred ictors are of effective 
thrombus aspiration in patients treated with routine th rombus. A total of 1 7 1 2  patients 
underwent routine thrombus aspiration, which was effective in 82.6%. Multivariate 
independent pred ictors of effective thrombus aspiration were reference vessel d iameter 
(>3mm), ang iographic vis ib le th rombus and tota l ischemic time (>3 hours). However, the 
d iscriminative va lue of these pred ictors together was low. Th is a nalysis demonstrated that 
routine manua l  thrombus aspiration in STEM I  patients is feas ib le and resu lts in successfu l 
thrombus retrieva l in the majority of the patients. 
Discussion rema ins if the presence of vis ib le thrombus or other base l ine characteristics 
shou ld be used as a gu ide to perform thrombus aspiration. In the TA PAS study, subana lyses 
did not demonstrate s ign ificant d ifferences in c l in ical benefit of thrombus aspiration 
across prespecified subgroups (TIMI  flow, age, sex, tota l ischemic time, infarct related 
vessel, proximal lesion and thrombus seen on in itial ang iogram). 1 9  Also in a recent meta­
ana lysis of i ndividua l  patient data of most thrombus aspiration tria l s, no d ifferences were 
found across these subg roups or other base l ine patient cha racteristics. 14 These findings, 
together with the observed h igh efficacy rates across a l l  patient subgroups in this study, 
support a strategy of routine thrombus aspiration over a more selective approach. 
I n  chapter 8 the resu lts of a prospective cohort study are shown. Th is study i nvestigated 
whether a l a rge-lumen-diameter catheter is superior in removing thrombus load and 
improving angiographic and electrocard iographic outcome compared to a med ium­
sized catheter. A tota l of 1 60 patients, treated with the Diver (n = 80) or Export (n = 80) 
aspiration catheter, was enrol led. No sign ificant d ifference was found in rate of effective 
thrombus aspiration, MBG or electrocard iographic outcome between the 2 devices. Size 
d istribution of retrieved thrombotic partic les was s imi lar per device. 
Th is  study ind icates that a la rger i nterna l  l umen diameter does not result in retrieva l of la rger 
thrombotic particles, nor i n  improved ang iographic or electrocard iographic outcomes. 
The nonsuperiority of a la rger- lumen catheter may be expla ined by the fact that fresh ly 
formed thrombi a re easi ly friable. Further, it could a lso be related with better hand l ing 
characteristics of medium-sized catheters. When eva luating a l l  the d ifferent adjunctive 
mechanical devices to prevent d ista l embol isation, the best resu lts are ach ieved with the 
most s imple and easy to use devices.20,2 1  Besides larger lumen diameter, a lso mechanic 
thrombus aspiration seems to be an i nterest ing concept to improve thrombus remova l . 
Severa l RCTs have been performed compa ring mechanic thrombus aspiration with 
conventional  PCI, however with conflicting and l ess convinc ing resu lts.22-24 Nevertheless, 
no d i rect compa risons have been performed between manua l  and mechanic thrombus 
aspiration, so it is cu rrently unclear if manual is superior to mechanic thrombus aspiration. 
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Manual thrombus aspiration in NSTEMI 
In chapter 9 the results of a prospective cohort study are presented, in which the feasibility 
and safety of thrombus aspiration during PCI for NSTEMI were investigated. Thrombus 
aspiration was effective in 58 patients (83%) and resulted in a marked reduction of TIMl­
thrombus score and increase of the rate of TIMl-flow. 
This study demonstrates that thrombus aspiration in most NSTEMI patients is feasible and 
safe and is associated with a high rate of retrieval of thrombotic material. Currently the 
efficacy of thrombus aspiration in patients with NSTEMI is investigated in the Thrombus 
Aspiration during Percutaneous coronary intervention in Acute non-ST-elevation 
myocardial infarction Study (TAPAS 1 1).25 This study will include 540 patients with acute 
NSTEMI who are candidates for urgent PCI. Patients are randomised to treatment with 
manual thrombus aspiration or to conventional PCI. The primary endpoint is the incidence 
of MBG 3 after PCI. 
Direct stenting 
In chapter 10, patients treated with direct stenting were compared to patients who 
received thrombus aspiration prior to stenting. A total of 751 patients was eligible for 
direct stenting. Direct stenting was performed in 32.6% and thrombus aspiration prior 
to stenting in 67.4% of the patients. Despite worse angiographic baseline characteristics, 
thrombus aspiration prior to stenting was associated with significant improved primary 
endpoint MBG and TIMI flow compared to the direct stenting group. The benefit of 
thrombus aspiration prior to stenting remained significant after correction for well-known 
prognostic factors. 
These findings support the hypothesis that when thrombus is present, even in spite of 
normal antegrade epicardial flow, distal embolisation is still a risk in patients undergoing 
primary PCI. As thrombus aspiration reduces thrombus burden, it reduces the risk of distal 
embolisation. 1 4•26•27 Further, the risk of distal embolisation is thought to be highest during 
thisfirst intervention, as well during balloon dilatation as stent implantation.Therefore, also 
in patients eligible for direct stenting, a PCI strategy starting with thrombus aspiration is 
likely to result in less distal embolisation and improved myocardial reperfusion compared 
to stenting. 
Impact of the operator on microvascular reperfusion 
In chapter 11 the presence and extend of inter-operator variation during primary PCI 
for STEMI was investigated using objective safety and efficacy endpoints. The primary 
endpoint was incidence of optimal myocardial reperfusion after primary PCI. All PCls 
were performed by six experienced interventional cardiologists as part of the TAPAS. 
The primary endpoint of this study was optimal myocardial reperfusion (MBG 3). In the 
six operator groups the rate of the primary endpoint MBG 3 ranged between 29.2% 
and 55.5%. The variable operator remained significantly associated with MBG 3 after 
adjustment for baseline and procedural differences. There were no statistical differences 
observed with regard to safety endpoints. 
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This study makes evident that even in a controlled setting significant interoperator 
variation exists in the efficacy of primary PCI. This study supports the routine collection of 
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Summary in Dutch 
Samenvatting in het Nederlands 
Chapter 1 2 
Een acuut ST-elevatie myocard infarct (STEMI) wordt ge·in itieerd door het openscheuren 
van een atherosclerotische plaque, waarna door blootste l l i ng aan het bloed een trombus 
ontstaat, die het b loedvat gedeeltel ijk  of vol ledig afs lu it. Afs lu iting van het bloedvat 
leidt tot ischemie van het myocard. Snel herstel van de epicardia le en microvascu la i re 
b loeddoorstroming na een ischemische periode is essentieel voor de beperking van 
schade aan het myocard. De laatste jaren is gebleken, dat een percutane coronaire 
interventie (PCI) de beste reperfusie therapie is bij patienten met een STEMI. 
Tijdens een PCI wordt de bloeddoorstroming door een afges loten bloedvat hersteld door 
deze te d i lateren. Echter, deze d i latatie zorgt oak voor compressie en fragmentatie van 
de atherosclerotische plaque en trombus. Deze beschadig ing is verantwoordel ijk  voor 
de belangrijkste complicaties tijdens en na PCI; restenose, stent trombose en dista le 
embol isatie. Het doe l  van d it proefschrift is om n ieuwe strategieen te onderzoeken om 
deze PCl-gerelateerde complicaties te verminderen en zo de epicardia le en microvascu la i re 
reperfusie te verbeteren. 
Part I Strategieen voor het induceren en behouden van epicardiale 
reperfusie. 
Restenose 
I n  hoofdstuk 2 wordt de vei l igheid en effectiviteit van medicijn-afgevende stents (drug­
e luting stents, DES) onderzocht in patienten, die een PCI ondergingen voor een STEMI .  
I n  deze reg istratie studie was het gebruik van DES geassocieerd met u itstekende 1 -jaa rs 
resu ltaten. I n  vergel ijking met patienten, die behandeld werden met n iet-medicijn­
afgevende stents, gaf het gebru ik  van DES een s ign ificante afname van het aanta l 
revascula risaties. De resu ltaten van deze studie tonen aan,  dat DES oak in patienten 
met een STEMI effectief zijn om restenose te verminderen. Echter, het is de vraag, of DES 
standaard gebru ikt moeten warden in a l le patienten met een STEMI . Subana lyses van 
gerandomiseerde studies laten namel ijk  zien, dat DES maar i n  een deel van de patienten 
effectief zijn. Tevens zijn er twijfe ls  over de vei l igheid van DES in STEMI, voora l in  verband 
met een mogel ijk verhoogd risico op stent trombose. Op basis van de hu idige data kan 
dan oak niet geadviseerd warden om DES standaard te gebru iken in a l le patienten met 
STEMI. Per patient moet het voordeel van minder restenose afgewogen warden tegen 
een mogelijk hoger risico op stent trombose en hogere kosten van DES. Momenteel zijn 
d iverse n ieuwe stents in ontwikkel i ng, d ie mogelijk  effectiever en vei l iger zijn .  
Trombotische complicaties 
I n  hoofdstuk 3 wordt onderzocht, of voorbehandel ing met een startdosis c lopidogre l  
l eidt tot een hogere incidentie van vroege epicardia le reperfusie en een betere k l inische 
u itkomst ten opzichte van het pas geven na de PCI. Een systematische eva luatie van de 
huidige l iteratuur  toonde aan dat STEMI patienten, d ie een primaire PCI onderg ingen 
en voorbehandeld werden met een startdosis c lopidogrel , vaker vroege epicard ia le  
reperfusie hadden en het k l in isch beter deden dan patienten die n iet voorbehandeld 
werden. Deze bevind ingen zijn in l ijn  met ervaringen van clopidogre l  voorbehandel ing 
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in andere patienten groepen. Recent zijn de voorlopige resu ltaten van de eerste 
gerandomiseerde studie over clopidogre l  voorbehandel ing in patienten, d ie een 
primaire PCI voor STEMI moeten ondergaan, gepubl iceerd. Deze studie randomiseerde 
337 patienten naar  clopidogre l  voorbehandel ing (n=1 66) of  n iet (n= 1 7 1  ) .  De voorlopige 
resu ltaten toonden een toename in vroege reperfusie aan in de voorbehandelde g roep en 
een lagere incidentie van sterfte en reinfarcten ( 1 .2% versus 4.2%) . Er werd geen toename 
gezien in b loedingen (8.6% versus 8.2%) of  cerebra le vascu la i re accidenten (0.0% versus 
0.0%) . Deze resu ltaten tonen aan, dat het vei l ig  en effectief is om zo spoedig mogel ij k  
na de  electrocardiografische d iagnoseste l l ing van een STEMI  een startdosis c lopidogre l  
te geven. De relatieve voordelen van n ieuwe type ADP-inh ibitoren warden momenteel 
onderzocht in versch i l lende gerandomiseerde stud ies. 
Meervatslijden 
Meer dan de helft van de patienten, die zich presenteren met een STEMI, heeft naast een 
vernauwing i n  het i nfarct gerelateerde vat ook 1 of meer bijkomende vernauwingen i n  
andere kransslagvaten. Als het infarct gerelateerde vat behandeld is, kunnen bijkomende 
vernauwingen in andere kransslagvaten volgens 3 versch i l lende strategieen behandeld 
warden: ( 1 )  conservatief, (2) tijdens een tweede gestadieerde PCI of (3) d i rect tijdens de 
acute PC I  (zgn. meervats-PCl) .  I n  hoofdstuk 4 warden op basis van de bestaande l iteratuu r  
deze 3 strateg ieen voor meervatsl ijden in patienten met STEM!  met e lkaar vergeleken. 
Paarsgewijze en netwerk meta-ana lyses werden verricht van a l l e  gepubl iceerde data over 
deze 3 strategieen. Achttien studies met in totaa l  40.280 patienten werden ge'inc ludeerd. 
De paarsgewijze meta-ana lyses toonden aan, dat een gestad ieerde PCI van bijkomende 
letsels geassocieerd was met sign ificant betere korte en lange termijn  overleving 
ten opzichte van een conservatieve strategie of  een meervats-PCI. Verder b leek een 
conservatieve strategie gere lateerd aan een betere korte en lange termijn over leving 
ten opzichte van een meervats-PCI. Ook in de netwerk analyse was een gestadieerde PCI 
geassocieerd met betere overl eving dan de conservatieve strategie of meervats-PCI. 
Deze ana lyses suggereren, dat de mogel ijke voordelen van een meervats-PCI n iet 
opwegen tegen de negatieve effecten (met name een hoger compl icatie risico) van deze 
agressievere strategie. Zoa l s  ook geadviseerd in de hu idige richtl ijnen, dienen s ign ificante 
bijkomende vernauwingen, d ie geschikt zijn voor een PCI enke l  behandeld te warden 
met een gestad ieerde PCI .  Echter, meer prospectief onderzoek moet verricht worden om 
verder te onderzoeken, wel ke van deze strategieen superieur i s, i n  zowel hemodynamisch 
stabiele a l s  instabiele STEMI patienten. 
Part I I  Strategieen om de microvasculaire reperfusie na primaire PCI te 
verbeteren. 
Manuele trombus aspiratie in STEMI 
In hoofdstuk S  warden de hoofd resu ltaten van deTrombus Aspi ration during Percutaneous 
coronary intervention in Acute myocardia l  infa rction Study (TAPAS) gepresenteerd .  Deze 
studie randomiseerde 1 071 patienten met een STEMI  na een behandel ing met trombus 
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aspiratie (n=535) of conventionele PCI (n=536). Het primaire eindpunt was optimale 
microvascula ire reperfusie (gedefinieerd a ls  myocard ia l  b lush g rade 2/3), welke s ignificant 
hoger was in de g roep die behandeld werd met trombus aspiratie. De TAPAS toonde aan, 
dat trombus aspiratie vei l ig en toepasbaar is i n  de meerderheid van de patienten met 
een STEMI  en in een betere microvascula i re reperfusie resu lteert dan conventionele PCI. 
In  hoofdstuk 6 wordt onderzocht, of deze verbetering in microvascu la i re reperfusie in 
de trombus aspiratie groep zich ook vertaa lde i n  een betere k l in ische uitkomst na een 
jaar fol low-up. Vergeleken met conventionele PCI l eek trombus aspiratie i n  de TAPAS 
geassocieerd met een verbetering van de 1 -jaars k l in i sche u itkomst. 
Manuele trombus aspiratie wordt momenteel in toenemende mate gebruikt tijdens de 
behande l i ng van STEMI .  Dit omdat het een eenvoudig, goedkope en vei l ige methode 
is om trombus te verwijderen en de microvascu la i re reperfusie te verbeteren. Naast 
een verbetering in microvascu la i re reperfusie hebben verscheidende gerandomiseerde 
studies en meta-ana lyses ook een verbeteri ng in kl i n ische u itkomst gevonden. Echter, er 
zijn er tot op heden geen gerandomiseerde stud ies gepubl iceerd, die specifiek ontworpen 
en groot genoeg waren om een versch i l  in een k l in i sch e indpunt te kunnen detecteren .  
Momenteel loopt er een gerandomiseerde multicenter studie, d ie het effect van trombus 
aspiratie versus conventionele PCI za l onderzoeken i n  5000 STEMI patienten. Aangezien 
het prima i re eindpunt van deze studie een k l in isch e indpunt betreft (sterfte na 30 dagen) 
za l deze studie meer du idel ijkheid kunnen verschaffen, of trombus aspiratie ook in  staat is 
om de kl i n ische uitkomst sign ificant te verbeteren .  
In  hoofdstuk 7 wordt onderzocht, wat de voorspe l lers waren van succesvol verwijderen 
van trombus met trombus aspiratie (effectieve trombus aspiratie) . In totaa l  onderg ingen 
1 7 1 2  patienten trombus aspiratie, wat in 82,6% van de geva l len resu lteerde i n  effectieve 
trombus aspiratie. Mu ltivar iabele voorspel lers van effectieve trombus aspiratie waren 
arteried iameter (> 3mm), angiografisch zichtbare trombus en tota le i schemische tijd (> 3 
uu r). Echter, de d iscriminerende waa rde van deze voo rspel lers samen was laag. 
Er bl ijft d i scussie, of trombus aspiratie standaard in al le patienten verricht moet word en of 
s lechts in een meer selectieve populatie. I n  de TAPAS waren geen s ign ificante verschi l len 
in effectiviteit van trombus aspiratie in de versch i l lende subgroepen (gemaakt op basis 
van in itiele epicardia le b loeddoorstroming, leeftijd, geslacht, tota le  ischemische tijd, 
infarct locatie, proximale laesie en angiografisch zichtba re trombus) .  Ook in een recente 
meta-ana lyse van individuele patientgegevens van de meeste trombus aspiratie stud ies 
werden geen versch i l len in effectiviteit gevonden tussen deze subgroepen of andere 
basel ine kenmerken van patienten. Deze bevind ingen, samen met de waargenomen 
hoge inc identie van effectieve trombus aspiratie i n  a l l e  patientengroepen, ondersteunen 
een strategie van routine trombus aspiratie in p laats van een meer selectieve aanpak. 
I n  hoofd stuk 8 werden de resu ltaten van een prospectieve cohort studie getoond, 
waarin onderzocht werd, of een trombus aspiratie katheter met een grotere diameter 
van het aspiratie lumen beter in staat is om trombus te verwijderen dan een katheter 
met een kleiner lumen. Tevens werd onderzocht, of een g rater lumen resu lteerde in een 
betere angiografische en electrocardiografische u itkomst. In totaa l  werden 80 patienten 
behandeld met een katheter met een g root l umen en 80 met een katheter met een 
medium l umen. Er werden geen s ignificante versch i l len gevonden in percentage van 
effectieve trombus aspiratie, epicardia le bloeddoorstroming, myocard ia l  b lush grade of 
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electrocardiografische uitkomst tussen de 2 katheters. De grootte van de geaspireerde 
trombi was eveneens vergelijkbaar. 
Deze studie toont aan, dat een groter aspiratie lumen niet direct leidt tot het aspireren van 
grotere trombi noch in een betere angiografische of elektrocardiografische uitkomst. Oat 
een groter lumen geen meerwaarde lijkt te hebben, kan verklaard worden door het feit, 
dat vers gevormde trombi broos en daardoor gemakkelijk te fragmenteren en aspireren 
zijn. Verder kunnen de betere gebruikseigenschappen van kleinere katheters ook een 
verklaring zijn van de vergelijkbare resultaten. Bij de evaluatie van alle gepubliceerde data 
over de verschillende type hulpmiddelen om distale embolisatie te voorkomen, worden 
de beste resultaten behaald met de meest eenvoudige en gemakkelijk te gebruiken 
hulpmiddelen. 
Verschillende gerandomiseerde studies zijn uitgevoerd, die mechanische trombus 
aspiratie vergelijken met conventionele PCI, maar met wisselende en minder overtuigende 
resultaten dan met manuele trombus aspiratie. Echter, er zijn tot op heden geen directe 
vergelijkingen verricht tussen manuele en mechanische trombus aspiratie. Het is dus 
momenteel onduidelijk of manuele trombus aspiratie echt superieur is ten opzichte van 
mechanische trombus aspiratie. 
Manuele trombus aspiratie in NSTEMI 
In hoofdstuk 9 worden de resultaten van een prospectieve cohort studie gepresenteerd, 
waarin de haalbaarheid en de veiligheid van trombus aspiratie tijdens PCI voor NSTEMI 
werden onderzocht. Trombus aspiratie was effectief bij 58 patienten (83%) en resulteerde 
in een duidelijke vermindering van de hoeveelheid aanwezige trombus en verbetering 
van de epicardiale bloeddoorstroming. 
Deze studie toont aan, dat trombus aspiratie in de meeste NSTEMI patienten haalbaar en 
veilig is. Momenteel wordt de effectiviteit van trombus aspiratie bij patienten met NSTEMI 
onderzocht in de Trombus Aspiratie during Percutaneous coronary intervention in Acute 
non-ST-elevation myocardial infarction Studie (TAPAS 1 1 ). De TAPAS II zal 540 patienten 
met een acuut NSTEMI, die kandidaat zijn voor een spoed PCI, randomiseren naar een 
behandeling met trombus aspiratie of conventionele PCI. Het primaire eindpunt is de 
incidentie van myocardial blush grade 3 na PCI. 
Direct stenting 
In de literatuur wordt gesuggereerd dat in patienten, die voldoende epicardiale 
bloeddoorstroming hebben, stent implantatie zonder balloon predilatatie (direct 
stenting) tot minder distale embolisatie leidt dan stent implantatie met ballon predilatatie. 
Onduidelijk is, of in deze patienten groep trombus aspiratie meerwaarde heeft. In 
hoofdstuk 1 0  worden STEMI patienten, die direct stenting ondergingen, vergeleken 
met patienten, die voorafgaand aan stent implantatie trombus aspiratie ondergingen. 
Een totaal van 75 1 patienten bleek geschikt voor direct stenting. Direct stenting werd 
uitgevoerd in 32.6% en trombus aspiratie voorafgaand aan de stent implantatie in 67.4% 
van de patienten. Ondanks slechtere angiografische baseline karakteristieken was de 
groep, die trombus aspiratie voorafgaand aan stent implantatie kreeg, geassocieerd 
met een aanzienlijke verbetering van het primaire eindpunt myocardial blush grade ten 
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opzichte van d e  d i rect stenting g roep. Dit voordeel van trombus aspi ratie voorafgaand 
aan stenting bleef sign ificant na correctie voor bekende prognostische factoren. 
Deze bevindingen ondersteunen de hypothese dat, wanneer trombus aanwezig, 
ook bij normale epica rd ia le b loeddoorstroming, er nog steeds een hoog risico is op 
dista le embol isatie. Aangezien trombus aspiratie de hoeveelheid trombus vermindert, 
neemt daarmee ook het risico op d ista le embol isatie af. Verder wordt gedacht, dat het 
risico op dista le embol isatie het hoogst is tijdens de eerste i nterventie, ongeacht of d it 
ba l londi latatie of stent implantatie i s. Dus ook bij patienten, d ie in aanmerking komen 
voor d i rect stenting, leidt een PCI strategie die beg int, met trombus aspiratie waarschijn l ijk  
tot minder dista le  embol isatie en een betere microvascu la i re reperfusie in verge l ijking 
met enkel d irect stenting .  
Impact van de interventiecardioloog op microvasculaire reperfusie 
I n  hoofdstuk 1 1  wordt onderzocht, wat de impact van de i nterventiecard ioloog is op 
microvascu la i re reperfusie. Het primaire eindpunt was de incidentie van optimale 
microvascu la i re reperfus ie (myocardia l  b lush g rade 3) na de primaire PCI voor STEMI .  Er 
werden in  totaa l  1 07 1  patienten ge"includeerd, die een prima i re PCI kregen als onderdeel 
van de TAPAS. Deze PCl's werden verricht door 6 ervaren i nterventiecard iologen. Al ie 
gebru ikte eindpunten waren gescoord door onafhanke l ijke onderzoekers. Tussen de 6 
interventiecardio logen varieerde het percentage van het prima i re eindpunt myocard ia l  
blush g rade 3 tussen 29.2% en 55.5%. Deze associatie tussen microvascu la i re reperfusie 
en interventiecard ioloog b leef s ignificant, ook na correctie voor  base l ine en procedurele 
versch i l len. Er werden geen statistische versch i l len gevonden met betrekking tot 
vei l igheidseindpunten.  
Deze studie maakt du idel ijk, dat zelfs in de gecontro leerde condities van een 
gerandomiseerde studie een aanzien l ijke va riatie tussen interventiecard iologen bestaat 
wat betreft de effectiviteit van primaire PCI .  Dit onderzoek ondersteunt het routinematig 
verzamelen van hoogwaard ige datasets om de ind ividuele bekwaamheid en vaardigheden 
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